var title_f11_31_11760="Select opioids chronic pain and equianalgesic doses";
var content_f11_31_11760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected opioid analgesics for pain and equianalgesic doses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"16%\">",
"     </colgroup>",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"        <br/>",
"        (US trade names)",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Equianalgesic (mg) doses",
"        </p>",
"        <p>",
"         See important NOTE*",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sample initial dose for opioid na&iuml;ve adult",
"        <sup>",
"         &bull;",
"        </sup>",
"        <br/>",
"        (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Half-life",
"        <br/>",
"        (in hours)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of analgesic effect",
"        <br/>",
"        (in hours)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Morphine",
"       </td>",
"       <td>",
"        10 IV/SQ/IM",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         2 to 5 IV every two to four hours",
"        </p>",
"        2 to 10 SQ every three to four hours",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        3 to 4",
"       </td>",
"       <td rowspan=\"2\">",
"        Standard for comparison for opioids; multiple routes available (including tablet, rectal suppository, concentrated enteral liquid, parenteral infusion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20 to 30 orally",
"       </td>",
"       <td>",
"        10 to 30 orally every four hours",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        3 to 6",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Controlled-release morphine tablet",
"        <br/>",
"        (MS Contin",
"        <sup>",
"         &reg;",
"        </sup>",
"        , Oramorph SR",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &loz;",
"       </td>",
"       <td>",
"        15 orally twice daily",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        8 to 12",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Sustained-release morphine capsule",
"        <br/>",
"        (Kadian",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &loz;",
"       </td>",
"       <td>",
"        30 orally daily in one or two divided doses",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        12 to 24",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Extended-release morphine capsule",
"        <br/>",
"        (Avinza",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &loz;",
"       </td>",
"       <td>",
"        30 orally daily",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Hydromorphone",
"       </td>",
"       <td>",
"        1.5 IV/SQ/IM",
"       </td>",
"       <td>",
"        <p>",
"         0.3 to 1 IV every two to four hours",
"        </p>",
"        0.3 to 1 SQ/IM every three to four hours",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        3 to 4",
"       </td>",
"       <td rowspan=\"2\">",
"        High potency (nearly seven times more potent per mg than morphine) and solubility may be beneficial for patients requiring high opioid doses and for subcutaneous administration. Multiple routes available (including tablet, rectal suppository, enteral liquid, parenteral infusion).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7.5 orally",
"       </td>",
"       <td>",
"        2 to 4 orally every three to four hours",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        3 to 6",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Controlled-release hydromorphone",
"        <sup>",
"         &sect;",
"        </sup>",
"        <br/>",
"        (Canadian trade name: Hydromorph Contin",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &loz;",
"       </td>",
"       <td>",
"        3 orally every 12 hours",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        12 to 24",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Extended-release hydromorphone",
"        <br/>",
"        (Exalgo",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &loz;",
"       </td>",
"       <td>",
"        8 orally every 24 hours",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Codeine",
"       </td>",
"       <td>",
"        200 orally",
"       </td>",
"       <td>",
"        30 to 60 orally every four to six hours",
"       </td>",
"       <td>",
"        2 to 4",
"       </td>",
"       <td>",
"        4 to 6",
"       </td>",
"       <td>",
"        Codeine is not recommended for chronic pain management because adverse effects increase disproportionately to analgesic effects, as dose is increased. Polymorphic metabolism, drug interactions and risk of accumulation are also disadvantages of codeine.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Oxycodone",
"       </td>",
"       <td>",
"        15 to 20 orally",
"       </td>",
"       <td>",
"        5 to 15 orally every four to six hours",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        3 to 6",
"       </td>",
"       <td>",
"        Available as a single entity or combined with aspirin or acetaminophen",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Controlled-release oxycodone",
"        <br/>",
"        (Oxycontin",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &loz;",
"       </td>",
"       <td>",
"        10 orally twice daily",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        8 to 12",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hydrocodone",
"       </td>",
"       <td>",
"        30 orally",
"       </td>",
"       <td>",
"        5 to 10 orally every six hours",
"       </td>",
"       <td>",
"        3 to 4",
"       </td>",
"       <td>",
"        4 to 8",
"       </td>",
"       <td>",
"        Only available in combination with acetaminophen in US",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Oxymorphone",
"       </td>",
"       <td>",
"        1 IV/SQ/IM",
"       </td>",
"       <td>",
"        <p>",
"         0.5 IV every four to six hours",
"        </p>",
"        0.5 to 1.5 SQ/IM every four to six hours",
"       </td>",
"       <td>",
"        7 to 9",
"       </td>",
"       <td>",
"        3 to 6",
"       </td>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 PR",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        5 every four to six hours (variable effect)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4 to 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15 orally",
"       </td>",
"       <td>",
"        5 to 10 every four to six hours",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Extended-release oxymorphone",
"        <br/>",
"        (Opana",
"        <sup>",
"         &reg;",
"        </sup>",
"        ER)",
"       </td>",
"       <td>",
"        &loz;",
"       </td>",
"       <td>",
"        5 twice daily",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Levorphanol",
"       </td>",
"       <td>",
"        2 IV/SQ/IM",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         0.5 to 1 IV every three to six hours",
"        </p>",
"        0.5 to 1 SQ/IM every six to eight hours",
"       </td>",
"       <td>",
"        11 to 16",
"       </td>",
"       <td>",
"        4 to 8",
"       </td>",
"       <td rowspan=\"2\">",
"        With long half-life, accumulation possible after beginning or increasing dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 orally",
"       </td>",
"       <td>",
"        2 to 4 every six to eight hours",
"       </td>",
"       <td>",
"        11 to 16",
"       </td>",
"       <td>",
"        4 to 8",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Methadone",
"       </td>",
"       <td>",
"        10 IV/SQ/IM",
"        <sup>",
"         &yen;������",
"        </sup>",
"       </td>",
"       <td>",
"        1.25 to 5 IV/SQ/IM every four to eight hours",
"       </td>",
"       <td>",
"        12 to 150",
"       </td>",
"       <td>",
"        <p>",
"         3 to 4 (initially)",
"        </p>",
"        <p>",
"         6 to 8",
"        </p>",
"        Increases following repeated administration",
"       </td>",
"       <td rowspan=\"2\">",
"        Potency of commercially available formulation (a d,l racemic mixture) is presumably due to the d-isomer, which is a NMDA antagonist and can reverse tolerance and augment analgesia. May be far more potent than indicated in the table. As total daily dose of morphine increases, the estimated equianalgesic dose of methadone decreases progressively. Effects may be further altered by drug interactions involving CYP3A4. Due to its highly variable and prolonged half-life, methadone has the highest risk among opioids of overdose and accumulation during initial titration to effect (as steady state levels are approached) and during dose adjustment in chronic use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20 orally",
"        <sup>",
"         &yen;������",
"        </sup>",
"       </td>",
"       <td>",
"        2.5 to 10 orally every four to eight hours",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fentanyl IV/SQ",
"       </td>",
"       <td>",
"        <p>",
"         100 micrograms IV/SQ (single fentanyl dose)",
"        </p>",
"        250 micrograms IV/SQ (after chronic fentanyl administration)",
"       </td>",
"       <td>",
"        25 to 50 micrograms IV/SQ every one to two hours",
"       </td>",
"       <td>",
"        7 to 12",
"       </td>",
"       <td>",
"        <p>",
"         0.5 to 1 IV",
"         <sup>",
"          ������",
"         </sup>",
"        </p>",
"        <p>",
"         1 to 2 SQ",
"         <sup>",
"          ������",
"         </sup>",
"        </p>",
"        Increases following repeated administration",
"       </td>",
"       <td>",
"        Can be administered as a continuous IV or SQ infusion",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fentanyl transdermal (TD) system",
"       </td>",
"       <td>",
"        <p>",
"         Approximate equivalent doses for oral morphine, IV/SQ morphine, and TD fentanyl",
"        </p>",
"        <p>",
"         60 mg/day oral &asymp; 20 mg/day IV/SQ &asymp; 25 micrograms/hour TD",
"        </p>",
"        <p>",
"         120 mg/day oral &asymp; 40 mg/day IV/SQ &asymp; 50 micrograms/hour TD",
"        </p>",
"        <p>",
"         180 mg/day oral &asymp; 60 mg/day IV/SQ &asymp; 75 micrograms/hour TD",
"        </p>",
"        240 mg/day oral &asymp; 80 mg/day IV/SQ &asymp; 100 micrograms/hour TD",
"       </td>",
"       <td>",
"        12 to 25 micrograms every 72 hours",
"       </td>",
"       <td>",
"        17 after removal",
"       </td>",
"       <td>",
"        <p>",
"         48 to 72 per patch",
"        </p>",
"        Up to 12 after removal",
"       </td>",
"       <td>",
"        Not usually recommended for opioid na&iuml;ve patients. Not recommended for acute pain. Onset of effect: 12 to 24 hours.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Oral transmucosal fentanyl citrate lozenge",
"        <br/>",
"        (ACTIQ",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        <p>",
"         2 (200 mcg)",
"        </p>",
"        3.25 (800 mcg)",
"       </td>",
"       <td>",
"        Not recommended for opioid na&iuml;ve patients. Recommended starting dose for breakthrough pain, 200 micrograms, even with high \"baseline\" opioid doses. Onset of effect: 4 minutes.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fentanyl citrate sublingual tablet",
"        <br/>",
"        (Abstral",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        11.5 to 25",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td rowspan=\"4\">",
"        Applies to sublingual tablet, sublingual spray, buccal tablet and nasal spray: not recommended for opioid na&iuml;ve patients. Recommended starting dose for breakthrough pain, 100 micrograms, even with high \"baseline\" opioid doses. Half-life and duration of effect are dose dependent. Onset of effect: 5 to 15 minutes.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fentanyl sublingual spray (Subsys",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        5 to 12",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fentanyl buccal tablet",
"        <br/>",
"        (Fentora",
"        <sup>",
"         &reg;)",
"        </sup>",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        13.3",
"       </td>",
"       <td>",
"        1 to 2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fentanyl nasal spray (Lazanda",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        15 to 25",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fentanyl buccal soluble film (Onsolis&trade;)",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"       <td>",
"        Not recommended for opioid na&iuml;ve patients. Recommended starting dose for breakthrough pain, 200 micrograms, even with high \"baseline\" opioid doses. Onset of effect: 15 minutes.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Buprenorphine injection",
"        <br/>",
"        (Buprenex",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        0.3 to 0.4 IV/IM",
"       </td>",
"       <td>",
"        0.3 every six to eight hours",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Partial agonist. Mu receptor antagonism, and associated risk of precipitating withdrawal symptoms, increased in patients dependent upon high opioid doses. Effects may be altered by drug interactions involving CYP3A4. Respiratory depression only partially reversed by naloxone.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Buprenorphine transdermal patch",
"        <br/>",
"        (Butrans&trade;)",
"       </td>",
"       <td>",
"        5 or 10 microgram per hour patch",
"       </td>",
"       <td>",
"        5 microgram per hour patch applied every seven days",
"       </td>",
"       <td>",
"        26 upon removal",
"       </td>",
"       <td>",
"        7 days per patch",
"       </td>",
"       <td>",
"        Slow onset of up to 72 hours following initial patch application requires tapering of previous opioid analgesia. Prolonged duration of effect following patch removal. Rate of absorption from patch may be increased with application of external heat or fever. Risk of QTc prolongation increases with doses &ge;20 mcg per hour. (See buprenorphine injection for additional detail).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"6\">",
"        <strong>",
"         Mixed mechanism",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        Tapentadol (Nucynta",
"        <sup>",
"         &reg;",
"        </sup>",
"        , Nucynta",
"        <sup>",
"         &reg;",
"        </sup>",
"        ER)",
"       </td>",
"       <td>",
"        75 mg orally",
"       </td>",
"       <td>",
"        <p>",
"         50 to 100 mg every six hours (immediate release)",
"        </p>",
"        50 mg every 12 hours (extended release)",
"       </td>",
"       <td>",
"        ~4 to 5",
"       </td>",
"       <td>",
"        <p>",
"         ~3 to 6 immediate release",
"        </p>",
"        Insufficient data: extended release",
"       </td>",
"       <td>",
"        Mixed mu opioid agonist and norepinephrine reuptake inhibitor. For chronic pain, titrate extended release preparation in increments of 100 mg daily, divided twice daily, no more frequently than every three days. Maximum dose 500 mg daily. Dose adjustment needed for moderate hepatic insufficiency. Not recommended for patients with severe renal or hepatic insufficiency (use contraindicated according to licensed information in some countries). Risk of interaction with other serotoninergic drugs.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        Tramadol (Ultram",
"        <sup>",
"         &reg;",
"        </sup>",
"        , Ultram",
"        <sup>",
"         &reg;",
"        </sup>",
"        ER, ConZip&trade;, Rybix&trade; ODT, others)",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        <p>",
"         50 to 100 mg every four to six hours (immediate release)",
"        </p>",
"        100 mg once daily (extended release)",
"       </td>",
"       <td>",
"        ~6 to 9 (includes active metabolite)",
"       </td>",
"       <td>",
"        <p>",
"         ~4 to 6 immediate release, initial use; ~3 to 11 immediate release, chronic use",
"        </p>",
"        Insufficient data: extended release",
"       </td>",
"       <td>",
"        Mixed weak mu opioid agonist and reuptake inhibitor of norepinephrine and serotonin. For chronic pain, titrate extended release preparation in increments of 100 mg daily no more frequently than every five days. Maximum dose 300 mg daily. Risk of drug interactions with other serotoninergic drugs and inhibitors or inducers of CYP3A4 and/or 2D6. Dose adjustment needed for moderate renal or severe hepatic insufficiency. Not recommended for patients with severe renal insufficiency or at risk for seizures, depression, or suicide. Effects of tramadol not fully reversed by naloxone, which may increase seizure risk.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NMDA: N-methyl-D-aspartic acid; IV: intravenously; SQ: subcutaneously; IM: intramuscularly; PR: per rectum; NR: Preparation not recommended for initial treatment of opioid na&iuml;ve patients. The total daily dose requirement for long-acting formulation should be established first with the use of an appropriate immediate-release opioid analgesic. See text.",
"     <br/>",
"     * Equivalence to a 10 mg dose of parenteral morphine sulfate, except fentanyl transdermal as shown. NOTE: Equianalgesic conversions serve only as a general guide to estimate opioid dose equivalents. For a review of multiple factors that must be considered for safely individualizing conversion of opioid analgesia, refer to UpToDate topic on Cancer pain management with opioids: Optimizing analgesia.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Dose reduction of approximately 50 percent required for older or debilitated adults or patients with low cardiac output or respiratory compromise.",
"     <br/>",
"     &Delta; IM route not preferred due to pain at injection site.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Opioids such as morphine and hydromorphone have the same equianalgesic potency whether administered in an immediate-release or a sustained or extended release form. To convert from oral immediate release to extended release, use sum of doses of immediate release preparation administered during usual interval for the extended release form. For example, morphine sulfate immediate release 30 mg every four hours (180 mg daily) converts to morphine sulfate controlled release 60 mg every eight hours (180 mg daily).",
"     <br/>",
"     &sect; Not presently available in US.",
"     <br/>",
"     &yen; Variable.",
"     <br/>",
"     &Dagger; These conversion rates, which differ from those available in other tables and references, represent the recommendations of an expert panel convened to evaluate equianalgesic dosing (Knotkova H. J Pain Symptom Manage 2009; 38:418).",
"     <br/>",
"     &dagger; Bolus administration to opioid na&iuml;ve patients.",
"    </div>",
"    <div class=\"reference\">",
"     Additional data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Swarm R, et al. Adult Cancer Pain. National Comprehensive Cancer Network Guidelines in Oncology version 2.2012, available at",
"       <a href=\"file://www.NCCN.org\" target=\"_blank\">",
"        www.NCCN.org",
"       </a>",
"       .",
"      </li>",
"      <li>",
"       Lotsch J, Walter C, Parnham MJ, et al. Pharmacokinetics of non-intravenous formulations of fentanyl. Clin Pharmacokinet 2013; 52:23.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11760=[""].join("\n");
var outline_f11_31_11760=null;
var title_f11_31_11761="Hunter syndrome";
var content_f11_31_11761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient with mucopolysaccharidosis type II (MPS II, Hunter syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 211px; height: 484px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A six-year-old boy with severe Hunter syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Neufeld, E, Meunzer, J. The Mucopolysaccharidoses. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver, CR, Beaudet, AL, Valle, D, et al (Eds), McGraw-Hill, New York 2001. Copyright &copy; 2001 The McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11761=[""].join("\n");
var outline_f11_31_11761=null;
var title_f11_31_11762="Stage 4 ROP";
var content_f11_31_11762=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stage 4 retinopathy of prematurity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 325px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFFAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxuiiisT0gooooAKKKKAClAoApwFAABTgKAKcBSEKBTgKAKeBQAAU8CkAqRVyQB1pAAFPAp1hBcajf/YNKtLjUb/vBaruKe7sflQe7GvSvDnwd1S9CTeJNSGnwkf8AHnpx3Sdj807Dg9R8gx71E5xgrydhpOWx5hc3FvaY+1zxQZGQJHAJ/DrVzS7W+1UxnSNH1jUI36SwWbCP8Xfao/OvorRPBXhLwogktNNsYJRz9onAklJ9d75bP41vf2nAeIIppiOmyI/zNc7xS+zFs1VB9WfO1n4D8bXWCvhuK2UnG661GPgepVASP1rVT4W+NCAfK0Bfrdzf0ir3Q3Gov/qrFEHYyzAfyzSqdUYfOlih9nZv6Csnip9kUqMe7PDB8LvGg6p4dI9BdT//ABqoLn4e+NrYjbpGmXY/6d9QKH/yIgr3vGpDobNvY7hTRLqiE77S1de3lznJ/NRQsVPyD2MfM+cbnQ/E1jG73/hPVl2nB+yGO6GPUbGyfyrLl1OztphDfPNYTcjy723kgI/76GP1r6i+3XCgfaNMuR/uFZP5GoZr/S508q8CIpHKXMRUY9wwxVrEt7x+5kugujPnS3KzwiWB0miPR42Dr+Y4qVRXr+qfC3wfqrG4ttPSwuSCBcaZIbdhn/cwp/EGuT1X4V69YAvoeswanEMYt9Tj2SY74mj6n/eWrjXpy0vb1M5UZrocgq1Iq1Wvpp9HuUtvEen3OjTudqNcYaCQ+iTL8p6d8Ve2EEZGMjI9/etWZgoqRVoValUUhAq1Iq0KtSqtIAVakVaFWpVWpECrUirQq1Kq0AKq1Iq0KtSqKkQKtSqtIq1Kq0gEC0VKBxRQB8+UUUV3GwUUUUAFLigCnAUAAFOAoAp4FIQAU4CgCngUAAFPApBgKzEgKo3MxOAAOpJ7Cuj8GeDNa8XyJJpyCy0on5tSuI87x/0xjP3/APeOF696ltJXYLXRHPFsSxQpHLNczHENvBGZJZT6Ig5PTr0r07wj8Ir/AFIJc+K5206z6/2fayDzXHH+tmHQdcqnY/eBr0Lwn4V0LwcHg0W0kvdVdf39xIwknk6f6yQ/dHA+UYHHTNdKLKS5O7UnV17QREhB9T1b9BXHVxVvh0/rojeFH+YoaNa6VolkmneG9OiEMfHl2yBUB9Wbufckk1oG3vbjP2m6WBD/AAW45/Fj/QVdVVjjCqFSNRwAMBRXH614+sraSS30a3k1a5Q7WaNtkCH0aQ8H6Lk1x80pu6Rva2h09tp1pbvvjgVpf+eknzv+Z/pUOsa9pWjJv1bUrW1HpJIAx+g615PrGteJ9Y3LcagbKBv+WFgCgx6Fz8x/SudXw6gcyGPdIert8zH6k81Xsr6zZrGlJ+R6RqPxc8O25YWUV/fsP+eUO1T+LYrIm+M8YH7jw7dP/wBdLhV/oa5QaGT/AAViX97pVnO0HmPc3K9YrZDIR9ccD8a0jSj0Rp7GC+KT/A9Cj+NBI/e+GZl/3bxW/wDZRV+z+MelSYF5o+qW2TjKhJQPf5TXkn9pwdTpGqBP73kg/pnNSQaroskqxyzyWsjdBdQtFn8SMU/ZReyCVKnH4m166fmj3vS/iH4W1J1SLVooJT0jugYW/wDHgK6mOSOeING6Sxt3Uhga+eRoyTRg7VkjYZHRgam0/S7rTJBJpV1dWD/9O0hVT9U5U/lWbpRezJlRa2dz3V9LsyxZIfJf+9CTGf04pvlX1t/qZlukH8E3yt+DDg/iK870zxl4jstq39vbarCOrIPJmx/6CT+VdlovjHRtWlW3S4Nrenra3a+VJ+APX8M1DU1vqjFrl30Ltw1hqcMljqlqn70bXt7qMEOPx4YfnXnuu/CkWe+48F3f2PncdMui0lo/Unb/ABxE56qSOBwBXqc8Mc8RjnjWSM/wsMiqRiuLHm133Nv3hZsuv+6T1+h5qqdVx+F/LoROCl8R4FFNIl+2nalaTabq6LvaxuCCzLz80bj5ZV4PK+hyKuKK9g1/Q9F8Z6WbbUIRKsb7kZSY5reQdGVh8yMP/wBYI4ryXxBpuo+Dp9niCX7VpTOEg1gIFwWPCXKjhDngSD5TxnBzjshUVTTZ9jkqUnDXoIq1Iq0uwqcEYNSKtUZAoqRRSqKkVaABVqVVoValVakQKtSqtCrUirSAFWpVWhVqVVpAIF4oqQLxRQI+c6KKK7zcKUCgCnAUAAFOAoApwFIAAp4FAFPAoEAFO/jiRY5ZppW2RQwIXllb+6ijkmrOkabf61qX9m6Ja/a78AF1J2xwKf45X/hHt949hzXuvw98EW3h1WntCt/rMq+XPqs6YRF/55xL2Ueg6n7x6AZ1KigrsqMXLY5vwb8Lre2S31Lx4I5ZzhoNIQ+ZEjdt+P8AXP2x90c8Ht62kF1cqFf/AEG2xgRRkeaw9yOF+gyfpVm0s4rZ2ky0twww00nLH2HoPYVZry6tdzZ1wpqK0I7eGK3iEUCLHGOcDufU+p96y9d1+30mSK2WOS81OcEwWUHMj/7R7Ko7scCoNT1e6uNQl0jw6kcuoIoNxcSg+TZg9C+PvMeyDk98DmruiaBa6TFLseS4vLghrm7m5lnb3PZR2UcCojD7UgcukTk77TNW10Z8QXIWA8jT7NisKj0d+sh/IexqWLQUijWOONUjUYVFGAB6AV3Rt41QuwwijJY8AfU1zs/ibSmkeHSY7rWrhTgpp8YdAfeUkIPzNaq72GpqGxlf2MP7tKNEyQAtaA1HxBy7eE4/J7KNVTzvy2bf/HqyfF3jWDSvDGpzDT9SstUWErBHdW5CGQ8A+YuUwCc9egNNRcnZD9vbc8r8da2dQ1K50jTZWg0u0cxXVxGcPcSDrGh7KOhPc8dq5hbuG0iENpGscY/hQYpukaLrOo2aJpGl311bxj5rplEUTMeWYySFRycnjNSyeGNQjwLi+0K3foUN+Zmz6YjRua0dGc+mh6lHFYfCxtzXl1a1+WnRFY6k+eP508akZEKTKHQ9VYZB/CmXGgXkXS6tJD/sQ3J/XyqqyabqMSFzbh1HUrvX/wBCQVLw77GyzOm/tfg/8jY0XUp9DmE+kAy2mcy6ex+Vh3Mefut7dDXtGgCx1/SLfUtMcS20w4OMFSOCrDsQeCK+eFmlgbLxSpjnIG4fX5Sa7r4SeK30XxDcW9vayahaaouTawyIhW5X+PLEBQyg591Hc03GW0jkxCpyj7Sg15pfml0818+569/Yw/u1Hc+H4LqEw3dvHPF/ckUMPw9D7itRdV1p1Dr4QlKEcf8AE0gz/LFKfELW4zqfhrXLVe7xRx3SD/v2xb/x2s9ej/E8/wBt3Rl2dprehjOj3JvrQddPvZCSB6RynkfRsj3rodC1+z1hpIYxLb38IBms7hdksfuR3HuMg+tSaPrGi605j0vULeeZfvQZ2Sr9Y2ww/Kn61oFpqqxGYy295bnNvdw/LNAfY9x6qcg+lKUU/i0ZPMt4k13ZR3D+ajNBdAfLNH976EdGHsfwxVSeRXjax1uCJ4pwYt5XdDMD1Ug9Cf7p4PvVOz1i60+/j0vxIqJcS8W19EMQXfsP7jjuh+oyK35EWSNo5UV0YYZWGQR7is7uGkv69Ck1LVHjHifwnd+DCbrS457/AMMZzJbrmSfTh/ej7yQjun3l6jIzVe3eOeGKe3ljmglXdHLG25XHqDXr0iS6WpeLzJ7EfeizueEeqnqQPTqPevO/FXg2bS5Jde8Fwrc2dwfOvdIQgLN6y2/ZJfVfuv8AUDPZTq8+j/r/AIJy1KNtYmYq1Kq1W0y8ttSs0urGQyQsSp3LtZGHVHU8qw7g/wAsGryrWj0OYFFSKtCrUqrUgCrUqrQq1IopCFVakVaFWpVWkAgWipQtFID5ppQKMU4CvRNwApwFAFPApCACnAUAUrukUTyyuEiQbmZugFACgABiSAqgsxJwAB1JPYV1vgrwPfeJ4F1C6ll0rw6Vz9sxie5z2hUj5R/tsOcjaDzXRfD74dRywW2ueNLdxCzK1jpDrlnPVWmX+JjwRH0UfezyK9ttbWRpvtN8VaUf6uJeVhH9W9+3auWtiFDRGsKTlqzH8NeGLHStNSzsbJLDTR8wtlz5krf35W6knHQnPr6V0qgKoVQFUDAAGAB7UtLXmTqSm7s64xS2CsbxXeXtlpO/TY3aaSQRtKkRlNuhzmTyxy+PQc5I7ZrZqvf3ttptlNe39wltaQLuklc4Cj+p9AOSamLswkro5vRNSi0zTI7LQdD1q/5LvPNCLYSyHlndpSCST32mrcg8UXqlprjTdDt+/kj7TKP+BvhB/wB8muKuPiJrusPKvh3RHitg5WO5uZo0JXsW3HC/TmsltQ1Z5nbVfFnhmCWPnmRrllPcckAY9q6HJ/1qaQwM3u/6+R3cmjaEzCXVrm+16ZTkG6kadAfZBiMflWnLrAsrNTDYxWlog+VriVYI1A9hkV5D/aGoalJJHD45u7puqw6To8krZPRQQBj6E0608Hn+1dPfWPDPiHWbi73eV/bF8luo2gHe6qWcIMjcT0yAASQCKPO7N3/r5Fyw0aKbk/0/Ox6DceObANBH/bekCS4JWGO1b7Q7kdQu0ncfoKp69Zah4mhs1uJLmxt7acXMbzFTMXAwMRKAijk/f3nnoDW5ovhyx0eSWe2traO7lAV3ghESoo/gjUfcTvjkkkliTV94s5rtpUIQd1uc6hzfFp/XU5C50G1mfzL/AM7UJuu+8lMv5A/KPwApGsY4l2xxIi+iqAK6eWDrxVOaDrxVzjc0UUtjmJoGA4yKozRNnqa6ae368VnTwD0rmnTA5q7tUmBE0aSD/bUN/Osk6RBBdJdWam2uUO5JIxnafUZ6fgRXWTQdeKoyw1l70PhZEqcZbot6L491vSVWLVRb6harwJZMxuB7yKDj/gakerjrXdaf460O4Mcd5ctpNy4BEOo7YtwPIKyAmN1PZlYg15dJEQcjINQQi3hhe2vdPTUtKkbdJYk7SpPV4G48uT6YDdDzzU3hPSSs+6MlBwd09O2/3Htuq6JpWu26PqFja3sR5jmKhiPdXHI/A1mpour6WP8AiQ63K8A6Weqg3MY9lkyJFH4mvC7uyvfB/iCF/DOralDoV6BNY3Kn5bkDG5GXco3KcgqQDkciu+0PxvdxkxX/AIv0prgDPkappj2bL7F9364NJKUdEzqq4T3VUh7yeum/9fM6/UtXmewmsvFvh26S1kGGudPb7XCD2cYAkQjqDtOPWrHgnVl1GwubZrpbuawlELTgEeahXdG5B5BKnkdiDUGmeLQb+2tdVWzh+1j/AEa7tLjzbeY+gbsfrXVEnoc8dqmpLTlaOaMGncQHByOtZ8sEtnK01kgkgc5mth192T39V79ueDo0lZxlY0aueb+MfCss1y/iXwgscl7Io+12RbbHqCjtn+GYc7X/AANYGj6ha6tZ/abJnKK5iljkXZLBIPvRyKeVYen5ZFes3Nq8Ur3Vgq+c3MkROFm/wb379/WuD8ZeFpry7bxR4RRF1pV2XljKdiagg/5Zv/dlH8L/AEB46dtKopKz/r1/zOStRv70SkoqVVqloupWusWAu7IyBA5ililXbLBIv3o5F/hYen4itFVrR6HICipVWhVqVRUgCrUirQq1KopAIBxRUoXiikI+YwKcBQBTgK9E3ACngUAU8CgAVSSAoJJOAK7v4T+GF1a/g1++g+0WEEpXTLYf8vk69ZjngIhyAfXJ7YPL+FdBn8W+If7FtPN8tE82+li+9HH/AM8wTwrN03NwoycE/KfqPQtIh0m0jjjSNZFjWICIYSNFHEaDso/M9TXPiKypK3Vl0o88vQnsrPyXM9w3m3bDBfnCD+6o7D36nvVunU2vIbcndnclYdSVWvr61sFU3cyxlvup1dvoo5NeceKvEPiHUsxaVJ/Y9pg7gGQ3D/VgSF+in6mnGDkOMXJ2SO38T+J9H8MWrTa1exwsBlYFIaaT2VOv58V89+NfGuseMNQSS609E0KF99vZGXjPTc7Kcs5/QdO5OrB4Kg1LeL1pJJn5aaR1Dk/Uk5/HNEnwstcZiurknttaNv6it4qMDvoUqVN3m9fRnOwX1zBKTH4a0JRtyq3Mbvgevzvg/XFbNldeLZxHaWP/AAjtmXP7sRQ2kZGemDg/zqKT4fapZyg2mrSRS9FLho8j0DA4qxo8XiDw8lxDq+gWXiHTWHz27gb/AF3I2N2fwP0p38jsk6UleDTt3/4Lsb4sfiBFYh/FXjuLQtMjy0sn25WlUA/9MsZz2BcentXe/DnQv7O0qS+vLjUL3VdQO+a51CQvOsQJMUJJ6BVOSP77N7V5/oq/DjxNLZW+maM1jrj30AEExYEgSK0mMMVI2I/BAPqK90c7mLHucmtYSsjxavx2atbyS/IqslRtHVsjNNK1spBcovH7VVmi9K1GT2qCWMkVakMwJ4uTxWfNF7V0U8FZ00HWm1cDAniqhND1rfmhNUZoc1jKAjBlh68VTlh9q3pYfaqksHtXPKAilp15Y21re6Xr6W0miagd5F1kJBcgcOCOV3qCCR/EFP8AEc0Jm022hlh0LXGS3jwApSW5tEbA+8TG8ZGMZO3Pv1qzqSSxWk01vu8+EedHtO070O9cHtyo/Ous1Lx3p0Fy8Fro3iQEkkea0kUZPXGTKB3/AM8VLTtc2w9SUG4RTfXey/Jo8unsN1xcPBrOgXEL4d7SzuBbKX6CREYBM46gEV6v4G8bq6R6T4kuI1vo/kivfMDR3A7bmHAb36H61h3d1reqR7xo1j5YyUhnMtwy49WbCA+2fxri9fsdLutTU6vq+laZPCNoTTbUu0h4J3qGIUjpSdmrM7JRWJ0e67a/kj6RIIOD1pa8W8F+KtU07VYdN0sXOuaI7bUM8TRNB9HIwB7HivYrWdbmLeiuuCVIYdCPfoR7ispQcdTzpwdOXLLclqpeW0nmfabPaLkcMrfdmX+6ff0NW6KlOzuS1c838Y+HZWu28VeFYj/aSgJqOn9Pt8a/wsO0y87G7/dOQaraXe2up6fb32nyia0nXcj4wfdWHZgeCOxr0S+tZfOF1ZEC4Aw6McLMvofQ+h/OvNvE1nF4Z1ObxHp0cg0K9k/4nVqi82sp4F2E6jHAkA6ghuSMjupz51br/Wn+RxV6VveRpqKkUUoUcYKsCAQynIYHoQR1BHepFFM5QVakVaFWpVFIQgXiipQOKKQHy+BTgKAKeBXpG4AVd0bSr/XNXtNI0aMPqN2SEJ+5Ag+9NJ6Io59zgDJ4qlI6wxNI4dlXHyouWYk4CgdySQB9a+j/AITeCT4S0d7nU41PiHUArXZyG+zp1W2U9ML1Yj7zdzgGsa9ZUo36jjFzfKjofCPhvTfCehQ6XpEeI1+eadh+8upf4pZD1LE5+g4HFbNABJwOTXn3jvx41jdy6L4algfU0yLu9Yb47Ef3RjhpvbovfnivHbcm2zvhDaEUbvi3xrofhUCPU7kyXzY2WNqPNnb6qPuj3bFcHJ8YbS5LRyLc6VIc7UeHOB6tJzz7AVw08UOnWz+WCZXy8s8h3SzMTks7HksTya5KJGv719xOwZZj6CnBxfQ9CODSV5PU9ctkj1pmns9esbh5T8ypcjefY5O6ln8N38JD+VMVH8SnrXjF5DC8pHlJxwOKvaTq+q6G6vpOp3dow/gWQsh+qnINaaHUnUhorfkeu21pcKvzhiB2YYNaMGmSzJvglbHQ+oNcv4a+KcNwwt/GNrHFGeP7RtIzhf8ArpGMkD3X8q7Cd5bQx3tm6NbTDMU6OskFwvbDrkZ/L0oszGVdqXK9GRmPULBSHLXEP05H1HerVi4ZPNgUDnOVUMv4qeP5U+DxFAJRDqMEkG7hZQuVJ9D6GrsMYik+2WWyWNuXRDkSD1H+0KWqMpyUl7yKWpnR7eWy1uTT4ItRtLmA/bLdSAUaRVk3r1B2M3Jz9a9FIwSPSuI1jT4bq0M9v+8tbhGjkVe6sMEY9a2PB+qNfaX5Fyw/tCyIt7lc9WA+Vx/suuGB9yOxqlLQ46kEnzJ3TN/FNxTqK0jMgYRUbLUxppFaxkNMqSx8VRmirVdarSx5reMikYk8NUZYM1vSxVVkgqnG4zBkt/aqktv7V0MkFVZbf2qJQEcd4hza6LfzB44ikLfPJ91SRgE/iRTr3WZIrWO9t72O3sAoj/t/WlbMoA6W0ON8nHZFCj9ayPiT4nl0K90600ownUEkW7kaRd4iC/6sFehJb5sH+6ODmvNdbu73V9QbVNVu5r28m+/NM24/QdlHoBgD0rlqpLRnRh6UpPmsvV/5f16M6bXvFNpKcwx6rrjHG641WcwQMfRbeIjj/ef8KxW8T606LDBdx6fb7siPT7aO2C/iq7j+JOaq6e4eGW3cZVlOB744qgDwDWSqNfDodzoxkrT19f8ALYvz6nqzzBLvVtSl2HgNdyYH05rfstV1+2tlm0bX9VgdASIftTOp/wCAsSM1h6hD5llBdL2/dv8A0NW9BuMEKT0qJVJNXuP2NP8AlR3vhP4ua5HtTXIINThHDSRoIZgPw+Un8BXq/hjxjofiY+Xpl4BdjraTjy5h9FP3vwzXzhfRiy1aOdBiG5yT6Bx1/wAa1LmyiuYBcIuJovmJU4OB3BHQjrkVm5JmFTBwlrHQ+nKoajp0d3udVTzWXY6yDdHMmMFHHcYJH/1uK828DfEOa3eLT/FVx5lswCw6m/3kPZZvUdg/b+L1HrBGKabi7o86pTcHyyPH/D8g0PXZvCNwZFiRGuNIM7kyGAZ32zE8louq4zmPnsK6pVrS8c+Fo/E+lAWzR2uu2bCfS78jDW868rk4PyMRtYEEYOcZArA8O6qmt6THeiA2twHe3u7Un5rW5Q4lib6HkZ/hKmu1TVRcy+Z5VWm6crGioqRVpVWpFFIzEC8UVKBRSA+WwKeoJIAGTSAVb0vS7vXNWsNF0xtl7qMvkRydfJTGZJTyOEQE9euK9Ju2pu3Y9D+BfhMatqx8T38YbT9NlMWnIy5E1yPvzjsVjztU8jdkggrXvNVNJ02z0fSrPTNLhENjZxLBCnoo7n1J5JPckml1O+Gn2olVRJO7rFBEf+WkrHCr9M8n2Brxq1R1Z3OunH2cbvc8v+L3xGk025m8NeHpni1DAW+vkODbKwz5UR/56EEZf+AHA+b7vCaHHFDbLFBGkcEa5CKMCsL/AIRzW9Ti/teDOqSXk0ryyBlRy4kYEkEgYOMjB74ruLHwvLb6YA06f2g4AfJJjUdgMfjz3rCvUpx9256tBwpQT6vf+uxxviW6+Xy1PLHFQafbG30jzMHzJxvPsOwr0Cw8LWlpeC9uWN5cr/q964SP3C9z7np2Hep77TLKeR3mtIJHb7xK9aw+twS5UaSxC5lZaHlNjpl1qFywt12qOsrD5VqndKY53RuGQ7SPpXq1xGFTYihUHQKMAVh39nBI5eS3hd8Y3MgJrWOK5tGtAjVblzM4eOGZ4spE5ycggdR6/wA63vB/ijUPCNw32cfatMmP+ladKf3cg7lc8K/uOvenXiEZxxWLcqcmt41b9C+RVFaZ7vaf2brukjVPDkj3emsSstq4/e27DquOvHp6cgmq9oX0+dXtZkME2NpkJ8uT0VyOme0g5B4INeTeA/FU/g/XftiRyT2E4Ed5bIcF1HR17b17evI717pcR2eoWMeq6M8d9pd8pkKxjhx/Eyjsw5DIec56Ec29PQ5ZJ03yS26Mlt7wbJJ7MMr7tl1ZTYB3fyD+jdGH5ivP5yXMeq6C0f2uNdjxS/Ks8ecmGTupByVb+EnupINBo5rd4prVlnJTbEzniZBz5Tn1HUH/AOvU9peW94RLZSNDc5KmOQYO4dUYeo/PuMil5k8itY7DQtetNXicwMyTRELPbyjbJA2PuuOx9xweoJrXVge9efNZQ6tKsqPLY6pAu1ZoWAkQenPDofQgj6GrtvrOraOQms2T3sA/5e7BCT/wOH7w/wCAlh7Cl6GUqdtjtqKzNH1zTNXBGnX1vPIv3olfEi/VDhh+IrTII6g/iK0UmtzC40ionTNTUhFbxmUmU2jqFo60HXClm4UdzwK5jXPGfhvRyy3mrW7Tgf6i3PnSfkucfjit4yHzI0Xiz2rkfGfia30NWtbTyrnWGA2QHlYs9Hkx29F6n2HNct4g+I+pavut9CgbTbU8GdiDO49uyfhk+4rnLC3ELFjmSVjksTkknqaxrYuMFaOrOinQlPV6IxpfC2p313Nd3eowzTzuXeaYt5jk92wMfgOB0FaUvg+P+xZooJmn1EfPEzfKpI/gA9xxk98V0NtC7csK0UhO3GK8qeIm3c678qsnseNWXmm/jgijc3LPsEOCH3ehHUf0p+padd6VdG11CBoJgMgHlWHqrDhh7ivYShWfzfKj84jaZdg3kem7GccDvUGr2UGrWJtb+IvHnKOOHjb+8p7H9DVfWFfbQ09o27nn+hol1Yvby/ccFT7e9ZFr5lnfNFKNsiMVYe4rrdP8KX9pcOkV3avATw7blbHqVxjP41f8X+FFu4or3R4wL1FCyxA487AxuGf4uPxp+0ina+5fOrpGJqKC60eXAzJEPOTHXI6/pmrWgXYeFGyDxzWh4L0aebzv7ahkt4mjeJFYfNllI3kegzketcnZC40a+m06+Ux3EJ2kHv6MPUEcg0tJXiuhS1lyo3QUS6mtiAUzkA/3TXovw08Vmxlh0HWJybRyqafPJz5THgQMf7p/gJ6H5ehWvM7yN/7NttVUMY/tDQSEfwqQNp+m7Iz6kVObiOSFQ4RwGU7XPyn5h19qa0ZnVpe1i090fTR9DXn3ie2HhzxpBrCnZpHiB0sr8c7Yb4DEE59A4BjY8DOCea2/BuryXSTabeuz3lnwsrHmeLOA5/2h0b8D3rW8Q6NZ+ItB1DRtTXNnfQmGQgAlM8q4zxuVgGHuorWlPld+jPBr0+aNuqMbaQSGBBHBB7VIq1i+D9Qu7/SpLfWMDXdLmOn6kMn5pkHEoyBlZFw4OOSWx0reVa6npoeWAHFFSBaKQHywoz0616/+z3oe5tX8TTr95jpdjkHhEIaZx2O59qg+iEV49dSSQWkskCM84G2JFXcWkYhUAHf5iOK+sPCWhReGPC2k6HBs22FusLsgwHk6yN+Llj+NdGLnywt3OulHmmvI1a5DxfqZs4Nb1ZZCg0WyaK2IGf8ATJlwCPUqGQD/AHzXWXM8drbTXM5xFChkc+gAya8u8cyM+j+F9MlGJtVvH1a7X/ZUbwD7Aug5/u+1ebF2Tk+h225mo9yloNoNP0eytAOYolU+5xyfzzWkKrI2TmrCnivEndu7OuSsDDIqpOtXKhlXg1KJMe5TrWRdJ1rfuErKuk610QZrFnM3sfWsO7TrXUXsfBrCvI+tdtOR0wZhSDDVv+CvF1/4Tu5PsxM+mzuHubNjwT/z0T+6+O/fv2rFuFwTVeutM1lBTVmfRljqOn6vp63+mT5sLhgHYcNazZ4Yjtk9e2fYmq+t6O95FJfWCrFqMJCXUGCVfHI4HJ9VI57A5rxbwjr914e1Iz2u14pRsmt5OY51PVWHv69q92027F1aW1/pheZXh3Qqx+aaIfeib1dD0P8Aiae2qPPqQlSl5GFpmsea3l3oZZ4gCXB+dAejZ43If734MAc12+l6orKsd8BIh+7Oo4/H0rmtV0m21CGLULKTYrNuWVeDDIeP++WPBHY1m273do5jy0UyNgouAC3+zngE/wB0/K3Yg0NJhZTR6RqOhaXqyBryztrnj5XkQMR9G6j8DWRf+EZvssn9h61qemXYyYiLySSEt2DIxPH0qLw9romwgZUnyR5fISTHXbnkN6qeR79a6y2uY7hcocMOqnqKhSlB6HNUp9z5t1zx38RdD1SXTNW1Sezu4jkr9nhIdezKxQ7lOOCKq/8ACxPGsybW8QXPI6rHEp/RBX0N4v8AC2l+LNM+xavDkpkwXCcSwMe6n+Y6Gvnbxh4O1bwZeBdQUXGnyNtgvox+7f2YfwN7H8M1sqra0NqKoy92UdShdX2q6pj+1NVvrsYxiadmH5E4p9nZxRn5V/DFNtVDAEVrWkQyMisJ1JPdndGMIfCrE1rGzYCjAresLUKAW61Ws0AxxWvCMAVyTkTKZZiUAcCrcaiqqMB3qZZRjg81izIupErdQDUy2sbdQKhtSSOa0IxUNkttFY6bGxyBzThptaMQqzGPaocmLnZlJpoA4Wqmp+E7XU0X7ZbRTlR8pdeV9geuPauoRRVmMUvaSWqF7WSODk8OEW72zQo9syeW0RHylfTFUdK8A20F1HKFuJPLYMiTSblB7EjHPqM16eqKeoFTxoo6AU/rEkrIv6zJHIahayaG9rqsPL25zIP78Z++D+HP1ArvEZXRXjO5GAZT6g9Kw/EsQl0edcZ+Uj9KueG5BL4c0pw+/NrEC3qQoB/UGuvCzcoO/Q46ju7nJ+MI18P+M9M8RqAmnaqE0jVSBwkmf9FnbA7HMZYnhWWuh2FWKsCCDgg9jVvxJott4k8P6jot9j7PfwNAzEA7CfuuAe6sFYe4rmvAmqz614Ws59Q41S2Z7DUEJBK3UJ2SZx3OA3/Aq9SEuaHoeXiIck79zdAoqQDiimYHzx8NNK/tj4j+HraSPfb2sj6nNyeBAv7vPYgyMnX096+nOvXrXhv7PdtHN4s8TXhT97Z2FraK+e0rvKeP+AL+Ve50sZK9S3Y9HDrRsyfFI36Fc24+9dlLUf8AbRgp/QmvN/Gc63fxOvFT/VaVp8Noox91pMyH9Clekav+81PQ7cclrlpiPZI25/76Za8lllM/i/xdc794fVHiVvaNVTH4YI/CuSppSZ2Ydc1T0NKM1ZQ1RjNW4zXkzR1TRYpjjIpw6UGsjAoTr1rMuU61tTLms24TrWsGXFnP3cfWsO9j61010nWsW9j61105HRBnMXScms9hg1tXcfJrJnXBrug7nVFkVen/AAb1mSW5utDll27x9qtWP/LOVeuPYjqK8wq7oWqNoeuafqqgkWkyvIo/ij6OP++Sa0WuhnXhzwaPoeGdLS8kldB9juyUu4T0jk6Fvx6H8D61JfaWt03kM3+kRqWikYZ82LPII/ixwGH0I60urRJDdeehV4Jgu/P3XQgbX/IgH2+lXdKthdx/ZJJnjuLY74ZByyjoGGeuPusO44PWpTueY24+8jmLvTpYrhyqlZ1ALxsdwdezZ/jX0b7y9DW1p+oSxgeZ5jomMsPmkj+v95ffrWnLa/bfMtroeRqEI80Knp08yI90PQjqM4bsTzVwJ7G9AnbyVY4S4A+WNj6j+4f0NVvoNVVJHcWGoieIOrrNEf40NXbiC3vrOW3uoori1mXbJFIoZXHoRXHWsqy3D7W+waog/eLjKSD1I/iX3HIrYsL6SOVYLoeRcv8AcUnMc3+43f6Hms2uxM4LqeY+Mvhbd6VJLf8AhUPeWH3msCczQj/YP8a+33h71x2nXKSjg4YHBB4IPoRX01DMJP8AZcdq5Txn4E0/xGz3cJFjq+OLlF+WT2kUfe+vX60naW5cK8oaS1R5RDcrHUsmpkDCVXvtOvdGv/sGt25t7g5KNnMcw/vI3Rh+o7gVYs7FXcE8iueUeV6ndBwkuZD7WeeZh1xW/YwnaC1RQRRQrwBUj3ioPlrGTvsTJ82yNdCqDmkS7BkCrWL9sab5VzWtploQQ79azatuQ48q1NqDlQatxiq0YwKk89UOM1i9TDcux9qsJVa3beuatoKhksmSpVqNKlWoZJU1n/jwkrN8K3sWn+DdDLAsk0q2ynPQvIwB+maueJJfK0mdvRSa43xvqa+GfBPhEqAA15bEhu3G4n8Ca9PL48yaMqt7Kx6ca4W1jOlfFLW7LDC112yj1aHoFFxCfJnA92Uxua7t8bzjpniuJ+Iyiy1TwXriplrLWUs5WzgLBdIYXz7Z2V30X71u5zYmPNC/Y6QCipShUlSOQcGitbnnHkf7OnGqeOB33acfw8qWvaa8T/Z+PleJvFMeR/pFlZzgf7jyR/1r2ypxf8V/L8j08N8HzZnbQ/iyxyMmO0lYH03SRj+leJ6Oys2qSJ92TVLyRfoZ2r3C1+bxQTgYjtUXP1kJ/pXg3hfK6TsYEMtxcBgex81s1zVv4f3fqd+DV6j9DfjNWozVGM1ajavNmjrmi6hqSoIzUwrnaORqwyUZFULhetaLDIrN1W6isYY5bjd5bypDuUZ2ljgE+gz396cLt2QIzLpOtY95Hwa6K6jIJB7dax7tOtdMGbQZy95H1rGuU5NdNex9aw7uPk13U5HVBmQeDSEBgQ3IIwaklGDUeRu24IOMn3roRqe8/DXVV8QeArW2ncNeaZ/oMwJ5KAfIfxXj8K1v7Wis9SsLKW4EOquxSIspxIyj16fMuODXkfwm1P8As7xXJExIjvIChHYlTkV7LpviTTv7WXSrkSpeXDBUZbdnUjoCzgYXuOaiV4yv3PKkuWbha6R1K+VrFmvmB4LmB+q48y2lx1Un1B+jKcHIrDS8s9Uur7S3ubOTVrI7bmGM5U5H3tp52kcFedpyPQnFtNSmtLzXdfdtat004BLm0vrfbFPCCcGFhnODkqffB4NdVdQ22p2Fvrel2aPqIiFxamQeS77l+457ZHUHuB6U9jDk5XqciIbiO++zXkYm0sSeVb3EMv8ApNjNjIjJ7j+6T1GBz0rYg1BI0FnrYins5WCLcKNqM3YN/wA839OxPQg8VS0XRBaNfazf6fHb3uo/8hKzExcGInhsZ4KnnI98HphviaefSRawrpt7qlxdSeRDJAivHcoRyk4JA3Yzz/FgH+8KvSRbfvcvQv2OrXkWuXOl3VhfywW5HlagUwsoIBC7uhcZx2z9evXWtzFdRF4H3BTtYHhlPow6g1xVrNc6Q00Uiyy6WnySxSZd7QY6N1Lx478leuSvKxwabfDxlDew6z5NnJAI7UFd/muOfLlbowK8q3Uj3B3S43JnZHa6np9nqti9nqNvHc2z8lHHQ+oPUH3HNea694JvtFZrnQjLf2A5a3Y5njHt/fH6/WvSrG8+0+ZHJH5N3CQJYSc7c9GB7qex/DqCKtfTis2ujJhNrWJ4XBdJdrmJ+ehHcH0IqUwseteleJvB9jrchuoibLUv+fiIcSf9dF/i+vX3rgb+3vtDmEGt2/lqTiO4T5opPo3Y+xwawnTa1idtPEJ6PRljS7JQQzVvK6RJknArnmuxHHujIIqlJqE9w21cgVzOLka8jnqdLPqI+7GcmptPiedgz5rO0WxLYeU5NdRAqRJxgAVnK0dEZzajoi1AgVQKsAhRzVCS9iiXlhWfNqLTnZFWXK2ZKDZrT3uG2p1rQs2ZowW61labZkkPL1qXWNVh0y1JJzIflVV5LE9AB3NLlu+VClZaIoeLHa9e20m3b99eSCLP91erN+CgmvMf2m9RR73QtGhOEt4mupAP4QSFT9FavWNJs10iG71/xDMsUywM0m4/Law9SPdjgZ/AD3+ZfGesS+JtW1fW51ZBck+TG3WOIDCL+X6k17WEh7FK5lTj7SemyPryGRZoIZYzlJI1dT6gqCK5T4u2bX3wx8SLE2yWC1+2xt6NAwlB/wDHD+dbPhMY8JaCCSxGm2vJ6n9ylWtXtFv9G1Kyddy3NpNCRjOd0bDH61cXyzT7M55Lmp/II7lL6GG8hYNHdRpcKw6EOoYH9aKwPhnci9+GvhOdeh0u3jP1jQRn9UordqzseUeW/BAtH8Tbj95hJ9DlXZ6slxGQfyZq99r5y+GMxt/ir4ZIU4uI722Y9hmDcufxU19GUYxe+vQ9HDbNGdayKviueIn5ntIpR9BIyn+YrxDTMrPrEZBVo9VvFKnt++Y/yNezXGIvGli563OnzRD2KSI38m/SvJtUhNp478X2pIOb9bpcf3ZY1YCuWprTfy/yPQwbtV9V/kTIasxmqaGrEZrgkj0JovRmrK5wCQcHpVKM1RsBLbeLL+I3DyQXlsLwRvg+W6uIyF/2duOK53G9zllG5u1heNEH/CM6gzLuEapIRjP3XU5/StykcZB+mDmohLlkpdjKLs0zldUu/tXiLRBYzLLayrcTuUbIZdgCk+2T+dF3GxVhGAXx8oY4GfeoNMtLK08Xa0ttFFbqscMaRqcDcw3ttHbPHAp/iK5e0t1jtub65byrdf8Aa7sfYDmuq2sYx7f8H9Ta1mkv66mDDI13p8c0ibJCSGX0IJB/lWXeR9a6NbJLKzitoiSkS7dx6sepJ+pyayL2PrxXRCSvobxkr6HN3CcmqknygOei8N9D/wDXxWpdJyaymQGaQOCcHIBPGD0rsgzojqaXh6YW/iTSpGbapuVjY+gY7f5kV6xqsmo20Fxc6XMIb+3G/wCYZWRR95G9iM14x55tZIrlRloJUlA9SrA/0r3nU4A93cxNkJKGQkdQCMf1qKrsos8/EpKpd9i/YX0OqQaBrs+papZRQxJcLbQXGyJskMRKAPnHGMdMV0M+txPNa3dvMk1pdR5EiNlWHYg15ZoE11ph/wCEf1LDPBFvtplHyTwg4/Bh3FSaFFDout3mlo7R2lxGt5ZRMTsBGRKqk8e+PSk5XkzCVLSy6beh6TojaXdeNdUnXRb2LVI7ZY5dSmRhDcRnA2Rndg9u3Y1tmCL7LcabcIHiKFoskjcvbnqGU45HI4NedaZr+r/YLm+sIDLpVtbvJCjj95cSDsn+yuDz1OcdqtXXjs3OnaVqdnAs+lSSGO4mTJe3cgBMjsCTg5pwuyJ05S2/ryOk0OPxDNphXXRbpq8aHyru1bcrp/zzk4HzDnkDB6jHIMMdsi2nlbQbSVxFJGDjyZc8FcfdBOCP7rYxweOV8dX9yNOhu7OSeLVbO6iFm0TEZkd1Uow6MpGQQa60zC31K4M6ZtZ1IlTqAOh/Cq5rq6Jl7vvd/wCvuLYlkulMEzNHrltGxt5xhTMP5EHgMp4zzxwaq2Wp+JdW0LyltLPQ/EW7LR3YMsZiBwXTHXtx2z9Klgv9N1K+k0hb+KTV7NRPE4Pz7ezH1I6N69e/GnNnVNNkwpi1G33NHtba0UwBwQfQ9PQgkEEU/Uj4dUi3pYvVsIBqrW73oX961uCIyfYHmrEqJLE8UqJJE4wyOoZWHuDXLeC9Z1+7jdfGWnW+lXkrJ9mjj4Vxj5gTuOGz/D1HvUur+IbDTBZTaxqs1iuoXBgs4YlAJw23c3BOMkEk8AEVPK7ltXbW5maz4BhYtLoE4s3JybabLQn/AHT1T9R7Vy1zaXuinGsafLbrnAmX54j/AMDHH54r1Zob+3YiO5juQOClwuxv++1GP/HaaNSjjPl3sclmzcfvRmNvo4+U/jiolBS3LhVnHSLuee2eoRPAPIkUj2NJNfT8hTXbX/hXRdQPmvZJG7f8tbVzET+KnBrLPgOz58rUtSTPQMyMB/47mud4ddGaxxC6o5mGK4uW+ZuPc10OlwQWyhpXGRUh8H21rGTcazejPC4VBz7DBJ+lQp4JW4XN1qmp+QDudnZISV9MKPlHuT+FDwrl1VvmTPFJ6JEs+szXly9hoUBu7tQN+DtSIHoXfoo/MnsDU/2bS/Ctm2ueKdSg85ePtMowkZP8EKcsze4yx9hxXH+KfinpHhq3/sbwVaQX9zF8vmc/ZIT3JIOZW9cH6ntXj2q3uo69qP8AaGv3st9d9FaQ/LGP7qKOFHsK3p0YUVd/8H/gGcYTqvsjqfiR4/ufG0i2Gnxy2fh6Ng/lycS3bjo0mOijsn4nJxji9SQLpswH9w/yq2i4HAqDVht02cn+4f5Uvac00uh6VGgoRsj6v8L8+F9Fx0+wwf8Aota2LUA3MQPQsB+tZPhqJ4PDOixTDEsdhbo49CIlB/WtSJxHIsjHAT5z9Bz/AErSXxM8feJwXwT/AOSQ+FP+vV//AEdJRU3wViZPhH4TDDn7GzfgZZCP50V11PjfqeMtjxPR7ttN8T+Gb5X2Jb6xbeacZ/duTG/6Oa+oWUqxVuoODXyZrkTyaHfiJnSRYTKjIcEMhEgx+KCvqnTNQj1fS7HU4P8AVX1vHdIM54kQN/WnjFsz0cO/eaKGu5h1LQLofcS9Nu/0ljZR/wCPBa81+Jloq/ERg/mLHqOlRsWjYod0UjDhhznBWvT/ABNG8mg3jRDMsCi5j/3o2Dj/ANBxXEfGGJSvhnXYeYY7hrZ3HaOdQVJ9tyj864942/rud9B8tSLOAuUuNPuLKaO9uZ4nnWCWKdw24OcAjAGCDzW6hwaz9RskvrVreV3jBYMHT7ykHIIpuh3NxNHcQXrK9zay+U8ijAkGAQ2OxweRXJJc0bnryV0bkZrM1F3Txj4aMYIEkV3HKR3XYpAPtnn61fjNZ+rz/Zdb8PXBI2PPLaMD/wBNEBBH0KCsIr3vk/yZyyR0qnIpTyKYhqSuRnMzm/Enhq31SG6lgQRanKFZJ9xB3KMKPYcYrIvZjeabomtKQstvIqTR/wC+RFIv1DV27juK4GTTriTxTeaZFuGmLcJqMzH1I3BB9W/lXXRm5K0nt+WzX+RtTd93t/wxp3keGYelYl7H1rpbtdxYnqeaxryPg1VORUGcpqOIY3kfO1Rk4rHeNi5kdQpIwoB6Drz710t/CHVkb7rDB+hrAQE2yhzl0yjexBx/hXoU37p1wehSuQTbS467SR9a+h4nW7tbO6DBxPBHJuHQ5QHNfPxHJBr2z4b3I1DwLphLZktQ1o/tsbj/AMdK1c1eJxY5WcZFXxRb6guoaffaZBHdG3WRJYGkCMysB90njPFUoHg8YSadaQm5tHtpZHnO3EtuwXG0/U8H1rqrtcvis63ktPD/AIqlvL1kgtNUtAGmbO0Txtzk9BlCPyrng7uxjGfu6LVbHYaTZQWcFrbWyCK3hCoig/dA965TwrZQ6v4O8R2AQW2qSvcR3sJG0QzYOzCjoowuPpXc2yLJCjxsrxuoZGU5DA9CD3Fcx4qjXwxrA8XQITayx/ZdViTq6/wSD/a/h/EVvCPc56cm3yrd/p/X3nN2mof8JbH4ej0yO4e7W7tru9cRkRweVy4ZjxnPQD2r1KSIG5U4/iqj4J0+TTPCWnW1ynlTFDK8Wf8AVlyWC/UAgH3zWxkeYp9DmlKKjohVqicrR2Rwug26TpdXrpGL601KeGK4VcEhGxg+2Dj8K39M12G61u4tU+TU7WFJZoT/AMtYmONw9cEfqKzvD4kSTXNHuI1S4tL2S6Qqc+bDcO0iP+GSp+lZ+oFNP8a+Hr2SNTJFbXXmsDhxFmMAn1UFm6+9K/valqKba/ruemwtFcKhwrpuDYIzgg/zryW8vLT+1rjQ7/Vbu/0/WpEsLu3azfbpTFAsbRzfdBMgUlQOnJ5GT6lBDsmWWBwEb7y9iPauR8bHyPBsLkBYNN1y3lk3HHyC55Yep+cfrVQsFN2e2+n9ehqeCtR1XUU1D+1RbLFBJHFbiMkybRGuS5756/nXSnlSDyDwQehrl/h2xudEmv8AaFju590RH8SKirn6bg+PpXUf/rqCqySm0Uv7LtQ2YFltmJ5+zSNGD9QOP0qjNHJcztFZXl7NsJWSRpQIkPcZCgsw9AeO5qwZH1ONmjk8jTBndNu2tOB1Kn+FP9rqe2ByfNPHHxatNOjbS/BiRXFwg8v7WB+5g/3B/Ef0+tWkzNXudfrmq+HfANm15qlw73soyiF/MuJz6IpPyj34HvXhnjTxzrfjOVo7hzYaRn5LGFuGHrI3Vz+ntXNzGe9vZb3UbiW7vZTukmlbczH61KoqZVbbb9zelQS1Y2GFI1CooAHpVhRSKKlRa5pSvuejTpiotV9YiMtmIVOGmZYwfQsQP61fRauaDaDUPGnhyyI3LJfRswxwVU7j+gpUXeojqqR9nRlLyPqMJ5SrH/cUJ+QxWZ4ovf7M8K65fgZNrp9zOB67YmP9K1HOWJ9TmuL+MLyN8PdQsLeVY7rVZrfS4SxxlpplUgf8A3/gDXXTXNNI+YqPlpv0NzwJaNZeA/C9rKnlyw6Vao6ejeUpb9SaK6GVESQpEAsafIgHZRwB+QorZu7ueSfK8QAdSwBXPIIzkV7B8DL43Pw5tbKWQyT6Rcz6ZIx64jfKf+OOo/CvIVWu2+C1+bPxnrGlOzeVqlml/FkjaJoT5cgA9SjIx9l9q68RHmps66cuWaZ7MMHhxlTwR6iuJm0eXXPh1q/hqc/6dZiSyjfpl4yHt3/FfL/Wu3rHlBsPE8NyMCDUoxbSH0njy0R/FS6/UKK82LsegzxfSLz7fpltdYw0iDev91hwR+eaz7W5TRtRvxqO6GC7m86K5OShO0AqcdDx3roNf08aF431fTlG21u8alaDsFc4kUfRwfzFRg4BHY9R61hNKEmujPZpTVSCkTW00c8SywSJLE3R0YMD+Iql4rtpLrw/O1uN1xasl3GPUxnJH5ZqlJDHpGp291aKIrS7lEF1EowgZvuSAdjng+ua6OJip9xWD9ySkiJx6lq0uI7q3huIWDRTIJFI7gjNWh0rl7QvoF/HaqgOjXk22Db1tJW52H1RjnHoTXTKa5KkOV6bHJUjZjiMisOIH/hJNXHpbWp/9GVu1gXUq2vjCJZG2x6hYiNMjgyxyEgZ9drniinrdeX6pkx6jrlOtZF1H1rfuE68VlXSdeK0gy4s5q9i68Vzk8ey9uFI/wBYBID644P9K6+8j61zN8obVVTp5cBb65OP0xXfRludVNmTKuDXbfCTWlsdXn0m4bbBqGHhJ6CZR0/4EP5CuPuUxmqQkkULNASksbCSJu4ZeQfzFdUdR1qftabR9C3uUlzVuxljmj8qVI5I26o6hlP4Gsxbsano9jfqMC6t0nxjH3lBP60mmyFZcZrik3Cdjybc0S/Z2GraBdxxeHLYahpE5ObKe5Ef2N+xjYgnYf7vOO1Q2M174y1CJdSsltdI0u5Zp4xJ5i3VyhwqBhwUQ5J9TgV1GmTAPGx5AINYvgKN7PQJNMlC+bpt1NauynIc7t+73JDjJ9a61LS5PPo3bXudS85Ykk5JpVOaqE81ZhHFZ3uYHP8AjKwSO0uPEFrctZanptsz+cBlZYl+YxyL/EODj0zVXw1pYi0uPV9Wi36zqsQkuSxJ8uNhlIlB+6ApHA7mpPiXmbwlNp8cpjl1O6ttPQjqfMlG4D/gKt+VaPijUrTRtInvrrzDaWoVFSMZdzkKiKO5JwPzPanfSxvGT5VHuaHhK4lME9lcf6y1fYp/vR/wn8qdrWkx6/omuaVK/lxXc3ls4GSmNhyB6jH51h+CjqMWoRy6wY47q/DsbZG3C3APCbu5AIyfWur0Y+ZaPMMkT3Esgz6FyB+gFPbVFbPRlu3gitreG2tYxFbwxrFFGvREUYUfgBWZfTwXEMs11MkOjW4Mk8zthZcds/3B3/vHjp1my2pyPHGStip2Oynmc91HovYnv06V4N8Z/GMmuaxL4f0yXbo9kwSbyzhZpB1HH8I6U4rqxJNuxU+I/wARbzxhLJp+ll7Pw6pxtHyyXWP4n9F9F/OuMhiWNQqAAD0oRQoAHSpVFROd9FsdNOFthVFSKKFFSotYNnbTgCLVhFpI1qdFrGUj0aNIVFrq/gzZC++JD3RGY9Nsnk+juQi/oWrlmISMse1es/AHS/s/ha91eRcS6pckoT1MUfyr/wCPbq1wy1cjLNZ+zo8nc9Nrj/EwGr/EXwboa7HjsWl8Q3ak8qsQMUB/GR2/75rslUswVRkk4H1rkvh0f7Z1jxT4r3F7e+uxpunMSrKbS1ym9COcPKZG/wCAiu6it5dj5LFztHl7nb4zRTgKKo4D5aVacmoPoOp6V4hiUs2kXInlVVyWtnGydR/wA59ttPUVIER1KSoJImBV0boykYIP1HFej6mx9H5RgGidZI2AZHU5DKeQQfQjBqlrNidR0ya3jk8qc4eCX/nnKp3I34MB+Fcb8F9Wa68LSaHdSF77QHWzLHrJbEbreTpj7nyfWP3rv68mcXTk12PQpy54pnm/xOh/tXwjYeKLWEreaUxlniXkiInbPGf90jd/wGuBtL4DVLizuJQRKwnsnYACSJlGVU9ypz7817TEq6frktncKslhqoYqr/d8zGHQ/wC8v8vevG9T0KLS9T1DwrfqZILbE9jIxwzWzHKMp/vIcqT6rU1Ipq/9f0j0MFUs3TfyLN5axX1nLa3A/dyDGR1UjoR7g81HoF+8i/YdQkA1OD5XDcGVezr6gj0qnp91PaX507UZXldxutbhwB5qgcqcfxD9a07qxtL9FW9t45gv3SeGX6MORXLJWXK9juku5d1GxGpafNZM7RtIBsdeCjg5Vh9CBUvh2+k1DRrS5nG24dNso/6aKSrfqDWGh1XRMeQk2saavRN3+lQD2/56D9aXwpqVnJq99a6bcLNZXC/boQAQ0Lk4ljYHkc4bHvWMqbcHbVb/ANf10OacdGjrqyfFFg99pD/ZwDeWzLc2xxyJEOcD6gEfjWqpyKWuWMnFpo5k7O5mQ3UGo2kV5aMHgmXepHb1B9weCKpXSdeKW58PxR3M11pN1caZcysXfyvnhdj3aNuPyxVe0vWuJpbO9RINTgGZIlJKuvaRCeqn9OhrZJbw2LS6oz7uPrXL67asyCeFWM8PK7erDPI/LNdldJ1rntYkaHy0hQvPMSsY7DAySfpXVQk09Dem9TlryeKRCsHzySD5VA6A9z6VUmARGBPAXk/hWutmLWDZnc5JLtjqaytTXFpP/uN/Ku6LTdkdXMktD3Hw3Gw8F6CHBVvsEOQe3y06IbJvStO2QDRtPCkEC0gAI6EeWvNUXGJK5K699s8Sm9Czq+qy2NpZ21rKlvc6hN9nS5flbcYyz47tj7o9a6HStPtdK09bWwVxDuLl5G3PIx6uzd2NZCR2lxp80epJE9ntLSeZ0UAfez2I9ad4Ilnl8K2T3G853+UX+80QYhCfwxWsX7pM/h07m+vJq7AMgADJrPQ/NXPfEDUnjXQ9Cjma1GuXXkT3I4McC4Lqp7M2QM+madNXZlGPM0iv8Q/EGmWb6TEt6k+o2upwXYtLb97KwUOCNq9OHPWqItb7xFex6v4ggubGwtnWTT9KkbGGA/10wH8WegPT+faQWdlpkYh0yzt7SNPlAhjCn05PU1Tv/miOaiU7aI3jNJJRXzKlhOYr22ujn91DcEHtnCn+ldYI2FraaVCxRhComcHlEAwfxJyPzNcVdl4Lax8sFme5RSoGSVLoG/Q11et6va+E/Dd9rOp/MU+dlz800h4SMfoPYZNXBPlQNo5T4x+Nf+EX0qLRtGZU1a8jIUp/y7Q9N31PIH4mvn+3hWOPacnPU5IJ/Hrn3qzqF/ea3q13q2qv5l7dPvf0UdlHoAOBTVFOpK3uo2pw7nNXms3miXxtr5BeW5XdFLkI7L2yRwT2ORnitrTdZ0/UCFguFWT/AJ5y/I34dj+BpNc0pdW08wjAnT5oWPZu4+h4/IVxOkaVJI73d5aTvp9rJtuQnDj1GDycd8dB6da6oU6Nem5PSS/Htp5/LU55Tr4aqopc0X36d9fL56HpgXnBGKmjWorJoZ7aKW0ZHtmGI2ThcDjA9Meh5FXEWvIm7aH0tCnezQqLUyikUU5iFBJ6CsW7npQhZFW9invZbbTrEZu72VbeIf7THH6da+o9J06DR9KstNsxi3s4VgT3CjGfxOT+NeN/A7QTqevXXiW6jJtbHNvZlhw0xHzuP91Tj6t7V7fXowhyQUT5jMa/tqztstDm/iHq1zpPhS5/sth/bGoSJpmmgttJuZzsUg/7I3P/AMAro/D+j23h/QtO0exJa10+3S2jYgAvtGCxxxljlj7muUs4/wDhIfii0+WbTfCcJiTBIV9RuF+b2by4cDHUM9d4BXVblio/M+brz55vyDFFPxRUmJ8uqtSKtCipVWvSNx2nau/hbX7LxGis1tAptdTjQZL2bsCWAwcmNsOMdRkZxX0GjI6K8UiSROodJEOVdSMhge4IINfP6DB6BgeCGGQR3BHpXX/CXXv7OuY/B+oSMYyry6JM77i8Q5e2Oed0ecr1yh7YArlxFPmXMt0bUanJKz2Z6PqthHqVk9vIzRtkPHKv3onByrD3BrjvFejXPi/R0e1RIfFmjSEIrHakpbG6Ik/wSDlT2bHvXeVlazbXCSx6npiGS9gXbJAP+XqLqU/3xyUPrkdGrji+h2Ntao8Kn/4nelpJZgwXkEwdUmXDQzIcNG46g9Qa0dJvk1GyS5RDGSSkkbHJjcHDKfoa6zxvoC6rFH4w8HR/a5pU3XtrCMG9iH8ar/z3ToR1YAjqBnz3zBhdc0JmuoJyGubeM8TLjG5Qekg9O9Y1KfRf15Hr0K3to67o6iNulVNR02SW8h1PS/Ih1WHIy64S5Q9Y5CP0bt/J1hdwXtslxaSCSF87Wxj6gjsfar8ZrileLFNWF0fUo9SgkZY3guIXMU9vIfnhf0PqD1BHUVo1zF1fW+j+JmubwmG2vbRUM2CV8yNv4sdPlPWuhtLmC8tkuLSaOeB/uyRnINY1IW95LRnLONtUOkGRWJrulpqMcZErW95Axa3uk+9E39VPcVvHkVWnXg1EJOLuiYtp3Ry1jdtfW8i3CrFf27eVdQj+Bx3H+yeoNZWqJ/xNNO9CJv8A0AVta5p85u4tR0xUN/EpjaJuBcx/3CezD+E/hWJHcDVtQhurdJUtLaN1PmrtYytgFcf7IHPvXbTt8a2/L+uh0wtujOvY+TWHfQ745EPRlINdRex8GsO7TrXTTkbQZ694K1Eat4M0q4JHmpCLeUDs8fyn9AD+NTzjD1wfwl1T7Pqd9osrYjux9pt/+uijDqPquD/wGvQLpcEmrxC1v3PLcPZzcSj4iEh8OTMkbzRRyRyXESfekhDfOB+H8q6+3uYrq1hntnV4JUDRsvQqRxWLpkvzDHWm+FZIB/a1rZEG0gvCYtp+VQ6hio9gc1mn7pE1deh0cXWsX4kWFhfeCtRfU9yLZRtdQyocPHIo+XafckDHfIrahHNYHjtIZrzwzYX5JtLi/YzWxfb5wWJmjDL3UOAfSrp6akUvjTRe0e4urjQ9Nl1EAXsltG8w/wBsqM/41LMpkGKllJZyT1qaNo7e2luZwTHEu4gdW9APcnisYrmkK+tw0S3366oC5FrBjOOjSEHH5Kprxb4x+KD4m8UnT7STdpOlsUXB4lm/if8ADoPofWvUPHmqT+D/AIeX12rY1e+fygwP3ZZOpHsqg4+gr54tIRFEq8k9yeprqvyRub048zv2JVWpVFIoqVRXM2d9OAKKmhQIcoApLFjtGMk9T9fekRasItZSkd9Glcy5tOuLW7a+0YAyOcz2LNtin9SvZX/z7HQ0m/t9Sgd7YsHiIWaFxteFv7rD8Dz049eKtqtQyWML6lDf/Ol1GpQshx5qkfdf+8B1H0pSqKatPfo/0f8AWnmjsp4eVKXNT2e6/VdvNbPyertVAtrd6xqdpo2ljde3j+Wvog/ic+wGTTb66S1hLueegA5JPoK9q+EXguTw9p8mq6xEBrt8vKN1tYeoj/3j1b8B2q8PSu+eWyMcyxioQ5I/EztNC0q10LRrLStPXba2kYjTPVvVj7k5J+tVvFuup4a8PXeqGL7RcR4jtbYDJublztiiAHJ3MRnHYE9q1wCSABk1yOmIPFvxAe9Pz6D4WlaC3BGUudTIxJJgnkQqQqnH32JBrupx5pXex8hiKns4abs3/Afh1/C/hi1066mFzqLM9zqFz1M91I26V84GRuO0EjOFFdEBQBTgKuT5ndnmABRTgKKQHzEoqRRQoqVVr0TcFWo76yjv7UwSvLEQ6yxTwttlt5VOUljbqGU9xjuO9WVFSKtK4j0L4eeLZdcSXStbMaeI7OMPLsG1LyLoLiIeh/iUfdbsBwOyrwe7s2uDbTWty9lqVnJ51lfR/ftpPX/aRujIeGH4V6n4D8VL4o02f7RAtlrViwh1GyByInIyrp6xOOVP4ZOMnir0be9HY66FX7Eizdo2h3s+qWqsdOmJkvreMEmN/wDn4jA7/wB9R1+8OQd3HeOvCEiTS+KPB8a3DXA8++0+AgreKRn7RBjjzcclRw/UfN9700cHI61gTwy+HpnvNNSSTS2bfc2MS5MJJyZYQPflkHXqOcg4J30Z0xbg+aJ4pp/ns82oaI1hcWN2RKEZmjOcYbkAgHPtVv8At2WzYnV9NmtIAf8Aj5ibz4h/vEAFfxFdz4p8Gx6i7eIvBBtzf3B8y4tRIEt9Qz1YHpHL78A9+ea5HTr2DUY54mjKyxkxXVpcJh4m6FHQ/wD6q560LatXX4npU68aqs9GbMEmVBUgowyO4IrKtPK0PXJLYhYNN1Ih7c4wiXA4aP8A2dwwR2JFZru/hYQtGzTaE8mxo2y0loTkgqRyycdDyKuXU95rtlPa2WmILKQBTPqJaIN/tIgG446gnFcnJb/C/wCvvE4fczpz1qKUcVlWR8Q21ukNxb6XfsigCZbp4S2P7wZDz7iqVx4i1CznjXVfDlxa2zSCNrlLlZkTJwG4HTp1xWKpSb92z+a/4cw5XeyNOdcHI6jmuUt0+x6te6crM0DL9riDcmPcx3Ln0zyPrXZTr+NcvHGJfEeqTgf6qOK3B7E8s36kCtKL0f8AXU0pvRlO8j61g3kfWuouk61gamY4BundIwem4gZrppM3gzAaaexu7e9tDtubWQTRn3Hb8ele5Wl7Bq+lWuoWuPJuYxIB/dPdfwORXhsshnk/cKTCPvSEYB9hXefCLUSYtR0WU8RH7VB7KThx+eDXbJc0LPoY4yna1T5HS6yzR6NdEM6ruQSFDg7C4Dc/SuvsbaG1hWG2iSKJeiqMVz19ZteWV3axuiSSxlUZx8obqM+2a2fDuoHU7aQzQm2vrZ/Ju7YnJifsQe6sOQe4rngtDiqaxKF22p3/AIrudKg1htLtIrWK4UW0KtPKGLBiHb7uCOwPap9L8K6NpFybu3tnuNRJJa+vJDNOxPBO49PwAqxripBrPh++XaJjcNYtzy8cqk4/BlDVpS9aubaVkQ5NJJbDFXcwFWreH7TqsMAP7m0AmmHYyH7g/DlvyqIOltBJcS/dQcDuT2H4mtjQbFrSzVZv+PiZjLM3+0f8BgfhRCNlclHkf7RmoBpfD+kIx3ZkvJAD2+6uf/Hq8qUVr+ONa/4SbxxqmpI2bZH+z23/AFzTgH8Tk/jWYoorO1o9j0MPT90VRUqLSItWI1rmkz06VO4sa1Oi0iLUoGKwkz06VOwAYqG7uY7WFpJWCqozzTb28itYy0jYPYdzXpHwz+HE811Br3i63MYjIks9NlHIPaSYe3UJ+J9K2o0HP3pbGONxsMNHTWXREvwl8BO8sHiXxJARLxJYWcg/1Y6iVx/e7gdutevnnr1oJJJJOSe9ZniTXLHw5o0+p6mZDDGVRIoV3y3ErHCRRr/E7HgD6k8Amu1LmaUUfKVark3UqMzPGurXsIstB8PNjxHrJaK2fGRZwj/XXb8gAID8oJ+ZiAM4IrqPDmi2Ph3QbDRtJjMdhZRCKJTjJ7lmx1ZiSxPqTWJ4C8P31j9s1vxKI28T6rtNyqNvSyhX/V2kZ6BU6sR95iSS2Aa68Ct3aK5EePVqOpLmYAU4CgCnAVBmAFFKKKAPmdVqRVoUVKq16JuCrUqrQq1IopCBVqKaG9g1C11fQrhLXXLNSkUkn+quIictbzDvG3Y/wnkYPItKKlUUhHovhDxNZ+KdMkubWOS2urd/JvbCY/vbSX+63qDyVbow9wQNwHH1rxae0uU1K31fRbsafrtsnlx3LLujni7wzp/HGfzU4I6Cu88HeNbfXbs6VqNsdK8RRruexkfck64/1lu/SRPb7w5BHGa4qtC3vR2OyjXv7szTu9PmsbqTUNEjDPIc3NlkKlx/tL2WT36N39axfEOgaT45iTULC6ew1y2Xy0u1TEsfrFcRnG5Qex5HY+vZ1m6npQubpL6zm+x6pGu1bkJuDr/ckX+Nf1HYislLudO2qPJZLi+0PUU07xHCtjevxDcRsTb3P/XN+x/2TzWqhOfm6129zcWupwHRfFumwxNcfKscp8y3uT6xPxhv9k4Yds9a5DVPBesaAWk8PF9Y0sc/YJ5ALqEekbniQf7LYPua5a2F5tYb9v8AI3jXvpMRTUd3bx3dpNbXCloZkKOoOMg+9UtJ1a01F5IoHdLqLiW1nQxzRn0ZDyK0682UZQlZ6Mr0MFdHurRESy1zUFjQbQlwkc4/VQRWDMbvw/qarevFc6bqNx/rlj8s28p9RyMH/Hp0ruZBxWL4htYrrRtQhuF3RGB2I75VSwI9wQK2pVbu0tmXGb6mLr13Hp0BeTBnb5YYf4pG7AD0z1rEi0yOCIS3EYlvXG6WWT5m3egz0HsK1fD9jGNNg1OSUXl9dRK0t0Tuxx9xf7oHQj1Bp12mc10KXJ7qN07aI5i9UnOam8D3X2DxtpjHO24LWrY/2hx+tSXsfWqmiof+Es8PhRk/2hFwPTPP6V2UXd2HW1pS9D2OdjHN+NR67bRrp0+uW9zcWOpWUBKzwc+co6RyJ0dcnA7jNS32PM/Gq3iS5VPD5sEw15qDJbQR9yS4y30Ayc1nB2kecr3VjV8PaVcFodX16UXGrPHlEAxFagj7qD+9jq1bgTe4AoYjcVToOB9KJjKWSysn239wpIfGfIjzhpD/ACUdz7A1rbmMXJydyWxgW+1DdjdaWTYBzxJP3x6hOn+8fasP4x+Kv+Eb8KvbWkgGramGt7cA8ohGJJfwBwPc+1dJq+paV4P8NteXrGDTrNAiIOXkb+FF/vOx/qT3NfMet6vfeJ9euda1bAnm+WOJTlYIx92NfYevc5PendL33stjalSc3y9ClaQLDCkajgDFWVWhVqdFrjlK+rPapU7iotTotIi1Hc3sNsAHbLscKo5LH0ArKzk7I9KEYwV5FoYUZNQwm61LUYtN0W2kvdQl+7FGM4H95j0VR3J4rrPCvw113xII7nWDJomlthgrL/pMq+yH7g92/KvaPDHhvSfDFibTRLNbdHwZZCd0sxHd3PJ/l6CuiGHUdZ/cefis2SXJQ18zk/h98NLXw9LHqetPHqOuD5kbGYbY/wDTMHq3+0fwxXoZ5OT1pahuriC0tZrq8nit7WBDJLNK21I1HVmPYVvdvQ8Kc3JuU3qM1G+tdM0+5v8AUbhLaytozLPM/wB1FHU8cn2A5JwBzXN+ENOufFOrWnjLXoJbW2hVv7C0qXg28bDBupx3mcfdUcIuOp5Eek6fL4/vrbWdWgkh8IWzibS9PmTa+oyD7t3Op6RjrHGev3iMdfRuSSSck9Sa6Ir2a8/yPKr1vaOy2EAp4FAFOAqDAAKWiigAooooA+cFWpVWhVqRVr0DYFFSqKFWpVWpAFWpFFCipVWgQKtQappdpq9otvfxuyxuJIZY3KS28g6SRuOVYEA56ccg1cUVKq0rgP0Txte+H3jsvG832jTncR2/iBE2qucBUu1H3Gzx5g+U98cmvSwQVVlIZWAZWU5DA9CD3B9a802K6OjojxyKUdHUMrqeoIPBB9DVLSTq/hAn/hGU/tHRC5eTQZpMNDn7zWkp+7zz5TZU845PGFSipax0ZvSruOktUep3VvBd20lvdwxz28gw8ci7lb8KyUtNQ0gH+zmbUbEdLSeT99GPSOQ/eHs3PvT/AAv4k0vxRYPdaPcFzC2y5t5V8ue1fkFJYzyjAgj0ODgmteuV3i7M7YtSV4s5nUtO8PeOIjHeRMb+2H3hmC9tD9fvAfmp965a98L+KNFDNZSw+I7FeQj4gvFH/oEh/In0r0LU9KstTMTXkOZoTmKeNjHLEf8AZdSCPpnB71AY9Wsl/cSpqsQ/guCIZwPZ1GxvxVfc0pQjUVpK/r/mCbjseY2et2V1ctaO0tnfrw1peRmGVf8AgLdfqKtzIR2/Ou01eXw/rsa2XiWxVWHCxajDsZT/ALEnT8VasK7+HBhUyeGdfvLNDytvdgXUP0DH5gPxNck8Et4O3r/maqr3OAufDtpC7SaW0umTtyWtmOxv95DkH9Ky11EITbaqyQXqN5ZbaRHL6Mp6DPp612OoaX4n0wH+09Da8hX/AJedKbzgfcxnDj8jXM32q6VcK9pdzLFvG1oLtGiJ9sMBSUKi+NX8/wDgnTCqpbu5nX0JBIKkGmeD7bz/AB9osZyPK825b6Khx+pFRab4fvdUNydIkgm02KfDQXUzBZfURyLyv4nrjrXS+E9L0611+4msTqWk6rFH5EtlPMkyhCQdyFgdynA5/lXRCUKWrYq1X3HGOp2OoyQWkUt3eyrFawrvkdjwB6e5PYU3wfZObZtYvoNt/fEyL5nLwwn7iDPTjrj1rnLO0l8QajdXurTzyWtpdSQ2VoXysbJ8rTHjkkg4GMDmuu03Uby7vJNMtVW61Dy/MWaRCIokzjMpHGR2Uct7ckOnOEpOK3OSbcVy9ev+RqyzSRyx2tlGs+pTKWiiYnaq95JCOiD8yeBWjLNpvhDQ7jUNa1DbHkNc3ko+eaTHCqo+mFQdB+JrP1zWtD+Hujm51W4kmu7k7towbm9cDqF6Ko6Z4VRx7H578X+LNR8Yaml7rckcNvDkW1lEf3UAPfn7zHux6+wwBvbTy/MKdNzdkXfHPiy88ca0l1PE1rpdtlbKzY5KA9ZHxwZG4z2AwB3JyUXAwKqQXInlWGziluZScBIYy7E/QV1ujfD/AMZaxtaPSv7OgbnzdQfyuP8Ad5Y/lWU4TqO7VkejB0qCs2YSgL1IFM+2x+ckFurz3DnCxRKXZj7Ac163onwUtFKyeI9YuL1u8Fovkxn2LH5iPpivStB0DSPD0Pl6HpttZAjBaJPnb6ufmP51CoxXxO5UsxUdKaPD/D/wz8Ua3tk1Hy9Csj1M43zsPaMdP+BEV614Q8B6D4VImsLY3GoYwb66O+X/AID2T8BXU0taJpK0VY4atepW+NiE5JJ5JpaFUsCQOFGSewHqfSuRuvHVjcXj6d4StpfFOrL96LT2H2aDgkGa5P7tBwehY8YxTjCU9kc86kYL3mdBrWq6foWlXGp6zeRWVhAMyTSngegAHLMeyjJNc5pmiaj41vYtS8YWMlh4ehcS2Hh+f/WTkcrNegcZ6EQ9F75wd2hoPgyeTVLfXfGt5BrGuW/NrDDGVsdOOc/uI25Z8/8ALV8twuMYrtRknnrW6Sp7av8ArY82tXdTTZCklmLMSSeppwFAFOAqDEAKWiigAooooAKKKKAPnlVqVVoValVa7zUFWpVWhVqRVpACrUqihVqVVqQBVqRVoValUUhAq1Iq0KtSqKQGbqeixX97FqNvc3Om63Cu2HU7M4mVeDscH5ZY+BlHzxwCKvW/jjUNDjK+ONO/0NP+Y5pUbS2+OeZoQDJCcAZI3KSeMCrKrU0RaNgyMVYdCpwaTSkrSQ4zlB3izqdNvrPVLFL3S7u2vrJyQtxbSrJGSOoyO/t1qevNZ/CumnUH1HSmudC1Z+WvdJk8gyHOf3kf+rkGTyGXJ7mrltrfjDRti6lYWviqyGAbnTQLS+AwSWa3Y+XIe2I2FYSofys6oYpfaR30irJGY5FV4zwVYZB/A1lnQbBWLWqTWbHqbWZox/3yDj9Kq+G/F+heI7h7XTL4DUo/9bp10ht7uM4BIMT4Jxnkrke9b/fHesWpQdnodMZRnrFmWtpqlsc2uppcKOkd7CCfpvTB/MGquoXsEkRi8U6RGtueDNIi3Vv+LYyo92UD3rfpBQpDcTEt/DHh4Qo1jplnDAw3IbMmNGHqNhANQyeD9Je6S5IvPPQFUb7SxCqewB7VrWWn2tjJcPZxCETtvkRCQhb1C9AT3I696uVMkmwUTn7Lwjo1pJK6W8kjSuZHEszMpY9TjOK0b23ulsRb6M9pZnszw7lUeyjAz9av0ULTYbjc8rvfg1Y6vq76n4h8Q6tf3Uh/eFQsYI7AHkgD0Fb2k/C3wdpm0ppAu5B/y0vJWmJ98E4/Su2orR1ZPqO2lrkNlbW9jF5djbQWsY/hgjWMfoKlPJ5paSsxWSForI8R+JdE8NIp1/VLWxdwCkMjFppMnA2RKC7c8cCsaLWvFPiDA8NeHjpFkxx/afiIGNiA2CY7RTvbjkFyoPetI0pS16GU68Ibs6m9u7awspbzULmC0s4v9ZcXEgjjT6seK5KDxPrPiYj/AIQTR0fTz/zHdZDwWjdP9TCMSzcFhn5VyKv6Z8P7D7ZBqPim7ufFOsRcpcakqiCE4APk2y/u4+gPRjnnNdsSztuckse5rRRhDzf4HHUxM5fDocIvw5g1PD+N9a1LxQ4IIt5G+yWKlWypFtEQCe3zFs121jaW1hZx2en21vaWcf8Aq7e3iWONO/CqABUwFOApubejOYAKeBQBTgKgAApaKKACiiigAooooAKKKKAPA1WpFWhVqVVrtNQValVaFWpFWkAKtSqtCrUqrSECrUqrSKtSqtIAValVaFWpFWkIFWpFWlVakVaQAq1Iq5oUVKq0hGfreiaZ4ggji1ywhvRHgxSPlZYSCDmOVSHTkDoR75qlFp3ijSMf8I/4l/tC3Xpp/iNDMMbskLdJiQcZA3BhwM10KrUiii+lhptO6K3hrxQurXtxpeo6fPo+v20Yml0+d1kDxnpLDKvyyx5OCRgg8Ed66OvPvHe23vvBOoRskd9B4jtbWFyAWaK43RzRg+jLyf8Adr0CsKsFGzXU78NVc00+gtFFFYnSFFFFABVfULy002za81K7trKzQ4ae5lWKMH03MQM+1Zvi/WZdB8PXF9aWZvr4vFbWlru2+dcSuI41JyMDcwJ56A1Q0zwHYi+TU/FTjxH4gHW4vV329sePktoD8kagqMHBY9c81rCmmuaT0OaviPZvlS1KkXj6HVsp4L0TVvEr4bbcQxfZbIFTghrmUAev3Q2ccVMNA8W62SfEPiSPRrNgwNh4cTbJjIK7ruQFs9jsUA9q7ZmeQguzNjpk9PpTgK1TjH4V+pwzrTnuzD8NeEdA8NO02iaVb2925Je8fM1zJnrumcl+fTIHtW/yTk5JPUmkAp4FJyb1ZmAFPAoApwFSAAU8CgCnAUAAFLRRSAKKKKACiiigAooooAKKKKAPDFFSqKKK7TUkUVKooopCJFFSqKKKkCVRUiiiigRKoqRRRRSAkUVKooopASKKkUUUUhEoFSKKKKQHNeJXMvjz4eae4UwSXl9esCM5eC1/d/kZWNd1RRWdf7Pp+rO3B7MWiiiuc7AooooA5X4pQySfD3Wri3mMF1p0S6nbygZ2y27CVePcrj8a6rT7oahYWl95flfa4I7jy852b0DYz3xnFFFdEPg+Z52KXvlkU8Ciig5R4FOAoopAPApwoooAeBS0UUgCiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stage 4 ROP signifies a partial retinal detachment, indicated by the arrow. In this example, the detachment excludes the macula and is therefore stage 4A.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11762=[""].join("\n");
var outline_f11_31_11762=null;
var title_f11_31_11763="Periph blood anal II";
var content_f11_31_11763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral blood analysis by flow cytometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 336px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of immunophenotyping of peripheral blood by staining with antibodies specific to monocytes (CD14) and neutrophils (CD15).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11763=[""].join("\n");
var outline_f11_31_11763=null;
var title_f11_31_11764="McBurney incision 2";
var content_f11_31_11764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    McBurney incision 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (C) Peritoneum and transversalis fascia incised. (D) Fibers of internal oblique reapproximated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11764=[""].join("\n");
var outline_f11_31_11764=null;
var title_f11_31_11765="Towel clamp on myoma";
var content_f11_31_11765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Towel clamp on myoma during myomectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Towel clamp placed on myoma for traction to aid in dissection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11765=[""].join("\n");
var outline_f11_31_11765=null;
var title_f11_31_11766="Developmental milestones 12 through 24 mos B";
var content_f11_31_11766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Developmental milestones: 12 through 24 months (continued)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 697px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     &copy; 2007 Chris Johnson, MD, AAP Council on Children with Disabilities. Adapted with permission and contributions from: Frances Page Glascoe, PhD and Nicholas Robertshaw, authors of PEDS:Developmental Milestones; Franklin Trimm, MD, Vice Chair of Pediatrics, USA/APA Education Committee; the Center for Disease Control \"Act Early\" Initiative; the National Institute for Literacy/Reach Out and Read; and the Inventory of Early Development by Albert Brigance published by Curriculum Associates, Inc. Permission is granted to reproduce these pages on the condition that they are only used as guide to average development and not as a substitute for standardized validated screening for developmental-behavioral problems.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11766=[""].join("\n");
var outline_f11_31_11766=null;
var title_f11_31_11767="Overview of pediatric injury prevention: Epidemiology; history; application";
var content_f11_31_11767=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of pediatric injury prevention: Epidemiology; history; application",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/31/11767/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11767/contributors\">",
"     Anne C Gill, DrPH, RN, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11767/contributors\">",
"     Nancy R Kelly, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/31/11767/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11767/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/31/11767/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11767/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/31/11767/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries are a leading cause of death for infants and children in the United States. Treated as diseases, both intentional and unintentional injuries are cured by prevention. The clinician's role in injury prevention includes education, instruction, and even advocating for changes to improve child safety [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pediatric injuries are such a significant healthcare problem that major authorities, including the American Academy of Pediatrics, the American Medical Association, the American Academy of Family Physicians, and the US Preventive Services Task Force, have issued recommendations that injury prevention counseling be provided as a part of the well-child exam [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/1,3-5\">",
"     1,3-5",
"    </a>",
"    ]. The American Academy of Pediatrics (AAP) developed a policy statement recommending age- and locale-appropriate injury prevention anticipatory guidance for all infants, children, and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the contributing factors for intentional injuries (ie, gun-shot wounds, assault) differ from those for unintentional injuries, many of the principles of injury prevention are the same [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology of pediatric injuries, historical trends, and principles of injury control are reviewed here. Evidence-based interventions for specific mechanisms of injury are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13225?source=see_link\">",
"       \"Prevention of bicycle injuries in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14921?source=see_link\">",
"       \"Prevention of firearm injuries in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12106?source=see_link\">",
"       \"Prevention of falls in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37944?source=see_link\">",
"       \"Prevention of poisoning in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma is the leading cause of pediatric mortality, potential years of life lost, and medical cost in the developed world [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. In addition to the financial burden, injuries lead to emotional trauma for children, parents, and society.",
"   </p>",
"   <p>",
"    Unintentional injuries are the leading cause of death and disability for children &ge;1 year of age, adolescents, and young adults in the United States (",
"    <a class=\"graphic graphic_table graphicRef67131 \" href=\"UTD.htm?26/29/27102\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/7\">",
"     7",
"    </a>",
"    ]. In 2009, unintentional injuries resulted in the deaths of more than 16,794 children, adolescents, and young adults ages 0 to 24 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/8\">",
"     8",
"    </a>",
"    ]. Unintentional injury deaths peak during the toddler years (ages 1 to 4) and again during adolescence and young adulthood (ages 15 to 24). Primary mechanisms of injury are development- and age-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The Table provides data for the leading causes of unintentional-injury deaths for 2009 (",
"    <a class=\"graphic graphic_table graphicRef81602 \" href=\"UTD.htm?17/61/18398\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Each year in the United States, more than 12 million children are injured seriously enough to require medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/11\">",
"     11",
"    </a>",
"    ]. Unintentional falls are the leading cause of nonfatal injury in children presenting to US hospital emergency departments, followed by being struck by or against an object (",
"    <a class=\"graphic graphic_table graphicRef65440 \" href=\"UTD.htm?7/46/7918\">",
"     table 3",
"    </a>",
"    ). In a population-based study of injury among 96,359 Canadian children (0 to 10 years of age) for which any medical attention was sought, the types and severity of injuries range from superficial injuries and contusions to multiple fractures and increased intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/9\">",
"     9",
"    </a>",
"    ]. The most common injuries were open wounds; superficial injuries and contusions; and dislocations, sprains, and strains; followed by upper-limb fractures; intracranial injury; foreign body; burns; and poisoning. Although hospital discharge rates for injuries declined from 1988 to 1996 for children under 15 years of age, those rates have remained unchanged through 2005. Fractures to the head and neck remain the leading cause of injury hospitalization for children under 15 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to data from the Centers for Disease Control and Prevention, the lifetime medical cost (ie, treatment and rehabilitation) of unintentional injury among children ages 19 and younger is over $77 million [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/13\">",
"     13",
"    </a>",
"    ]. The total work loss cost (ie, lost wages, benefits, and self-provided household services) is approximately $12 billion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/13\">",
"     13",
"    </a>",
"    ]. Worldwide unintentional injury accounts for 12 percent of the years lost due to disabilities among young people age 10 to 24 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historical trends in pediatric injury control reveal the effectiveness of certain prevention activities. Between 2000 and 2009, the unintentional injury death rate for children ages 19 and younger declined by 29 percent in the United States (from 15.5 to 11.0 per 100,000) (",
"    <a class=\"graphic graphic_figure graphicRef83770 \" href=\"UTD.htm?22/33/23070\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/7\">",
"     7",
"    </a>",
"    ]. Since 2002, the unintentional-injury death rate per 100,000 has averaged 8.6 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/8\">",
"     8",
"    </a>",
"    ]. Reduction in mortality can be attributed to the increased use of seat belts and child safety seats, the reduction in drunk driving, the increased use of child-resistant packaging, better safety awareness, and improved medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous reliable sources provide injury statistics. The",
"    <a class=\"external\" href=\"file://www.cdc.gov/injury/index.html\">",
"     National Center for Injury Prevention and Control",
"    </a>",
"    , the",
"    <a class=\"external\" href=\"file://www.cdc.gov/nchs/\">",
"     National Center for Health Statistics",
"    </a>",
"    , the",
"    <a class=\"external\" href=\"file://www-nrd.nhtsa.dot.gov/\">",
"     National Highway Traffic Safety Administration",
"    </a>",
"    , the",
"    <a class=\"external\" href=\"file://www.hcup-us.ahrq.gov/kidoverview.jsp\">",
"     Kids' Inpatient Database",
"    </a>",
"    , and the",
"    <a class=\"external\" href=\"file://www.safekids.org/\">",
"     National Safe Kids Campaign",
"    </a>",
"    are examples of such sites. The National Safe Kids Campaign maintains a useful, up-to-date Web site that dramatically illustrates the scope of pediatric injuries for children ages 14 and younger. The National Center for Injury Prevention and Control provides a useful Web site of injury data for all ages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The healthcare provider should recommend patient-specific and age-appropriate prevention measures based upon well-known risk factors for pediatric injury, including age, development, sex, ethnicity, socioeconomic status, behavior (both parent- and patient-specific), and the child's environment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age of a child is predictive for risk and type of injury. Infants are more likely to sustain fatal injuries from suffocation, motor vehicle crashes, drowning, and burns (",
"    <a class=\"graphic graphic_table graphicRef81602 \" href=\"UTD.htm?17/61/18398\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/7\">",
"     7",
"    </a>",
"    ]. Toddlers and preschool children are more likely to die from drowning, motor vehicle collisions, fires and burns, and suffocation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/7\">",
"     7",
"    </a>",
"    ]. Children at this age lack the motor skills to maneuver and the cognitive skills necessary to recognize safety hazards. The school-age child is more likely to engage in risk-taking behaviors that lead to pedestrian injuries, bicycle injuries, drowning, and unintentional firearm injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/16\">",
"     16",
"    </a>",
"    ]. Motor-vehicle occupant injury continues to be the most significant mechanism of injury for this age group, as well as for the adolescent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/7\">",
"     7",
"    </a>",
"    ]. Adolescents also are at risk for poisonings, drowning, firearm injury, falls, burns, and intentional injury. Data from the National Vital Statistics System indicate that between 2000 and 2009, an increased misuse of prescription drugs contributed to an increase in unintentional poisoning deaths among adolescents 15 to 19 years of age (from 1.7 to 3.3 per 100,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36535?source=see_link&amp;anchor=H268753611#H268753611\">",
"     \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF INJURY PREVENTION AND CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1986, Congress passed the Injury Prevention Act and in 1992 funded the National Center for Injury Prevention and Control (NCIPC). The NCIPC works with other federal agencies and funds research for injury prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/17\">",
"     17",
"    </a>",
"    ]. Increased research has led to new knowledge and strategies for the prevention and control of childhood injures. Injury prevention has become recognized as a field of science with its own theoretical framework and body of research. One well-accepted model of injury prevention, the Haddon Injury Control Model, proposes that all injuries are attributable to five forms of energy (kinetic, chemical, thermal, electrical, and radiation) and that injuries result when energy emanating from a vehicle or agent source is transferred to the host or child [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Countermeasure strategies can modify the potential or severity of energy transferred to the host or child and thereby prevent or diminish injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/19\">",
"     19",
"    </a>",
"    ]. Examples of countermeasure strategies are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduce the amount of energy produced &ndash; reduce the temperature of the hot water heater",
"     </li>",
"     <li>",
"      Prevent the release of energy &ndash; trigger locks to prevent discharge of the gun",
"     </li>",
"     <li>",
"      Modify the rate of spatial distribution of the energy release &ndash; reduce the slope of ski trails",
"     </li>",
"     <li>",
"      Separate the energy and the host in space or time &ndash; build sidewalks for pedestrians and bike paths for bicyclists",
"     </li>",
"     <li>",
"      Separate the energy and the host via barriers &ndash; use bike helmets or safety glasses",
"     </li>",
"     <li>",
"      Modify the contact surface &ndash; soften the playground surface",
"     </li>",
"     <li>",
"      Strengthen the structure that receives the energy &ndash; train athletes with appropriate conditioning and stretching",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the matrix of event phases and epidemiologic factors for injury prevention, 12 possible areas for injury-modifying interventions exist in the Haddon model (",
"    <a class=\"graphic graphic_form graphicRef62985 \" href=\"UTD.htm?8/14/8430\">",
"     form 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An injury event is divided into three phases:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pre-event phase &ndash; production or release of the energy has yet to occur and is modifiable",
"     </li>",
"     <li>",
"      Event phase &ndash; release of the energy has occurred, but potential transfer to the host is modifiable",
"     </li>",
"     <li>",
"      Post-event phase &ndash; energy has been transferred, but the extent of damage is modifiable",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Epidemiologic factors in injury prevention include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Host &ndash; human body that is affected by energy transfer",
"     </li>",
"     <li>",
"      Vehicle or agent &ndash; that which carries or transfers energy (eg, mechanisms of injury)",
"     </li>",
"     <li>",
"      Physical environment &ndash; changes to the environment that physically affect the impact of any of the three injury phases",
"     </li>",
"     <li>",
"      Sociocultural and political environment &ndash; attitudinal, legal, regulatory, or other changes that can affect the three injury phases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advent of this model brought the realization that 90 percent of injuries are both predictable and preventable, and, for that reason, experts in the field no longer use the term \"accident\" [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]. The principles of primary, secondary, and tertiary prevention strategies (eg, education, product design, and modification of the environment) can be used to develop interventions to prevent or control injury.",
"   </p>",
"   <p>",
"    Injury prevention strategies are active or passive [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Passive interventions (eg, automatic seat belts or air bags) are more effective than are active interventions (eg, manual seat belts) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/24\">",
"     24",
"    </a>",
"    ]. However, certain mechanisms of injury have not lent themselves to passive interventions. Child safety seats, for example, are an active intervention. Adults must purchase and install them and then ensure that the child is appropriately secured in the seat each time the car is driven. Despite these encumbrances, evidence shows that the frequency of safety seat use increases with the implementation of child safety seat laws, enhanced enforcement campaigns, community-wide information distribution, and interventions that combine giving incentives or distribution of free safety seats with educational efforts [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INCORPORATING INJURY PREVENTION INTO PRACTICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Office-based or outpatient injury prevention counseling is an integral part of medical care for infants, children, and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/1\">",
"     1",
"    </a>",
"    ]. The American Academy of Pediatrics recommends that every well-child visit include age-appropriate injury prevention counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parental education appears to be helpful in reducing injuries and improving home safety, particularly in families from disadvantaged populations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. In a 2013 meta-analysis of 10 randomized trials (5074 participants), parenting interventions decreased the risk of medically attended unintentional injury (relative risk 0.83, 95% CI 0.73-0.94) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/29\">",
"     29",
"    </a>",
"    ]. There was also fairly consistent evidence that parental interventions improved home safety.",
"   </p>",
"   <p>",
"    However, integrating injury-counseling practices during the average 16-minute well-child visit can be problematic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/30\">",
"     30",
"    </a>",
"    ]. In a survey conducted during 2001-2003, only 42 percent of the children younger than 15 years of age who had a medical visit in the previous year received any injury prevention information, according to a random-digit-dial telephone survey of 2541 households [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/27\">",
"     27",
"    </a>",
"    ]. In another survey, 55 percent of physicians responded that they provided injury prevention counseling always or most of the time, yet only 19 percent of their patients recalled receiving any safety information [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pediatricians report concerns of adequate time, perceived self-efficacy, perceived effectiveness of counseling, and reimbursement for counseling as barriers to counseling practices [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. These concerns are not without merit. Injury prevention strategies, such as legislation and product or environmental changes, can be more effective in preventing certain childhood injuries than education [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/34\">",
"     34",
"    </a>",
"    ]. However, evidence indicates that the most successful and effective interventions tend to combine all three strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although reimbursement concerns are not primary predictors of pediatrician counseling, financial concerns are legitimate and should be addressed in the appropriate forum [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/32\">",
"     32",
"    </a>",
"    ]. Managed-care companies have an interest in keeping their clients healthy and their costs down. Interventions that meet both goals should be considered in capitation analysis. Philosophic concerns about societal costs and burdens also can be problematic for the healthcare practitioner. One study estimated that injury prevention counseling for patients between the ages of zero and four years would result in a lifetime savings of $800 per child in future medical spending on injury treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INJURY PREVENTION RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of office resources (eg, chart aids, educational materials) was an important factor in the provision of preventive care, according to a survey of randomly selected members of the American Academy of Pediatrics (AAP), the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/37\">",
"     37",
"    </a>",
"    ]. Total resource use was significantly correlated with total preventive service provision and counseling, regardless of the origin of the resource.",
"   </p>",
"   <p>",
"    The AAP has developed a program to assist pediatricians and other healthcare providers with systematic and age-appropriate injury prevention counseling materials: the Injury Prevention Program (TIPP) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/38\">",
"     38",
"    </a>",
"    ]. Information about the TIPP program can be obtained from the AAP or via the",
"    <a class=\"external\" href=\"file://www2.aap.org/family/tippmain.htm\">",
"     Web site",
"    </a>",
"    . The program offers safety surveys and age-specific safety information sheets to be given to parents and children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/38\">",
"     38",
"    </a>",
"    ]. The surveys identify areas of specific individual risk, which can direct the counseling. Although some authors argue about the efficacy of these tools [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], the interventions do help to prioritize the delivery of safety counseling and aid in the development of a comprehensive and organized approach to injury prevention. These materials are copyright protected and are available by subscription from the",
"    <a class=\"external\" href=\"file://patiented.aap.org/categoryBrowse.aspx?catID=27\">",
"     AAP",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The National Safe Kids Campaign [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11767/abstract/41\">",
"     41",
"    </a>",
"    ] also offers brochures, videos, injury prevention programs, and resource guides. Another program,",
"    <a class=\"external\" href=\"file://brightfutures.aap.org/index.html\">",
"     Bright Futures",
"    </a>",
"    , provides patient education materials.",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention",
"    <a class=\"external\" href=\"file://www.cdc.gov/safechild/\">",
"     Protect the Ones You Love",
"    </a>",
"    Web site provides information about the steps you can take to prevent the leading causes of childhood injury.",
"   </p>",
"   <p>",
"    Additional injury prevention resources are listed in the tables (",
"    <a class=\"graphic graphic_table graphicRef55012 graphicRef78048 \" href=\"UTD.htm?25/38/26221\">",
"     table 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H796499988\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unintentional injuries are a leading cause of death and disability for children older than one year and young adults in the United States (",
"      <a class=\"graphic graphic_table graphicRef67131 \" href=\"UTD.htm?26/29/27102\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef81602 \" href=\"UTD.htm?17/61/18398\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The age of a child is predictive for risk and type of injury. Infants are more likely to sustain fatal injuries from suffocation, motor vehicle crashes, burns, and falls. Toddlers and preschool children are more likely to die from motor vehicle collisions (both occupant and pedestrian), drowning, fires and burns, suffocation, falls, and poisonings. The school-age children are more likely to sustain motor-vehicle occupant injuries, pedestrian injuries, bicycle injuries, drowning, and unintentional firearm injuries. Adolescents are more likely to sustain motor-vehicle occupant injuries, poisonings, drowning, firearm injury, falls, burns, and intentional injury. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of injuries are predictable and preventable through modification of human factors, the agent or vehicle of injury, the physical environment, or the sociocultural environment (",
"      <a class=\"graphic graphic_form graphicRef62985 \" href=\"UTD.htm?8/14/8430\">",
"       form 1",
"      </a>",
"      ). Injury prevention strategies are active (eg, manual seat belts) or passive (eg, air bags); passive strategies are more effective than are active interventions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Principles of injury prevention and control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injury prevention counseling is an integral part of medical care for infants, children, and adolescents. Injury-specific prevention counseling is associated with changes in behavior. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Incorporating injury prevention into practice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injury prevention resources are listed in the tables the tables (",
"      <a class=\"graphic graphic_table graphicRef55012 graphicRef78048 \" href=\"UTD.htm?25/38/26221\">",
"       table 4A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Injury prevention resources'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/1\">",
"      Gardner HG, American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Office-based counseling for unintentional injury prevention. Pediatrics 2007; 119:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/2\">",
"      Committee on Child Abuse and Neglect, Committee on Injury, Violence, and Poison Prevention, Council on Community Pediatrics. American Academy of Pediatrics. Policy statement--child fatality review. Pediatrics 2010; 126:592.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for Adolescent Preventive Services. American Medical Association, Chicago 1994.",
"    </li>",
"    <li>",
"     American Academy of Family Physicians. Clinical Preventive Services. file://www.aafp.org/online/en/home/clinical/exam.html (Accessed on September 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/5\">",
"      Safety counseling in children and adolescents. U.S. Public Health Service. Am Fam Physician 1995; 51:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/6\">",
"      Rivara FP, Grossman DC. Prevention of traumatic deaths to children in the United States: how far have we come and where do we need to go? Pediatrics 1996; 97:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: Unintentional injury deaths among persons aged 0-19 years - United States, 2000-2009. MMWR Morb Mortal Wkly Rep 2012; 61:270.",
"     </a>",
"    </li>",
"    <li>",
"     Web-based Injury Statistics Query and Reporting System (WISQARS). Fatal Injury Reports. Centers for Disease Control and Prevention, Atlanta, GA. Available at: www.cdc.gov/injury/wisqars/index.html (Accessed on May 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/9\">",
"      Spady DW, Saunders DL, Schopflocher DP, Svenson LW. Patterns of injury in children: a population-based approach. Pediatrics 2004; 113:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/10\">",
"      Mack KA, Gilchrist J, Ballesteros MF. Injuries among infants treated in emergency departments in the United States, 2001-2004. Pediatrics 2008; 121:930.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Prevention and Control, Health, United States, Injury, 2010. Available at: www.cdc.gov/nchs/hus/injury.htm (Accessed on September 22, 2011).",
"    </li>",
"    <li>",
"     Injury in the United States: 2007 Chartbook, National Center for Health Statistics, Hyattsville, MD 2008. p.49.",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. National Center for Injury Prevention and Control. National action plan for child injury prevention. An agenda to prevent injuries and promote the safety of children and adolescents in the United States. file://www.cdc.gov/safechild/pdf/National_Action_Plan_for_Child_Injury_Prevention.pdf (Accessed on May 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/14\">",
"      Gore FM, Bloem PJ, Patton GC, et al. Global burden of disease in young people aged 10-24 years: a systematic analysis. Lancet 2011; 377:2093.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson MH, Levin-Goodman R. Injury prevention and control. In: Oski's Pediatrics. Principles and Practice, 4th, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.134.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/16\">",
"      Rivara FP. Developmental and behavioral issues in childhood injury prevention. J Dev Behav Pediatr 1995; 16:362.",
"     </a>",
"    </li>",
"    <li>",
"     National Center for Injury Prevention and Control. Ten Leading Causes of Death, 1997. US Dept of Health and Human Services, Centers for Disease Control and Prevention, Atlanta 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/18\">",
"      Haddon W Jr. On the escape of tigers: an ecologic note. Am J Public Health Nations Health 1970; 60:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/19\">",
"      Haddon W Jr. Energy damage and the ten countermeasure strategies. J Trauma 1973; 13:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/20\">",
"      Cushman R. Injury prevention: the time has come. CMAJ 1995; 152:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/21\">",
"      Haddon W Jr. Editorial: Strategy in preventive medicine: passive vs. active apprroaches to reducing human wastage. J Trauma 1974; 14:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/22\">",
"      Dannenberg AL, Fowler CJ. Evaluation of interventions to prevent injuries: an overview. Inj Prev 1998; 4:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/23\">",
"      Stylianos S, Eichelberger MR. Pediatric trauma. Prevention strategies. Pediatr Clin North Am 1993; 40:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/24\">",
"      Rivara FP, Grossman DC, Cummings P. Injury prevention. First of two parts. N Engl J Med 1997; 337:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/25\">",
"      Ehiri JE, Ejere HO, Hazen AE, et al. Interventions to increase children's booster seat use: a review. Am J Prev Med 2006; 31:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/26\">",
"      Zaza S, Sleet DA, Thompson RS, et al. Reviews of evidence regarding interventions to increase use of child safety seats. Am J Prev Med 2001; 21:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/27\">",
"      Chen J, Kresnow MJ, Simon TR, Dellinger A. Injury-prevention counseling and behavior among US children: results from the second Injury Control and Risk Survey. Pediatrics 2007; 119:e958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/28\">",
"      Quinlan KP, Sacks JJ, Kresnow M. Exposure to and compliance with pediatric injury prevention counseling--United States, 1994. Pediatrics 1998; 102:E55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/29\">",
"      Kendrick D, Mulvaney CA, Ye L, et al. Parenting interventions for the prevention of unintentional injuries in childhood. Cochrane Database Syst Rev 2013; 3:CD006020.",
"     </a>",
"    </li>",
"    <li>",
"     Special Tabulation, 1991: National Ambulatory Medical Care Survey, National Center for Health Statistics, Hyattsville, MD 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/31\">",
"      Morrongiello BA, Hillier L, Bass M. 'What I said' versus 'what you heard': a comparison of physicians' and parents' reporting of anticipatory guidance on child safety issues. Inj Prev 1995; 1:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/32\">",
"      Cheng TL, DeWitt TG, Savageau JA, O'Connor KG. Determinants of counseling in primary care pediatric practice: physician attitudes about time, money, and health issues. Arch Pediatr Adolesc Med 1999; 153:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/33\">",
"      Cohen LR, Runyan CW, Downs SM, Bowling JM. Pediatric injury prevention counseling priorities. Pediatrics 1997; 99:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/34\">",
"      Grossman DC, Rivara FP. Injury control in childhood. Pediatr Clin North Am 1992; 39:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/35\">",
"      Dowswell T, Towner EM, Simpson G, Jarvis SN. Preventing childhood unintentional injuries--what works? A literature review. Inj Prev 1996; 2:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/36\">",
"      Miller TR, Galbraith M. Injury prevention counseling by pediatricians: a benefit-cost comparison. Pediatrics 1995; 96:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/37\">",
"      Dickey LL, Kamerow DB. Primary care physicians' use of office resources in the provision of preventive care. Arch Fam Med 1996; 5:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/38\">",
"      Bass JL. TIPP--the first ten years. Pediatrics 1995; 95:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/39\">",
"      Hansen K, Wong D, Young PC. Do the Framingham Safety Surveys improve injury prevention counseling during pediatric health supervision visits? J Pediatr 1996; 129:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/40\">",
"      Powell EC, Tanz RR, Uyeda A, et al. Injury prevention education using pictorial information. Pediatrics 2000; 105:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11767/abstract/41\">",
"      Mickalide A. The National SAFE KIDS Campaign (USA). Inj Prev 1995; 1:119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2870 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-24EF02F2C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11767=[""].join("\n");
var outline_f11_31_11767=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H796499988\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRINCIPLES OF INJURY PREVENTION AND CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INCORPORATING INJURY PREVENTION INTO PRACTICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INJURY PREVENTION RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H796499988\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2870\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2870|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/33/23070\" title=\"figure 1\">",
"      Unintentional injury deaths children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2870|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?8/14/8430\" title=\"form 1\">",
"      Areas for injury prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2870|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/29/27102\" title=\"table 1\">",
"      Causes death children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/61/18398\" title=\"table 2\">",
"      Causes fatal injury child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/46/7918\" title=\"table 3\">",
"      Causes nonfatal injury in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/38/4717\" title=\"table 4A\">",
"      Injury prevention resources US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/32/15883\" title=\"table 4B\">",
"      Injury prevention resources UK",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36535?source=related_link\">",
"      Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13225?source=related_link\">",
"      Prevention of bicycle injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12106?source=related_link\">",
"      Prevention of falls in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14921?source=related_link\">",
"      Prevention of firearm injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37944?source=related_link\">",
"      Prevention of poisoning in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_31_11768="Fetal blood sampling";
var content_f11_31_11768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fetal blood sampling",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/31/11768/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11768/contributors\">",
"     Alessandro Ghidini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/31/11768/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11768/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11768/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/31/11768/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11768/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/31/11768/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal blood sampling (FBS) refers to three techniques used to gain access to fetal blood: cordocentesis (also known as funiculocentesis or percutaneous umbilical blood sampling), intrahepatic blood sampling, and cardiocentesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28848025\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal blood is sampled to aid in the diagnostic evaluation of fetal disorders. The major differences between FBS and venipuncture in adults and children are the relatively high degree of risk (fetal blood sampling can have lethal complications) and the limited availability of normative laboratory values across gestation.",
"   </p>",
"   <p>",
"    FBS is often used to determine the fetal karyotype. Although this information can be obtained by amniocentesis or chorionic villus sampling, the results are available sooner when blood is the source of cellular material: 48 hours versus 10 days when amniocytes or chorionic villus cells are cultured. This is because cells from amniotic fluid and chorionic villi need to be stimulated to grow before they can be captured in metaphase, whereas cells from a blood sample are rapidly dividing and can be captured in metaphase immediately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maternal abdomen is cleaned with an antiseptic solution and draped.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to fetal viability, FBS can be performed in a room used for sonographic examinations or in a labor room. After viability, the procedure should be performed in proximity to an operating room since an emergency cesarean delivery may be required if nonreassuring fetal heart rate patterns develop during or after the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antenatal glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;We administer glucocorticoids at least 24 hours prior to diagnostic and therapeutic procedures in order to enhance fetal lung maturity, if this has not been documented in fetuses less than 34 weeks of gestation. The",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio of this practice has not been studied and may be difficult to assess, given the small risk of procedure related preterm delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory/imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sample of maternal blood is drawn before the procedure for comparison with the fetal samples that will be obtained. An obstetrical ultrasound examination is also performed to confirm fetal viability and to determine fetal position and the location of the placenta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intravenous access",
"    </span>",
"    &nbsp;&mdash;&nbsp;We place an intravenous catheter to provide easy and rapid administration of analgesics, antibiotics, and fluids, as needed, and to prepare the patient in the event of procedure-related complications necessitating emergent cesarean delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;We administer broad spectrum antibiotic prophylaxis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    1 g) 30 to 60 minutes prior to the procedure to reduce the risk of chorioamnionitis. Up to 40 percent of procedure-related fetal losses are associated with intrauterine infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/1\">",
"     1",
"    </a>",
"    ]; we feel potentially reducing the risk of chorioamnionitis far outweighs the risk of adverse reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Local anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthesia is optional for diagnostic procedures. However, it is useful for therapeutic procedures (eg, transfusions) to ease patient discomfort associated with prolonged needle insertion. Maternal sedation is not generally required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Needle guide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most real-time ultrasound machines are equipped with an on-screen template of the needle tract that is used to target the sampling site. A needle-guiding device attached to the transducer may decrease the risk of cord laceration or needle displacement [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/2\">",
"     2",
"    </a>",
"    ], but it restricts the lateral motion of the needle and hampers the procedure if the needle needs repositioning. This problem can be resolved by removing the guiding device during the procedure, if it becomes necessary. A \"free-hand technique\" is also commonly employed because it provides flexibility for adjusting the needle path.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Needle",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 20 to 22 gauge spinal needle is generally used for fetal blood sampling. Smaller bore needles prolong the period of time required to obtain fetal blood and are more difficult to manipulate because they bend. An alternative technique involves inserting a 20 gauge needle biopsy guide into the amniotic cavity, followed by threading a 25 gauge needle through the guide and then into the umbilical vein. A lower rate of procedure-related complications was reported in one study using this latter technique (bleeding from puncture site 23.1 percent, fetal bradycardia 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/3\">",
"     3",
"    </a>",
"    ]. However, only 53 percent of continuing pregnancies had been delivered at the time of publication, and the corrected perinatal loss rate (after excluding terminations of pregnancy and fetal malformations) was 2.4 percent, which is not different from the rate using other techniques (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Fetal losses'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The length of the needle should take into account the thickness of the maternal panniculus, location of the target segment of cord, and the possibility that intervening events, such as uterine contractions, may increase the distance between the skin and target. The standard length of a spinal needle is 8.9 cm (excluding the hub), but longer needles are available (up to 15 cm).",
"   </p>",
"   <p>",
"    Priming the needle with sodium citrate solution or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    immediately before the procedure helps to prevent clot formation. Modified needles with silicon coating of the bore have been shown in vitro to result in a significant increase in flow rate and lower clot formation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/4\">",
"     4",
"    </a>",
"    ]. Needles designed to optimize sonographic visualization (Cook OBGYN, Spencer, Indiana) are also available. A clear benefit of these new designs has not been adequately demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Assistants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most operators prefer to insert the needle while holding the transducer themselves. Once the needle tip is in place, an assistant is necessary either to hold the transducer or to draw the blood samples.",
"   </p>",
"   <p>",
"    Other operators prefer to be guided throughout the procedure by an assistant. A second assistant is useful to adjust the quality and size of the on-screen image during the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SAMPLING SITE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Umbilical cord blood sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in sampling the umbilical cord is to identify either a fixed segment of the cord or the insertion site of the cord in the placenta (preferable), as these sites will be the target of most procedures. Doppler color flow mapping can be used to confirm the cord insertion site by showing the branching of the cord vessels within the placenta.",
"   </p>",
"   <p>",
"    FBS is easiest when the placenta is anterior; access to the target portion of the cord may be hampered by the fetus when the placenta is posterior. Manipulation of the maternal abdomen to move the fetus may provide better access to the sampling site under these circumstances. Alternatively, intrahepatic vein access can be attempted (see below).",
"   </p>",
"   <p>",
"    It may be necessary to perform a therapeutic amniocentesis to gain access to the cord insertion in cases complicated by polyhydramnios with a posterior placenta. Oligohydramnios can also interfere with visualization of the insertion site of the cord; amnioinfusion or needling of a fixed loop of cord may overcome this difficulty. The following points are some additional insights related to the procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amniocentesis, if indicated, should be done prior to cordocentesis to avoid blood contamination of the fluid specimen. After aspiration of amniotic fluid, the needle is either advanced into the cord or, in cases with an anterior placenta, withdrawn within the placental mass, reoriented, and advanced into the cord. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link\">",
"       \"Diagnostic amniocentesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is easier and safer to sample the umbilical vein than an artery; puncture of the artery increases the incidence of bradycardia and prolongs post-procedural bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. The vein and artery can be distinguished by the differences in their relative sizes and by the direction of blood flow using Doppler color flow mapping. Correct identification of the origin of the sample (arterial versus venous) is crucial for accurate interpretation of the acid-base and oxygenation status of the fetus.",
"     </li>",
"     <li>",
"      Upon entering the umbilical cord, the stylet is removed and fetal blood is withdrawn into a syringe attached to the hub of the needle. The syringe may be primed with a small amount of anticoagulant, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or citrate. Proper positioning of the needle can be confirmed by injection of physiological saline solution into the cord and observation of turbulent flow along the vessel. After umbilical blood flow is documented by Doppler color flow, an initial sample should be submitted for red blood cell size determination (ie, mean corpuscular volume [MCV]) to distinguish fetal from maternal cells. If multiple samples are required, it may be helpful to attach a T-connector extension set to the hub of the needle to minimize the risk of needle dislodgement during attachment of the syringes. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Intrahepatic vein fetal blood sampling'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the desired samples have been obtained, the needle is withdrawn and the puncture site monitored for bleeding. If an intrauterine transfusion is performed after sampling, the fetal heart rate should be monitored intermittently by interrogating an umbilical artery near the sampling area using Doppler color flow or by assessing blood velocity waveforms by pulse Doppler. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13210?source=see_link&amp;anchor=H26#H26\">",
"     \"Intrauterine fetal transfusion of red blood cells\", section on 'Posttransfusion monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient has a viable fetus, the fetal heart rate is monitored for one to two hours after the procedure using an external fetal heart rate monitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Intrahepatic vein fetal blood sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 20 or 22 gauge needle is introduced into the fetal abdomen and aimed for the intrahepatic portion of the umbilical vein or the left portal vein. The risk of needle dislodgement (8.7 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/7\">",
"     7",
"    </a>",
"    ]) can be minimized by using longer needles and, after insertion into the target, allowing the needle to move with fetal movements.",
"   </p>",
"   <p>",
"    This technique has some advantages compared to cordocentesis, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of need for immediate laboratory support to confirm the fetal origin of the sample and certainty of the venous origin of the sample",
"     </li>",
"     <li>",
"      Less fetomaternal hemorrhage (therefore, less risk of alloimmunization) because the placenta is avoided",
"     </li>",
"     <li>",
"      Significantly less streaming from the sampling site compared with cordocentesis (0.8 versus 30.8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ease of access to the sampling site in cases with a posterior placenta or twins",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This procedure is often used as a second-line approach in cases of failed cordocentesis, but some centers have started using it as first-line procedure for the reasons discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The negligible risk of streaming from the sampling site makes intrahepatic vein sampling an appealing alternative to cordocentesis in cases at risk for fetal thrombocytopenia. The risk of procedure-related fetal loss ranges from 0 to 6.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/7-9\">",
"     7-9",
"    </a>",
"    ], because of the small number of series published, the risk of procedure-related fetal loss specifically in low-risk cases is not known.",
"   </p>",
"   <p>",
"    No significant changes in the concentrations of liver enzymes have been noted following the procedure, which suggests absent or minimal fetal liver injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cardiocentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiocentesis has few indications due to a high rate of fetal loss (eg, 5.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/10\">",
"     10",
"    </a>",
"    ]. It is reserved for cases where there is a high probability of a serious fetal disorder and FBS from other sites is technically impossible or has repeatedly failed.",
"   </p>",
"   <p>",
"    Ideally the needle should be introduced swiftly into the anterior thoracic wall to prevent fetal movements from interfering with the procedure. The needle should be inserted into the right ventricle, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     BLOOD SPECIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal blood samples are placed into tubes containing EDTA or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and mixed well to prevent clotting. The appropriate tubes and minimum volume of blood required for specific studies are listed in the tables (",
"    <a class=\"graphic graphic_table graphicRef77660 \" href=\"UTD.htm?1/34/1580\">",
"     table 1",
"    </a>",
"    ). The maximum volume of blood removed should not exceed 6 to 7 percent of the fetoplacental blood volume for the gestational age, which can be calculated as 100",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of estimated fetal weight [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Confirmation of fetal blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contamination with maternal blood or amniotic fluid can alter the diagnostic value of the fetal blood specimen. The purity of the fetal blood sample is commonly assessed using the mean corpuscular volume (MCV) of red blood cells (RBC) since fetal RBCs are larger than maternal RBCs. On occasion, this parameter can be misinterpreted (eg, in the presence of some maternal hematologic disorders, such as macrocytic anemia, or after repeated fetal transfusions of blood from an adult donor). Of note, an elevated (ie, greater than 95th percentile for gestational age) MCV has been proposed as a marker for trisomy or triploidy (",
"    <a class=\"graphic graphic_table graphicRef69845 \" href=\"UTD.htm?3/16/3340\">",
"     table 2",
"    </a>",
"    ). In a population of 267 fetuses in which the prevalence of aneuploidies was 4 percent, the sensitivity of this finding was 100 percent and the specificity ranged from 43 percent among growth restricted fetuses to 58 percent among appropriate for gestational age fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other methods to differentiate maternal from fetal blood include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Human chorionic gonadotropin (hCG) determination",
"      </strong>",
"      &mdash; This is the best marker for detection of maternal blood contamination [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/14\">",
"       14",
"      </a>",
"      ]. Maternal blood contains high concentrations of this hormone, whereas fetal blood is practically devoid of it. The fetal blood:amniotic fluid:maternal blood ratio for hCG is 1:100:400. HCG determination can detect as little as 0.2 percent contamination with maternal blood or 1 percent contamination with amniotic fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Hemoglobin alkaline denaturation test (Apt test)",
"      </strong>",
"      &mdash; 0.1 mL of sampled blood is added to a glass tube containing alkali reagent (5 mL of water and 0.3 mL of 10 percent potassium hydroxide) and the tube is gently shaken for two minutes. The sample is considered contaminated with maternal blood if the color of the mixture changes from red to green-brown [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Blood typing",
"      </strong>",
"      &mdash; The I antigen is present only on adult RBCs; fetal RBCs do not have this antigen. Monoclonal antibodies for the I antigen can detect as little as a 5 percent maternal blood contamination [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Kleihauer-Betke test",
"      </strong>",
"      &mdash; As little as 0.5 percent maternal blood contamination can be detected by this test, which is based upon different susceptibilities of fetal and adult hemoglobin to acid elution [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/14\">",
"       14",
"      </a>",
"      ]. The utility of the test is limited during the late third trimester since fetal erythrocytes contain increasing amounts of hemoglobin A near term.",
"     </li>",
"     <li>",
"      <strong>",
"       White blood cell differential count",
"      </strong>",
"      &mdash; Lymphocytes are the predominant white blood cell in the fetus, whereas neutrophils are predominant in the mother.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dilution with amniotic fluid can also be inferred by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A similarly proportional decrease in the number of RBCs, white blood cells, and platelets in the specimen.",
"     </li>",
"     <li>",
"      The presence of an amniotic fluid arborization pattern (ie, ferning) or multiple desquamated epithelial cells on a smear [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NORMAL VALUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of the most common hematologic and acid-base parameters in fetal blood in relation to the gestational age is listed in the tables (",
"    <a class=\"graphic graphic_table graphicRef75191 graphicRef62153 graphicRef51185 graphicRef50872 graphicRef68635 graphicRef75279 \" href=\"UTD.htm?18/50/19247\">",
"     table 3A-F",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding, bradycardia, and infection, all of which may be life-threatening, are the major fetal complications associated with cordocentesis. Maternal complications unrelated to the pregnancy are unusual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding from the puncture site is the most common complication of cordocentesis, occurring in up to one-half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]. Puncture of the umbilical artery is associated with a significantly longer duration of bleeding than venipuncture (mean duration of bleeding 35 seconds) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Post-procedural bleeding appears to carry a more ominous prognosis when it occurs at less than 21 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetuses with defects in platelet number or function are at significant risk for potentially fatal bleeding from the puncture site [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. Thus, it is prudent to slowly transfuse the fetus with concentrated, washed maternal (or compatible donor) platelets while awaiting the fetal platelet count when FBS is performed to diagnosis a fetal platelet disorder. These platelets are usually obtained from maternal thrombocytophereses to minimize the risks of transfusion-related infections with pooled donor platelets. A transfusion of 15 to 20 mL of platelet concentrate usually increases the fetal platelet count by 70,000 to 90,000, which is adequate to prevent bleeding from the cord puncture site. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36819?source=see_link\">",
"     \"Intrauterine fetal transfusion of platelets\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dislodgement of the needle before platelet transfusion can have fatal consequences for the fetus affected with a platelet abnormality. Because of its low risk of bleeding from the sampling site, intrahepatic vein sampling has been proposed as the optimal technique for fetal blood sampling in cases of suspected fetal thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If prenatal diagnosis is being performed for evaluation of a congenital hemostatic disorder, fresh frozen plasma should be available for fetal transfusion at the time of FBS since excessive bleeding has been reported after sampling in fetuses with bleeding diatheses, such as severe von Willebrand disease and hemophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cord hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cord hematoma is generally asymptomatic, but can be associated with a transient or prolonged sudden fetal bradycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/19,28,29\">",
"     19,28,29",
"    </a>",
"    ]. Expectant management is recommended in the presence of reassuring fetal monitoring and a nonexpanding hematoma. However, delivery is indicated if signs of nonreassuring fetal status persist.",
"   </p>",
"   <p>",
"    In one series that examined umbilical cords after delivery, hematomas were noted following FBS in 17 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/28\">",
"     28",
"    </a>",
"    ]. No relationship was documented between the size of the hematoma and either transient fetal bradycardia or bleeding from the cord puncture site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Fetomaternal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant fetomaternal transfusion occurs in approximately 40 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. These fetomaternal bleeds may be defined by either:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A greater than 50 percent postprocedural increase in maternal serum alpha-fetoprotein concentration from blood taken immediately before and after FBS",
"     </li>",
"     <li>",
"      Kleihauer-Betke staining of the maternal blood showing a calculated fetomaternal hemorrhage of greater than 1 mL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fetomaternal hemorrhage is more common with an anterior than a posterior placenta, with procedures lasting longer than three minutes, and with those requiring two or more needle insertions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The main consequence of a small fetomaternal hemorrhage is an increase in maternal antibody titers when the procedure is performed because of red blood cell isoimmunization [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. A large fetomaternal hemorrhage is rare and can result in severe fetal anemia and death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3800?source=see_link\">",
"     \"Diagnosis and management of massive fetomaternal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no consensus as to the clinical indications for obtaining preprocedural and postprocedural maternal blood samples to quantify the volume of fetomaternal hemorrhage. Further studies are required to obtain data to guide clinical practice and for interpretation of results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient fetal bradycardia is reported in three to 12 percent of fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/1,5,6,33\">",
"     1,5,6,33",
"    </a>",
"    ]. The higher incidence of bradycardia in procedures involving puncture of an umbilical artery suggests that this complication may be due to a vasovagal response caused by local vasospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A higher rate of bradycardia has also been noted among growth restricted fetuses compared to those appropriately grown (17 versus 4 percent). The greatest risk of bradycardia is in the growth restricted fetus with absent diastolic flow in the umbilical artery by Doppler analysis: bradycardia occurs in 21 of these fetuses versus 5 percent in those with normal diastolic flow [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maternal risk from FBS is minimal and is mainly limited to chorioamnionitis. Infection occurs after fewer than 1 percent of procedures, but is responsible for up to 40 percent of pregnancy losses associated with FBS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/1,6,33,34\">",
"     1,6,33,34",
"    </a>",
"    ]. Antibiotic prophylaxis is generally administered for this reason (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Antibiotics'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Failure rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cordocentesis and intrahepatic vein sampling have similar rates of failure to obtain a blood specimen (9 and 5 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/8\">",
"     8",
"    </a>",
"    ]. For this reason, it is useful to become familiar with both techniques, so that the appropriate technique may be chosen based upon indications and ease of access to the sampling site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Fetal losses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of procedure-related pregnancy loss is difficult to assess because many centers do not have long-term follow-up results for all cases. Losses which occur within a short time after the procedure are usually considered to be procedure-related. A review of the published series of low-risk cases found an overall risk of fetal loss of 1.4 percent before 28 weeks of gestation, and an additional 1.4 percent risk of perinatal death after 28 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/35\">",
"     35",
"    </a>",
"    ]. This loss rate is significantly greater than that related to amniocentesis (0.5 to 1.0 percent) and about six times higher than that of a general obstetric population near term. Another large study compared pregnancy outcome in 1020 women with no known fetal anomalies undergoing cordocentesis at 16 to 24 weeks of gestation to matched control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/36\">",
"     36",
"    </a>",
"    ]. The pregnancy loss rates before 28 weeks in the cordocentesis and controls groups were 1.8 and 0.7 percent, respectively, and 1.5 and 1.1 percent, respectively, after 28 weeks.",
"   </p>",
"   <p>",
"    The most important risk factors for procedure-related fetal loss appear to be:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal compromise &mdash; The risk of fetal loss is substantially higher if there is fetal pathology. The total spontaneous pregnancy loss rate within two weeks of the procedure is 1 percent when FBS is done for diagnosis of genetic disorders or karyotyping, 7 to 13 percent in the presence of structural fetal anomalies, 9 to 14 percent among growth restricted fetuses, and 25 percent in fetuses with nonimmune hydrops [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/34,37\">",
"       34,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inadequate operator experience &mdash; There is a higher frequency of fetal loss in smaller series, suggesting that operator experience affects the complication rate [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Obtaining the blood sample from the fetal heart or liver rather than from the umbilical vein (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Cardiocentesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Intrahepatic vein fetal blood sampling'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preterm delivery rate in a low risk population undergoing FBS is similar to that of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/20\">",
"     20",
"    </a>",
"    ]. FBS is associated with a transient irregular pattern of uterine contractions in fewer than 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22520534\">",
"    <span class=\"h1\">",
"     MULTIPLE GESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Access to an optimal site for cordocentesis can be more difficult when multiple fetuses are present, and the risk of complications appears to be increased, as well. In a relatively large study comparing outcomes after midtrimester cordocentesis in 122 twin fetuses and 336 singleton controls matched for maternal age and operator experience, twins had a significantly higher frequency of fetal bradycardia (13 versus 6.0 percent) and transient bleeding from the puncture site (34.8 versus 26.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/38\">",
"     38",
"    </a>",
"    ]. The fetal loss rate within two weeks of cordocentesis, however, was similar for both groups (1.4 versus 1.1 percent) after exclusion of pregnancies undergoing termination or feticide because of abnormal findings.",
"   </p>",
"   <p>",
"    Other studies have reported an 8 to 12 percent rate of fetal loss in twin gestations undergoing FBS, but are biased by factors such as a small number of cases, inclusion of both fetoscopy and cordocentesis procedures, and different indications for the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     IN-UTERO FETAL RESUSCITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In-utero treatment of fetal bradycardia can be attempted before viability or to avoid an emergent cesarean delivery in a very preterm infant. The option of emergent abdominal delivery and ex-utero resuscitation is preferable in the near term fetus. The following measures should be implemented in the presence of bradycardia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improve uterine perfusion and enhance fetal oxygenation by tilting the patient to the left-lateral decubitus position, increasing intravenous hydration, and administering oxygen via a mask. Maternal hypotension, if present, may be treated with ephedrine (10 mg intravenously).",
"     </li>",
"     <li>",
"      Palpate the uterus to evaluate for tetanic uterine contractions as the cause of the bradycardia. Subcutaneous or intravenous tocolytics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      0.25 mg subcutaneously or atosiban 6.75 mg in 4.9 mL saline given intravenously over one minute) can be administered to the mother to relax the uterus and potentially resolve the bradycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Persistent or worsening bradycardia may be secondary to prolonged bleeding or massive fetomaternal transfusion with hypovolemic shock. Fetal volume restoration can be accomplished by injecting maternal whole blood or normal saline at a volume of 15",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of estimated fetal weight into a fetal umbilical vessel (preferably the vein). If the umbilical vessels cannot be accessed due to hypovolemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vasoconstriction, a cardiocentesis should be performed [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11768/abstract/26,43\">",
"       26,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If all of the above measures fail, intracardiac administration of the inotropic agent epinephrine (1:10,000 solution at a dose of 0.1 to 0.3",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of estimated fetal weight) can be attempted and repeated every three to five minutes, as appropriate. There is no evidence in the neonatal literature to suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      is useful in the acute phase of resuscitation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal blood sampling (FBS) uses any of three techniques to gain access to fetal blood: cordocentesis, intrahepatic blood sampling, and cardiocentesis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In viable fetuses, we suggest that the procedure be performed in proximity to an operating room and with intravenous access in place since an emergency cesarean delivery may be required. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest administration of broad spectrum antibiotic prophylaxis to reduce the risk of chorioamnionitis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The maximal amount of blood removed should not exceed 6 to 7 percent of the fetoplacental blood volume for the gestational age. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Blood specimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amniocentesis, if indicated, should be done prior to the procedure to avoid blood contamination of the fluid specimen. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Umbilical cord blood sampling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal site for cordocentesis is the umbilical vein in the portion of the cord that inserts in the placenta. Proper positioning of the needle is confirmed by injection of physiological saline solution into the cord and observation of turbulent flow along the vessel. (See Umbilical cord blood sampling\" above).",
"     </li>",
"     <li>",
"      Intrahepatic vein fetal sampling is generally reserved for cases in which cordocentesis fails or cannot be performed due to fetal position. Cardiocentesis has a high rate of fetal loss and is used when there are no other options. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Intrahepatic vein fetal blood sampling'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Cardiocentesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The purity of the fetal blood sample is assessed using the mean corpuscular volume of red blood cells (RBC) since fetal RBCs are larger than maternal RBCs. On occasion, this parameter can be misinterpreted (eg, in the presence of some maternal hematologic disorders, such as macrocytic anemia, or after repeated fetal transfusions of adult donor blood). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Blood specimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fetal bleeding, bradycardia, and infection are the major complications; maternal complications are rare. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In utero resuscitation or delivery are management options if fetal complications occur. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'In-utero fetal resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/1\">",
"      Boulot P, Deschamps F, Lefort G, et al. Pure fetal blood samples obtained by cordocentesis: technical aspects of 322 cases. Prenat Diagn 1990; 10:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/2\">",
"      Weiner CP, Okamura K. Diagnostic fetal blood sampling-technique related losses. Fetal Diagn Ther 1996; 11:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/3\">",
"      Bovicelli L, Orsini LF, Grannum PA, et al. A new funipuncture technique: two-needle ultrasound- and needle biopsy-guided procedure. Obstet Gynecol 1989; 73:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/4\">",
"      Welch CR, Talbert DG, Warwick RM, et al. Needle modifications for invasive fetal procedures. Obstet Gynecol 1995; 85:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/5\">",
"      Weiner CP. Cordocentesis for diagnostic indications: two years' experience. Obstet Gynecol 1987; 70:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/6\">",
"      Weiner CP, Wenstrom KD, Sipes SL, Williamson RA. Risk factors for cordocentesis and fetal intravascular transfusion. Am J Obstet Gynecol 1991; 165:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/7\">",
"      Nicolini U, Nicolaidis P, Fisk NM, et al. Fetal blood sampling from the intrahepatic vein: analysis of safety and clinical experience with 214 procedures. Obstet Gynecol 1990; 76:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/8\">",
"      Aina-Mumuney AJ, Holcroft CJ, Blakemore KJ, et al. Intrahepatic vein for fetal blood sampling: one center's experience. Am J Obstet Gynecol 2008; 198:387.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/9\">",
"      Chinnaiya A, Venkat A, Dawn C, et al. Intrahepatic vein fetal blood sampling: current role in prenatal diagnosis. J Obstet Gynaecol Res 1998; 24:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/10\">",
"      Antsaklis AI, Papantoniou NE, Mesogitis SA, et al. Cardiocentesis: an alternative method of fetal blood sampling for the prenatal diagnosis of hemoglobinopathies. Obstet Gynecol 1992; 79:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/11\">",
"      Westgren M, Selbing A, Stangenberg M. Fetal intracardiac transfusions in patients with severe rhesus isoimmunisation. Br Med J (Clin Res Ed) 1988; 296:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/12\">",
"      Nicolaides KH, Clewell WH, Rodeck CH. Measurement of human fetoplacental blood volume in erythroblastosis fetalis. Am J Obstet Gynecol 1987; 157:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/13\">",
"      Sipes SL, Weiner CP, Wenstrom KD, et al. The association between fetal karyotype and mean corpuscular volume. Am J Obstet Gynecol 1991; 165:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/14\">",
"      Forestier F, Cox WL, Daffos F, Rainaut M. The assessment of fetal blood samples. Am J Obstet Gynecol 1988; 158:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/15\">",
"      Ogur G, G&uuml;l D, Ozen S, et al. Application of the 'Apt test' in prenatal diagnosis to evaluate the fetal origin of blood obtained by cordocentesis: results of 30 pregnancies. Prenat Diagn 1997; 17:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/16\">",
"      Sepulveda W, Be C, Youlton R, et al. Accuracy of the haemoglobin alkaline denaturation test for detecting maternal blood contamination of fetal blood samples for prenatal karyotyping. Prenat Diagn 1999; 19:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/17\">",
"      Lazebnik N, Hendrix PV, Ashmead GG, et al. Detection of fetal blood contamination by amniotic fluid obtained during cordocentesis. Am J Obstet Gynecol 1990; 163:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/18\">",
"      Chao A, Herd JP, Tabsh KM. The ferning test for detection of amniotic fluid contamination in umbilical blood samples. Am J Obstet Gynecol 1990; 162:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/19\">",
"      Hogge WA, Thiagarajah S, Brenbridge AN, Harbert GM. Fetal evaluation by percutaneous blood sampling. Am J Obstet Gynecol 1988; 158:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/20\">",
"      Orlandi F, Damiani G, Jakil C, et al. The risks of early cordocentesis (12-21 weeks): analysis of 500 procedures. Prenat Diagn 1990; 10:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/21\">",
"      Daffos F, Forestier F, Kaplan C, Cox W. Prenatal diagnosis and management of bleeding disorders with fetal blood sampling. Am J Obstet Gynecol 1988; 158:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/22\">",
"      Paidas MJ, Berkowitz RL, Lynch L, et al. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol 1995; 172:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/23\">",
"      Gruel Y, Boizard B, Daffos F, et al. Determination of platelet antigens and glycoproteins in the human fetus. Blood 1986; 68:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/24\">",
"      Takashima T, Maeda H, Koyanagi T, et al. Prenatal diagnosis and obstetrical management of May-Hegglin anomaly: a case report. Fetal Diagn Ther 1992; 7:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/25\">",
"      Lorenz P, Bollmann R, Hinkel GK, et al. False-negative prenatal exclusion of Wiskott-Aldrich syndrome by measurement of fetal platelet count and size. Prenat Diagn 1991; 11:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/26\">",
"      Ash KM, Mibashan RS, Nicolaides KH. Diagnosis and treatment of feto-maternal hemorrhage in a fetus with homozygous von Willebrand's disease. Fetal Ther 1988; 3:189.",
"     </a>",
"    </li>",
"    <li>",
"     Bussel, J. Minutes of the Neonatal Subcommittee of the International Committee of Thrombosis and Hemostasis Working Party on Neonatal Alloimmune Thrombocytopenia, Brussels, Belgium, 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/28\">",
"      Jauniaux E, Donner C, Simon P, et al. Pathologic aspects of the umbilical cord after percutaneous umbilical blood sampling. Obstet Gynecol 1989; 73:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/29\">",
"      Ch&eacute;nard E, Bastide A, Fraser WD. Umbilical cord hematoma following diagnostic funipuncture. Obstet Gynecol 1990; 76:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/30\">",
"      Nicolini U, Kochenour NK, Greco P, et al. Consequences of fetomaternal haemorrhage after intrauterine transfusion. BMJ 1988; 297:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/31\">",
"      Weiner C, Grant S, Hudson J, et al. Effect of diagnostic and therapeutic cordocentesis on maternal serum alpha-fetoprotein concentration. Am J Obstet Gynecol 1989; 161:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/32\">",
"      Chitrit Y, Caubel P, Lusina D, et al. Detection and measurement of fetomaternal hemorrhage following diagnostic cordocentesis. Fetal Diagn Ther 1998; 13:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/33\">",
"      Ludomirsky A, Weiner S, Ashmead GG, et al. Percutaneous fetal umbilical blood sampling: procedure safety and normal fetal hematologic indices. Am J Perinatol 1988; 5:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/34\">",
"      Maxwell DJ, Johnson P, Hurley P, et al. Fetal blood sampling and pregnancy loss in relation to indication. Br J Obstet Gynaecol 1991; 98:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/35\">",
"      Ghidini A, Sepulveda W, Lockwood CJ, Romero R. Complications of fetal blood sampling. Am J Obstet Gynecol 1993; 168:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/36\">",
"      Tongsong T, Wanapirak C, Kunavikatikul C, et al. Fetal loss rate associated with cordocentesis at midgestation. Am J Obstet Gynecol 2001; 184:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/37\">",
"      Antsaklis A, Daskalakis G, Papantoniou N, Michalas S. Fetal blood sampling--indication-related losses. Prenat Diagn 1998; 18:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/38\">",
"      Srisupundit K, Wanapirak C, Piyamongkol W, et al. Comparisons of outcomes after cordocentesis at mid-pregnancy between singleton and twin pregnancies. Prenat Diagn 2011; 31:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/39\">",
"      Antsaklis A, Daskalakis G, Souka AP, et al. Fetal blood sampling in twin pregnancies. Ultrasound Obstet Gynecol 2003; 22:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/40\">",
"      Cox WL, Forestier F, Capella-Pavlovsky M, Daffos F. Fetal blood sampling in twin pregnancies. Prenatal diagnosis and management of 19 cases. Fetal Ther 1987; 2:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/41\">",
"      Patriarco MS, Viechnicki BM, Hutchinson TA, et al. A study on intrauterine fetal resuscitation with terbutaline. Am J Obstet Gynecol 1987; 157:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/42\">",
"      Afschar P, Sch&ouml;ll W, Bader A, et al. A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG 2004; 111:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11768/abstract/43\">",
"      Shalev E, Peleg D. Fetal cardiac resuscitation. Lancet 1993; 341:305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5389 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-5203FA14AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11768=[""].join("\n");
var outline_f11_31_11768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28848025\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antenatal glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory/imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intravenous access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Local anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Needle guide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Needle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Assistants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SAMPLING SITE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Umbilical cord blood sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Intrahepatic vein fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      BLOOD SPECIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Confirmation of fetal blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NORMAL VALUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cord hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Fetomaternal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Bradycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Failure rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Fetal losses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22520534\">",
"      MULTIPLE GESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      IN-UTERO FETAL RESUSCITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5389\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5389|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/34/1580\" title=\"table 1\">",
"      Volume of fetal blood samples and collection tubes for lab tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/16/3340\" title=\"table 2\">",
"      Fetal mean corpuscular vol by GA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/38/5740\" title=\"table 3A\">",
"      Fetal neutrophil count by GA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/51/3900\" title=\"table 3B\">",
"      Fetal erythrocyte count by GA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/63/4092\" title=\"table 3C\">",
"      Fetal leukocyte count by GA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/45/1756\" title=\"table 3D\">",
"      Fetal hemoglobin by GA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/56/3980\" title=\"table 3E\">",
"      Fetal reticulocyte count by GA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/24/2444\" title=\"table 3F\">",
"      Fetal platelet count by GA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3800?source=related_link\">",
"      Diagnosis and management of massive fetomaternal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36819?source=related_link\">",
"      Intrauterine fetal transfusion of platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13210?source=related_link\">",
"      Intrauterine fetal transfusion of red blood cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_31_11769="Immunologic blood transfusion reactions";
var content_f11_31_11769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunologic blood transfusion reactions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/31/11769/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11769/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/31/11769/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11769/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/31/11769/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11769/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/31/11769/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untoward effects of blood transfusion are not unexpected and in many cases are benign. However, some reactions cause serious morbidity and may be fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/1\">",
"     1",
"    </a>",
"    ]. The problem is that the initial symptoms of reactions with serious or relatively benign consequences are often similar.",
"   </p>",
"   <p>",
"    Adverse reactions can occur in any blood transfusion recipient, but are more common in patients with hematologic and oncologic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. They can be categorized as immunologic, infectious, chemical, and physical; some also subdivide these reactions into acute and delayed types [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/4\">",
"     4",
"    </a>",
"    ]. The \"classic\" transfusion reactions are immunologic in nature and result from the interaction(s) of inherited or acquired antibodies with foreign antigens associated with cellular or humoral components of transfused blood products.",
"   </p>",
"   <p>",
"    The major immunologic reactions to blood transfusion will be discussed here:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Febrile nonhemolytic transfusion reactions",
"     </li>",
"     <li>",
"      Acute hemolytic transfusion reactions",
"     </li>",
"     <li>",
"      Delayed hemolytic transfusion reactions",
"     </li>",
"     <li>",
"      Anaphylactic transfusion reactions",
"     </li>",
"     <li>",
"      Urticarial transfusion reactions",
"     </li>",
"     <li>",
"      Post-transfusion purpura",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transfusion-related acute lung injury (TRALI) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=see_link\">",
"     \"Transfusion-related acute lung injury (TRALI)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another immunologic post-transfusion reaction, graft-versus-host disease (GVHD), is a rare complication that primarily occurs in immunocompromised patients and in immunocompetent subjects when the recipient is heterozygous for an HLA haplotype for which the donor is homozygous. This most commonly occurs when a recipient receives blood from a genetically related family member. The latter situation has led to the requirement for irradiation of blood products (to prevent lymphocyte proliferation and therefore post-transfusion GVHD) from a family donor or with transfusion of HLA-matched platelets from a related or unrelated donor. This devastating complication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to immunologic reactions, blood transfusions also are associated with infectious risks and with a number of chemical and physical complications (eg, citrate toxicity, hyperkalemia, hypokalemia, hypothermia, and iron overload). These problems are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link\">",
"     \"Transfusion reactions caused by chemical and physical agents\"",
"    </a>",
"    .) An overview of transfusion reactions associated with hemolysis is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37766?source=see_link\">",
"     \"Transfusion-associated immune and non immune-mediated hemolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analysis from the Serious Hazards of Transfusion (SHOT) group from the UK determined that adverse events following transfusion, with the most common event being the transfusion of a blood component which did not meet the appropriate requirement or which was intended for another patient, occurred twice as frequently in infants &lt;12 months of age as compared with older children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations underscore the fact that transfusion of blood to the wrong patient is the most important serious avoidable hazard of transfusion. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Acute hemolytic reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FEBRILE NONHEMOLYTIC REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common transfusion reaction is a febrile, nonhemolytic transfusion reaction (FNHTR). The clinical manifestations of this reaction include fever, often a chill, and sometimes mild dyspnea within one to six hours after transfusion of red cells or platelets. FNHTRs are benign, causing no lasting sequelae, but are uncomfortable and sometimes frightening to the patient. Furthermore, since fever, with or without a chill, also may be the sign of a severe, acute hemolytic transfusion reaction (see below) or infection, FNHTRs cannot be ignored.",
"   </p>",
"   <p>",
"    Data from the original 1962 article about FNHTRs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/6\">",
"     6",
"    </a>",
"    ], recently reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/7\">",
"     7",
"    </a>",
"    ], indicate that 40 percent of patients experiencing a FNHTR will experience a subsequent FNHTR, with 24 percent doing so on the very next transfusion.",
"   </p>",
"   <p>",
"    FNHTRs had been thought to be immune in nature since they have been associated with class I HLA antibodies (or sometimes granulocyte specific antibodies) directed against contaminating leukocytes in red cell concentrates [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/2,8\">",
"     2,8",
"    </a>",
"    ], however, such antibodies are not always found.",
"   </p>",
"   <p>",
"    FNHTRs also occur after platelet transfusions, which may also be contaminated with leukocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. As an example, in the Trial to Reduce Alloimmunization to Platelets (TRAP), FNHTRs were significantly associated with &gt;5 x 10",
"    <sup>",
"     6",
"    </sup>",
"    contaminating leukocytes per transfusion and with transfusions stored for more than 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is now clear that FNHTRs are commonly caused by cytokines, such as interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor-alpha (TNFa), which are generated and accumulate during the storage of blood components [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/3,11-13\">",
"     3,11-13",
"    </a>",
"    ]. In one series, for example, the dominant factor determining the risk of a reaction was the age of the component [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/3\">",
"     3",
"    </a>",
"    ]. In another report, the mean IL-8 concentration increased 100-fold between days two and five of storage and rose further with continued storage [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/12\">",
"     12",
"    </a>",
"    ]. At least one study has suggested that the increased IL-8 concentrations in stored unfiltered red cell products may be associated with transient post-transfusion leukocytosis in critically ill non-septic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been proposed that an interaction between donor leukocytes and recipient antibody leads to interleukin-1 (IL-1) release from donor leukocytes or recipient monocytes. IL-1 can then cause fever by stimulating prostaglandin E2 production in the hypothalamus. Two observations are compatible with the primary role for donor leukocytes: cytokine accumulation is reduced by prestorage leukocyte reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/11\">",
"     11",
"    </a>",
"    ], and leukoreduction is an effective preventive therapy (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Prevention'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Whether or not an inflammatory (febrile) reaction to platelet transfusions predisposes the recipient to red blood cell alloimmunization is currently under study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10433124\">",
"    <span class=\"h2\">",
"     Proposed alternative mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative mechanisms for",
"    <span class=\"nowrap\">",
"     FNHTR/allergic",
"    </span>",
"    reactions have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Release of platelet-derived CD154 (CD40 ligand), which is capable of inducing production of proinflammatory cytokines from fibroblasts, epithelial cells, and endothelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/16-19\">",
"       16-19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study, median concentrations of the direct allergic agonists C5a, brain-derived neurotrophic factor (BDNF), and CCL5 (RANTES) were 17, 42, and 14 percent higher, respectively, in the supernatants of apheresis platelet products that were most strongly associated with allergic transfusion reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of FNHTRs consists of the following steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stopping the transfusion and determining that a hemolytic reaction is not taking place (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Acute hemolytic reactions'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Administration of antipyretics (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      should be avoided in thrombocytopenic patients) and moderate doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      in patients with severe chills and rigors",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is the general consensus that FNHTRs can be avoided or minimized by using leukoreduction to reduce the number of leukocytes transfused. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    .) However, randomized controlled studies of this issue are scarce [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], and results of some retrospective observational studies have been conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three large retrospective cohort studies compared the frequency of acute reactions to red cells and platelets during two different periods: when nonleukoreduced products were routinely given and when universal leukoreduction had been implemented [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The frequency of FNHTRs to red cells was 0.33 to 0.37 percent prior to leukoreduction and was reduced to 0.15 to 0.19 percent following universal leukoreduction",
"     </li>",
"     <li>",
"      The frequency of FNHTRs to platelets was 0.45 to 2.18 percent prior to leukoreduction and was reduced to 0.11 to 0.15 percent following universal leukoreduction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The issue of whether all leukocyte-containing cellular blood products should undergo leukodepletion (ie, universal leukoreduction) includes multiple considerations in addition to reducing the incidence of FNHTRs. It is the author's opinion that, if cost were not a factor, prestorage leukoreduction should be performed on all cellular components intended for transfusion. Evidence continues to accumulate concerning the adverse consequences of transfusing components containing leukocytes, leukocyte debris, or leukocyte-generated cytokines.",
"   </p>",
"   <p>",
"    Whether this evidence is as yet sufficiently compelling is still a subject for debate. Nevertheless, despite a lack of scientific consensus, and the lack of an FDA mandate, approximately 75 percent of red blood cells currently distributed to U.S. hospitals by their blood provider are prestorage leukoreduced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H3#H3\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Febrile nonhemolytic transfusion reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Acetaminophen and antihistamine premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2007 review summarized the data from studies that evaluated the use of premedication to decrease the incidence of FNHTRs or allergic transfusion reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/28\">",
"     28",
"    </a>",
"    ]. Despite the fact that these medications are frequently ordered prior to transfusion, the authors concluded that there is no evidence to support the use of premedication with antihistamines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    for the prevention of these reactions.",
"   </p>",
"   <p>",
"    This conclusion was supported by a subsequent randomized, double-blind, placebo-controlled study of transfusion reactions in 315",
"    <span class=\"nowrap\">",
"     hematology/oncology",
"    </span>",
"    patients scheduled to receive leukocyte filtered blood products [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    500 mg plus 25 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    or matching placebos 30 minutes before transfusion and were monitored for the following four hours. There was no significant difference in the overall risk of transfusion reactions between the treatment and placebo groups (1.4 versus 1.5",
"    <span class=\"nowrap\">",
"     reactions/100",
"    </span>",
"    transfusions, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ACUTE HEMOLYTIC REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute hemolytic transfusion reaction (AHTR) is a medical emergency that results from the rapid destruction of donor erythrocytes by preformed recipient antibodies. AHTRs are usually due to ABO incompatibility, most often the result of clerical or procedural error [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/30-35\">",
"     30-35",
"    </a>",
"    ]. As such, transfusion of blood to the wrong patient is the most important serious avoidable hazard of transfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=see_link&amp;anchor=H5#H5\">",
"     \"Compatibility testing\", section on 'Specimen requirements'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some acquired alloantibodies, such as anti-Rh or anti-Jka, are occasionally implicated, but AHTRs more typically occur when a group O recipient is transfused with non-group O red cells. These reactions involve naturally occurring IgM anti-A and anti-B, which fix complement and cause rapid intravascular hemolysis. This may lead to disseminated intravascular coagulation (DIC), shock, and acute renal failure due to acute tubular necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On occasion, an acute hemolytic transfusion reaction may occur when a patient with blood group A, B, or AB is transfused with a blood product (eg, apheresis platelets, frozen plasma) containing donor plasma with a high titer of ABO alloantibodies (ie, high titer anti-A given to an A or AB recipient or high titer anti-B given to a B or AB recipient) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link&amp;anchor=H3#H3\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'Natural alloantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic presenting triad of fever, flank pain, and red or brown urine (ie, hemoglobinuria) is rarely seen. Fever and chills may be the only manifestations and, in patients under anesthesia or in coma, DIC may be the presenting mode, with oozing of blood from puncture sites and hemoglobinuria.",
"   </p>",
"   <p>",
"    The plasma of a patient with an AHTR will generally be pink (plasma free hemoglobin &gt;25 to 40",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and the direct antiglobulin (Coombs) test will be positive, unless all of the transfused red cells have already been destroyed",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    removed at the time of testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Initial approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, fever is also the presenting sign of a \"benign\" FNHTR. Thus, whenever fever occurs after a red cell transfusion, one must first rule out a hemolytic transfusion reaction and take the following steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stop the transfusion, but leave the intravenous line attached. The bag containing the transfused cells, along with all attached labels,",
"      <strong>",
"       should not be discarded",
"      </strong>",
"      , as repeat typing and cross-matching of this unit by the blood bank will most likely be required.",
"     </li>",
"     <li>",
"      Maintain the patient's airway, blood pressure, and heart rate.",
"     </li>",
"     <li>",
"      Begin an infusion of normal saline immediately to initiate a diuresis and avoid hypotension (see below). Avoid the use of Ringer's lactate solution because its content of calcium may initiate clotting of any blood remaining in the intravenous line. Avoid dextrose- containing solutions because the dextrose may hemolyze any of the remaining red cells in the line.",
"     </li>",
"     <li>",
"      From the other arm, obtain a sample for a direct antiglobulin test, plasma free hemoglobin, and repeat type and cross-match. Save a urine sample for hemoglobin testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link\">",
"       \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The blood bank should be alerted immediately, and a search for clerical error should be instituted. Every hospital has a protocol for evaluating transfusion reactions, which should be rigorously followed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is of critical importance, since if blood samples or blood bags have been switched in error, there may be a second patient at risk for a similar event (ie, if patient A received blood meant for patient B, then patient B may receive the blood meant for patient A).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is any suggestion (eg, clerical mistake, hypotension, pink plasma or urine) that an AHTR is possible, and even before laboratory tests are available, generous fluid replacement with saline (100 to 200",
"    <span class=\"nowrap\">",
"     mL/hour)",
"    </span>",
"    to support a urine output above 100 to 200",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    should be initiated immediately, in an attempt to prevent the development of acute oliguric renal failure. The beneficial effect of urinary alkalinization in patients with marked hemoglobinuria is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vigorous supportive care is also important for the treatment of AHTRs. If there has been massive hemolysis and clinical or laboratory signs of disseminated intravascular coagulation, cautious and early heparinization (10",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per hour) for the next 12 to 24 hours may be of value, although there are no recent studies on the effectiveness of this intervention.",
"   </p>",
"   <p>",
"    A vasopressor such as low-dose dopamine may be required. If massive intravascular hemolysis has already occurred, hyperkalemia is likely and cardiac monitoring and acute hemodialysis may be required. Accordingly, the patient's renal function and coagulation profile (eg, prothrombin time, partial thromboplastin time, fibrinogen, platelet count) should be monitored frequently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DELAYED HEMOLYTIC REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed hemolytic transfusion reactions (DHTRs) are due to an anamnestic antibody response occurring after reexposure to a foreign red cell antigen previously encountered by transfusion, transplantation, or pregnancy. The antibody, often of the Kidd or Rh system, is undetectable on pretransfusion testing but increases rapidly in titer following the transfusion.",
"   </p>",
"   <p>",
"    These delayed reactions are seen generally within 2 to 10 days after transfusion. Hemolysis is usually extravascular, gradual, and less severe than with acute reactions, but rapid hemolysis can occur. A falling hematocrit, slight fever, mild increase in serum unconjugated bilirubin, and spherocytosis on the blood smear may be noted. The diagnosis is often made by the blood bank when a new positive direct antiglobulin test and a new positive antibody screen are found when more blood is ordered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No treatment is required in the absence of brisk hemolysis. However, future transfusions containing the implicated red cell antigen need to be avoided. It is therefore important to make the diagnosis, inform the patient of the name of the offending antigen, and maintain appropriate hospital and blood bank records.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ANAPHYLACTIC REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid onset of anaphylaxis, manifested by shock, hypotension, angioedema, and respiratory distress, in a transfusion recipient requires rapid recognition and concomitant action, since it is a life-threatening occurrence. An anaphylactic transfusion reaction (ATR) may occur within a few seconds to a few minutes following the initiation of a transfusion that contains plasma, red cells, platelets, granulocytes, cryoprecipitate, or gamma globulin. An ATR is not generally seen following the administration of normal serum albumin, plasma protein fraction, or coagulation factors. It is the rapid onset that is characteristic of an ATR.",
"   </p>",
"   <p>",
"    Severe anaphylactic reactions have a reported incidence of 1:20,000 to 50,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], but are believed to be more common.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One well-characterized mechanism for this reaction is the presence of class-specific IgG anti-IgA antibodies in patients who are IgA deficient. Selective IgA deficiency is not uncommon, occurring in about 1 in 300 to 500 people. Fortunately, few IgA deficient patients develop antibodies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=see_link&amp;anchor=H24166172#H24166172\">",
"       \"Selective IgA deficiency: Management and prognosis\", section on 'Safe administration of blood products'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anaphylaxis via a similar mechanism has been described after blood product transfusion in patients with anhaptoglobinemia with antihaptoglobin antibodies; this disorder primarily occurs in East Asians [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe laryngeal edema or bronchospasm can occur in recipients of plasma exchange, occurring in 1 in every 500 to 1000 plasma exchanges in some studies [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. Some of these reactions may be due to ethylene oxide (or other) allergy, as noted in some hemapheresis donors [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A blood donor was found whose transfused blood components (platelets) were implicated in two cases of anaphylactic transfusion reaction in 2002. The donor plasma showed mast cell degranulation activity due to the presence of high molecular weight (dimeric and trimeric) IgEs that likely directly activated the recipient&rsquo;s mast cells by triggering the crosslinking of FCepsilon receptor 1 [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/46\">",
"       46",
"      </a>",
"      ]. The donor was ultimately diagnosed as having IgE kappa multiple myeloma in 2009.",
"     </li>",
"     <li>",
"      In at least one case, an anaphylactic reaction occurred due to passive transfer of a peanut allergen ingested by the blood donor and transfused via a blood product into a child with a prior anaphylactic reaction after eating peanuts [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial assessment and emergency management of anaphylaxis is summarized for adults (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"UTD.htm?16/26/16813\">",
"     table 1",
"    </a>",
"    ) and children (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immediate cessation of the transfusion",
"     </li>",
"     <li>",
"      Epinephrine, 0.3 mL of a 1:1000 solution intramuscularly (adult dose)",
"     </li>",
"     <li>",
"      Resuscitation of hypotensive patients with intravenous fluids",
"     </li>",
"     <li>",
"      Preparation, for possible administration, of an intravenous epinephrine drip (",
"      <a class=\"graphic graphic_table graphicRef75682 \" href=\"UTD.htm?7/17/7454\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Airway maintenance, oxygenation",
"     </li>",
"     <li>",
"      Vasopressors (eg, dopamine), if necessary",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of anaphylaxis is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention consists of establishing the diagnosis after the fact and using either IgA-deficient blood products (if the reaction is proven to be due to anti-IgA antibodies), which can be obtained through large, regional blood centers, or extra-washed (two to three times) red cell or platelet products [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link\">",
"     \"Intravenous immune globulin: Adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=see_link&amp;anchor=H24166172#H24166172\">",
"     \"Selective IgA deficiency: Management and prognosis\", section on 'Safe administration of blood products'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     URTICARIAL (ALLERGIC) REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticarial (allergic) transfusion reactions (UTRs) occur when soluble allergenic substances in the plasma of the donated blood product react with preexisting IgE antibodies in the recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/51\">",
"     51",
"    </a>",
"    ]. This causes mast cells and basophils to release histamine, leading to hives or urticaria. However, other mechanisms may be involved. (See",
"    <a class=\"local\" href=\"#H10433124\">",
"     'Proposed alternative mechanisms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An UTR is the only transfusion reaction in which the blood product can be continued. However, the transfusion should first be stopped and if the urticaria is extensive, 25 to 50 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    can be given orally or intravenously. Rarely, a UTR may be the first sign of a more serious reaction. If the urticaria wanes and neither dyspnea, hypotension, nor anaphylaxis are apparent, the transfusion may be resumed.",
"   </p>",
"   <p>",
"    The incidence of allergic transfusion reactions ranges from 1 to 3 percent, with growing evidence that premedications administered to prevent such reactions are ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/28\">",
"     28",
"    </a>",
"    ]. However, two small studies suggest that washing pooled whole blood-derived and apheresis platelets decreases such reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In a retrospective cohort study of 179 individuals who received unmanipulated platelets and subsequently received concentrated (ie, plasma removed)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    washed apheresis platelets, the incidence of allergic transfusion reactions was 5.5, 1.7, and 0.5 percent for unmanipulated, concentrated, and washed platelet products, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These manipulations (ie, removal of plasma, washing of platelets) should only be used for patients who experience severe urticarial reactions that cannot otherwise be prevented. It is appropriate to try concentrating the platelets first (by removing plasma) and only washing them if plasma removal does not prevent the urticarial reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14610169\">",
"    <span class=\"h1\">",
"     HYPOTENSIVE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hypotensive transfusion reactions are characterized by a drop in blood pressure (systolic, diastolic, or both) of 30mm Hg or more, occurring within minutes of onset of transfusion and returning to baseline once the transfusion is stopped. Other types of transfusion reactions which include hypotension (eg, TRALI, sepsis, severe allergic reactions) must be excluded.",
"   </p>",
"   <p>",
"    Primary hypotensive reactions have most commonly been reported with platelet transfusion and have also occurred during apheresis procedures. Factors associated with these rare reactions include filtration through a negatively charged leukocyte reduction filter (which are no longer commonly used) and the recipient being treated with an angiotensin converting enzyme (ACE) inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accumulated evidence suggests that these reactions are mediated by two vasoactive kinins (bradykinin and one of its derivatives) generated by activation of the contact system [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Because these reactions are rare, generally not serious, and rapidly reversible with cessation of the transfusion, there are no specific preventative or treatment recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TRANSFUSION-RELATED ACUTE LUNG INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to transfusion-related acute lung injury are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=see_link\">",
"     \"Transfusion-related acute lung injury (TRALI)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     POSTTRANSFUSION PURPURA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-transfusion purpura (PTP) is a rare transfusion reaction that occurs primarily in women sensitized by pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Severe degrees of thrombocytopenia, often lasting days to weeks, develop about 5 to 10 days following transfusion of a platelet-containing product such as red cells, platelets, or granulocyte concentrates. PTP is an immune thrombocytopenia and may be confused with drug-induced or immune thrombocytopenia (ITP), since the blood and bone marrow smears are essentially the same.",
"   </p>",
"   <p>",
"    Patients with PTP have been sensitized to a foreign antigen by pregnancy or by prior transfusion. The antigen most commonly implicated in this disorder is the platelet antigen PlA1, now known as human platelet antigen 1a, (HPA-1a) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/61\">",
"     61",
"    </a>",
"    ]. It is also the antigen system most commonly implicated in neonatal alloimmune thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H7#H7\">",
"     \"Neonatal thrombocytopenia\", section on 'Neonatal alloimmune thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The female-to-male ratio of the approximately 250 reported cases is 26:1. Approximately 98 to 99 percent of Caucasian women are PlA1 positive as are their spouses. A woman lacking the antigen in question can be sensitized by pregnancy, while a man or woman can be sensitized by prior transfusion.",
"   </p>",
"   <p>",
"    PTP might be thought of as a delayed transfusion reaction involving the platelets. The difference is that antigen-NEGATIVE platelets of the recipient are also affected. The mechanism by which this occurs is not well understood. Possibilities include that the patient's platelets adsorb immune complexes and are destroyed, that an autoantibody is elaborated in response to the foreign protein, or that the antigen is passively acquired from donor plasma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PTP is confirmed by showing that the patient has a circulating alloantibody to a common platelet antigen, most often against HPA-1a, and that the patient's own platelets lack this antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/62\">",
"     62",
"    </a>",
"    ]. However, specific tests to determine the platelet antigenic composition",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of anti-platelet antibodies may not be readily available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infusion of PlA1-negative platelets is generally not effective because even antigen-negative platelets are destroyed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/63\">",
"     63",
"    </a>",
"    ]. High dose corticosteroids have been useful in the past, as has exchange transfusion; however, both take two or more weeks to act and are not without negative side effects.",
"   </p>",
"   <p>",
"    The preferred therapy is intravenous immune globulin (IVIG) in high doses (400 to 500",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, usually for five days); alternatively, 1.0",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day for two days can be given for severe thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. It usually takes about four days for the platelet count to exceed",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. HPA-1a-negative patients with diagnosed PTP should receive only blood products washed to remove contaminating HPA-1a-positive platelets",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transfusion of HPA-1a negative platelets in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     THROMBOCYTOPENIA FROM PASSIVE ANTIBODY TRANSFER",
"    </span>",
"    &nbsp;&mdash;&nbsp;On rare occasions, the recipient of a blood transfusion will develop acute and severe thrombocytopenia, which may be accompanied by bleeding and an acute transfusion reaction, due to the passive transfer of anti-platelet antibodies from a previously immunized donor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11769/abstract/68\">",
"     68",
"    </a>",
"    ]. In a compilation of 19 cases from the literature, the median platelet count nadir was",
"    <span class=\"nowrap\">",
"     7000/microL",
"    </span>",
"    (range: 1000 to 35,000) at a median elapsed post-transfusion time of six hours (range: 1 to 27 hours) and a median time to platelet recovery of five days.",
"   </p>",
"   <p>",
"    The platelet antibody involved is usually anti-HPA-1a, the component transfused was usually fresh frozen plasma, and, to date, the donor has always been a female with a history of pregnancy. Implicated donors should be deferred from subsequent donations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     IMMUNOSUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunosuppressive activity of allogeneic blood transfusion (transfusion-related immunomodulation, TRIM), and its possible reduction with the use of leukoreduction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H6#H6\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Immunosuppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10237461\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"classic\" transfusion reactions are immunologic in nature and result from the interaction(s) of inherited or acquired antibodies with foreign antigens associated with cellular or humoral components of transfused blood products. The reactions discussed here include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Febrile nonhemolytic transfusion reactions",
"     </li>",
"     <li>",
"      Acute and delayed hemolytic transfusion reactions",
"     </li>",
"     <li>",
"      Anaphylactic and urticarial transfusion reactions",
"     </li>",
"     <li>",
"      Post-transfusion purpura",
"     </li>",
"     <li>",
"      Thrombocytopenia from passive antibody transfer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transfusion-related acute lung injury and transfusion-associated graft-versus-host disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=see_link\">",
"     \"Transfusion-related acute lung injury (TRALI)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/1\">",
"      Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009; 113:3406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/2\">",
"      BRITTINGHAM TE, CHAPLIN H Jr. Febrile transfusion reactions caused by sensitivity to donor leukocytes and platelets. J Am Med Assoc 1957; 165:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/3\">",
"      Heddle NM, Klama LN, Griffith L, et al. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993; 33:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/4\">",
"      Sanders RP, Geiger TL, Heddle N, et al. A revised classification scheme for acute transfusion reactions. Transfusion 2007; 47:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/5\">",
"      Stainsby D, Jones H, Wells AW, et al. Adverse outcomes of blood transfusion in children: analysis of UK reports to the serious hazards of transfusion scheme 1996-2005. Br J Haematol 2008; 141:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/6\">",
"      KEVY SV, SCHMIDT PJ, McGINNISS MH, WORKMAN WG. Febrile, nonhemolytic transfusion reactions and the limited role of leukoagglutinins in their etiology. Transfusion 1962; 2:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/7\">",
"      Aubuchon JP, Dzik WS. Reports on clinical transfusion medicine in the early days of TRANSFUSION. Transfusion 2010; 50:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/8\">",
"      de Rie MA, van der Plas-van Dalen CM, Engelfriet CP, von dem Borne AE. The serology of febrile transfusion reactions. Vox Sang 1985; 49:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/9\">",
"      Heddle NM, Klama L, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994; 331:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/10\">",
"      Enright H, Davis K, Gernsheimer T, et al. Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion 2003; 43:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/11\">",
"      Shanwell A, Kristiansson M, Remberger M, Ringd&eacute;n O. Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. Transfusion 1997; 37:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/12\">",
"      Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. Transfusion 1994; 34:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/13\">",
"      Muylle L, Joos M, Wouters E, et al. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions. Transfusion 1993; 33:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/14\">",
"      Izbicki G, Rudensky B, Na'amad M, et al. Transfusion-related leukocytosis in critically ill patients. Crit Care Med 2004; 32:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/15\">",
"      Yazer MH, Triulzi DJ, Shaz B, et al. Does a febrile reaction to platelets predispose recipients to red blood cell alloimmunization? Transfusion 2009; 49:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/16\">",
"      Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci U S A 2000; 97:6930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/17\">",
"      Zhang Y, Cao HJ, Graf B, et al. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J Immunol 1998; 160:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/18\">",
"      Phipps RP, Kaufman J, Blumberg N. Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion. Lancet 2001; 357:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/19\">",
"      Blumberg N, Gettings KF, Turner C, et al. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion 2006; 46:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/20\">",
"      Savage WJ, Savage JH, Tobian AA, et al. Allergic agonists in apheresis platelet products are associated with allergic transfusion reactions. Transfusion 2012; 52:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/21\">",
"      Heddle NM, Blajchman MA, Meyer RM, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002; 42:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/22\">",
"      Dzik WH, Anderson JK, O'Neill EM, et al. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002; 42:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/23\">",
"      Uhlmann EJ, Isgriggs E, Wallhermfechtel M, Goodnough LT. Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion 2001; 41:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/24\">",
"      Ibojie J, Greiss MA, Urbaniak SJ. Limited efficacy of universal leucodepletion in reducing the incidence of febrile nonhaemolytic reactions in red cell transfusions. Transfus Med 2002; 12:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/25\">",
"      Yazer MH, Podlosky L, Clarke G, Nahirniak SM. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004; 44:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/26\">",
"      Paglino JC, Pomper GJ, Fisch GS, et al. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 2004; 44:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/27\">",
"      King KE, Shirey RS, Thoman SK, et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004; 44:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/28\">",
"      Tobian AA, King KE, Ness PM. Transfusion premedications: a growing practice not based on evidence. Transfusion 2007; 47:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/29\">",
"      Kennedy LD, Case LD, Hurd DD, et al. A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions. Transfusion 2008; 48:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/30\">",
"      Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990; 30:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/31\">",
"      Moore SB, Foss ML. Ordering blood for the wrong patient--getting inside the minds of ordering physicians. Mayo Clin Proc 2003; 78:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/32\">",
"      Stainsby D, Russell J, Cohen H, Lilleyman J. Reducing adverse events in blood transfusion. Br J Haematol 2005; 131:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/33\">",
"      Dzik WH. New technology for transfusion safety. Br J Haematol 2007; 136:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/34\">",
"      Murphy MF, Casbard AC, Ballard S, et al. Prevention of bedside errors in transfusion medicine (PROBE-TM) study: a cluster-randomized, matched-paired clinical areas trial of a simple intervention to reduce errors in the pretransfusion bedside check. Transfusion 2007; 47:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/35\">",
"      Nuttall GA, Abenstein JP, Stubbs JR, et al. Computerized bar code-based blood identification systems and near-miss transfusion episodes and transfusion errors. Mayo Clin Proc 2013; 88:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/36\">",
"      Cooling L. ABO and platelet transfusion therapy. Immunohematology 2007; 23:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/37\">",
"      Fung MK, Downes KA, Shulman IA. Transfusion of platelets containing ABO-incompatible plasma: a survey of 3156 North American laboratories. Arch Pathol Lab Med 2007; 131:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/38\">",
"      Daniel-Johnson J, Leitman S, Klein H, et al. Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions. Transfusion 2009; 49:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/39\">",
"      Bjerrum OJ, Gersild C. Class-specific anti-IgA associated with severe anaphylactic transfusion reactions in a patient with pernicious anemia. Vox Sang 1971; 21:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/40\">",
"      Pineda AA, Taswell HF. Transfusion reactions associated with anti-IgA antibodies: report of four cases and review of the literature. Transfusion 1975; 15:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/41\">",
"      Koda Y, Watanabe Y, Soejima M, et al. Simple PCR detection of haptoglobin gene deletion in anhaptoglobinemic patients with antihaptoglobin antibody that causes anaphylactic transfusion reactions. Blood 2000; 95:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/42\">",
"      Shimada E, Tadokoro K, Watanabe Y, et al. Anaphylactic transfusion reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies. Transfusion 2002; 42:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/43\">",
"      Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion 1989; 29:124.",
"     </a>",
"    </li>",
"    <li>",
"     Reuther PA. Plasma exchange therapy in neurological disorders: a clinician's overview. In: Therapeutic Hemapheresis, MacPherson JL, Kasprisin DO (Eds), CRC Press, Boca Raton 1985. p.27.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/45\">",
"      Leitman SF, Boltansky H, Alter HJ, et al. Allergic reactions in healthy plateletpheresis donors caused by sensitization to ethylene oxide gas. N Engl J Med 1986; 315:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/46\">",
"      Abe T, Matsumoto C, Shimada E, et al. Immunoglobulin E oligomers identified in blood components activate mast cells: relevance to anaphylactic transfusion reaction. Transfusion 2011; 51:2327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/47\">",
"      Jacobs JF, Baumert JL, Brons PP, et al. Anaphylaxis from passive transfer of peanut allergen in a blood product. N Engl J Med 2011; 364:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/48\">",
"      Sandler SG. How I manage patients suspected of having had an IgA anaphylactic transfusion reaction. Transfusion 2006; 46:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/49\">",
"      Vassallo RR. Review: IgA anaphylactic transfusion reactions. Part I. Laboratory diagnosis, incidence, and supply of IgA-deficient products. Immunohematology 2004; 20:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/50\">",
"      Thibault L, Beaus&eacute;jour A, de Grandmont MJ, et al. Establishment of an immunoglobulin A-deficient blood donor registry with a simple in-house screening enzyme-linked immunosorbent assay. Transfusion 2006; 46:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/51\">",
"      Savage WJ, Tobian AA, Savage JH, et al. Atopic predisposition of recipients in allergic transfusion reactions to apheresis platelets. Transfusion 2011; 51:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/52\">",
"      Silvergleid AJ, Hafleigh EB, Harabin MA, et al. Clinical value of washed-platelet concentrates in patients with non-hemolytic transfusion reactions. Transfusion 1977; 17:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/53\">",
"      Buck SA, Kickler TS, McGuire M, et al. The utility of platelet washing using an automated procedure for severe platelet allergic reactions. Transfusion 1987; 27:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/54\">",
"      Tobian AA, Savage WJ, Tisch DJ, et al. Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction. Transfusion 2011; 51:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/55\">",
"      Hume HA, Popovsky MA, Benson K, et al. Hypotensive reactions: a previously uncharacterized complication of platelet transfusion? Transfusion 1996; 36:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/56\">",
"      Arnold DM, Molinaro G, Warkentin TE, et al. Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage. Transfusion 2004; 44:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/57\">",
"      Mair B, Leparc GF. Hypotensive reactions associated with platelet transfusions and angiotensin-converting enzyme inhibitors. Vox Sang 1998; 74:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/58\">",
"      Hild M, S&ouml;derstr&ouml;m T, Egberg N, Lundahl J. Kinetics of bradykinin levels during and after leucocyte filtration of platelet concentrates. Vox Sang 1998; 75:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/59\">",
"      Mueller-Eckhardt C. Post-transfusion purpura. Br J Haematol 1986; 64:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/60\">",
"      McCrae KR, Herman JH. Posttransfusion purpura: two unusual cases and a literature review. Am J Hematol 1996; 52:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/61\">",
"      Vogelsang G, Kickler TS, Bell WR. Post-transfusion purpura: a report of five patients and a review of the pathogenesis and management. Am J Hematol 1986; 21:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/62\">",
"      Legler TJ, K&ouml;hler M, Mayr WR, et al. Genotyping of the human platelet antigen systems 1 through 5 by multiplex polymerase chain reaction and ligation-based typing. Transfusion 1996; 36:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/63\">",
"      Gerstner JB, Smith MJ, Davis KD, et al. Posttransfusion purpura: therapeutic failure of PlAl-negative platelet transfusion. Am J Hematol 1979; 6:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/64\">",
"      Mueller-Eckhardt C, Kiefel V. High-dose IgG for post-transfusion purpura-revisited. Blut 1988; 57:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/65\">",
"      Becker T, Panzer S, Maas D, et al. High-dose intravenous immunoglobulin for post-transfusion purpura. Br J Haematol 1985; 61:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/66\">",
"      Berney SI, Metcalfe P, Wathen NC, Waters AH. Post-transfusion purpura responding to high dose intravenous IgG: further observations on pathogenesis. Br J Haematol 1985; 61:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/67\">",
"      Denomme G, Horsewood P, Xu W, et al. A simple and rapid competitive enzyme-linked immunosorbent assay to identify HPA-1a (PlA1)-negative donor platelet units. Transfusion 1996; 36:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11769/abstract/68\">",
"      Pavenski K, Webert KE, Goldman M. Consequences of transfusion of platelet antibody: a case report and literature review. Transfusion 2008; 48:1981.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7947 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11769=[""].join("\n");
var outline_f11_31_11769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10237461\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FEBRILE NONHEMOLYTIC REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10433124\">",
"      Proposed alternative mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Acetaminophen and antihistamine premedication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACUTE HEMOLYTIC REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Initial approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DELAYED HEMOLYTIC REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ANAPHYLACTIC REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      URTICARIAL (ALLERGIC) REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14610169\">",
"      HYPOTENSIVE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TRANSFUSION-RELATED ACUTE LUNG INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      POSTTRANSFUSION PURPURA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      THROMBOCYTOPENIA FROM PASSIVE ANTIBODY TRANSFER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      IMMUNOSUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10237461\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7947\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7947|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/26/16813\" title=\"table 1\">",
"      Emergent management of anaphylaxis in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/50/18221\" title=\"table 2\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/17/7454\" title=\"table 3\">",
"      Example of epinephrine infusion - adult",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=related_link\">",
"      Compatibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=related_link\">",
"      Selective IgA deficiency: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37766?source=related_link\">",
"      Transfusion-associated immune and non immune-mediated hemolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=related_link\">",
"      Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_31_11770="Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma";
var content_f11_31_11770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/31/11770/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11770/contributors\">",
"     Peter M Mauch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11770/contributors\">",
"     Richard T Hoppe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/31/11770/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11770/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/31/11770/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/31/11770/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/31/11770/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of Hodgkin lymphoma (formerly called Hodgkin's disease) has been established, subsequent therapy and prognosis are based upon the stage of the disease, as currently defined by the Ann Arbor staging system with Cotswolds modifications (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=see_link\">",
"     \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this discussion, early stage Hodgkin lymphoma is defined as those patients with stage I or II disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I &mdash; Involvement of a single lymph node region (I) or of a single extralymphatic organ or site (Ie)",
"     </li>",
"     <li>",
"      Stage II &mdash; Involvement of two or more lymph node regions on the same side of the diaphragm alone (II) or with involvement of limited, contiguous extralymphatic organ or tissue (IIe)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with early (stage I-II) disease, there is subsequent stratification into favorable and unfavorable prognosis disease based upon the presence or absence of certain clinical features, such as age, B symptoms, large number of regions involved, and large mediastinal adenopathy. Cooperative research groups have used varying definitions of favorable and unfavorable prognosis disease. These are described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10711?source=see_link\">",
"     \"Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two most commonly used definitions of favorable disease are those proposed by the European Organization for the Research and Treatment of Cancer (EORTC) and the German Hodgkin Study Group (GHSG):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The EORTC defines the favorable prognostic group as patients age 50 or under; without large mediastinal adenopathy; with an ESR of less than 50",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      and no B symptoms (or with an ESR of less than 30",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      in those who have B symptoms); and disease limited to three or fewer regions of involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The GHSG defines the favorable prognostic group as patients with no more than two sites of disease; no extranodal extension; no mediastinal mass measuring one-third the maximum thoracic diameter or greater; and ESR less than 50",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      (less than 30",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      if B symptoms present) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of favorable prognosis stage I-II Hodgkin lymphoma will be reviewed here. The treatment of patients with unfavorable prognosis disease, advanced stage disease, and the treatment of patients with the nodular lymphocyte predominant subtype of Hodgkin lymphoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27496?source=see_link\">",
"     \"Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34520?source=see_link\">",
"     \"Treatment of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5438137\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28940500\">",
"    <span class=\"h2\">",
"     Studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of a patient with HL must establish the precise histologic subtype, the extent and sites of disease, and the performance status of the patient. This evaluation is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=see_link\">",
"     \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28940507\">",
"    <span class=\"h2\">",
"     International prognostic score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HL can be further divided into prognostic groups using the international prognostic score (IPS), which incorporates seven factors (ie, serum albumin, hemoglobin, gender, age, stage, white blood cell count, and absolute lymphocyte count) to delineate six prognostic groups with very different rates of freedom from progression at five years (",
"    <a class=\"graphic graphic_table graphicRef76219 \" href=\"UTD.htm?11/50/12077\">",
"     table 2",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?4/32/4609?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). However, the IPS is largely used for patients with advanced stage HL and not in patients with stage I-II disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link&amp;anchor=H9398231#H9398231\">",
"     \"Staging and prognosis of Hodgkin lymphoma\", section on 'International Prognostic Score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5438145\">",
"    <span class=\"h1\">",
"     INITIAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of early stage, favorable prognosis Hodgkin lymphoma requires a careful balance between providing enough therapy to eradicate the tumor and avoiding unnecessary treatment that could result in excessive long-term treatment-related side effects. The preferred therapy for most patients with early stage, favorable prognosis Hodgkin lymphoma is combination chemotherapy plus involved-field radiation therapy. This approach is supported by clinical trials and meta-analyses of randomized trials evaluating the influence of radiation field size and the role of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These randomized trials have addressed three main questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How does multiagent chemotherapy plus radiation therapy compare with radiation therapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/5-11\">",
"       5-11",
"      </a>",
"      ]?",
"     </li>",
"     <li>",
"      What fields of radiation therapy should be used (ie, extensive versus less extensive) when combined with chemotherapy (",
"      <a class=\"graphic graphic_table graphicRef78652 \" href=\"UTD.htm?27/6/27756\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/5-7,12\">",
"       5-7,12",
"      </a>",
"      ]?",
"     </li>",
"     <li>",
"      Is there a role for multiagent chemotherapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/13-17\">",
"       13-17",
"      </a>",
"      ]?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Details on the specifics of these trials are discussed separately. What follows is a more general discussion of their impact on patient care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2792?source=see_link\">",
"     \"Clinical trials of specific regimens in favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the increasing availability of guidelines for the treatment of Hodgkin lymphoma, there must remain room for individualization of treatment. In particular, patient preference must be considered with different treatment options, some of which result in a higher recurrence risk at the gain of less toxic initial treatment (without any difference in long-term survival). Treatment should also be individualized when a particular approach might result in a higher risk of a serious late complication (eg, the use of large radiation fields and the risk of late breast cancer in young females and of lung cancer in smokers). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Combined modality therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined modality therapy comprised of combination chemotherapy plus involved-field radiation therapy is the preferred treatment for most patients with favorable prognosis stage I-II Hodgkin lymphoma. While the radiation therapy acts to control known sites of tumor, the chemotherapy is aimed at occult disease outside the radiation field. The combination of the two modalities allows for a decrease in the size of the radiation field used and the number of chemotherapy cycles given in an attempt to reduce long-term complications.",
"   </p>",
"   <p>",
"    In most of the modern trials, combined modality treatment has resulted in higher rates of freedom from recurrence but no difference in overall survival. This lack of an overall survival benefit in most trials may be related to the effectiveness of salvage with chemotherapy after failure of radiation therapy and the relatively short follow-up of patients enrolled in trials of combined modality therapy. However, one meta-analysis comparing chemotherapy alone to combined chemotherapy and radiation therapy demonstrated both a recurrence-free and overall survival advantage to combined modality treatment in early stage patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given effective salvage therapy, longer follow-up may be needed to see a difference in overall survival with initial therapy. Such a survival benefit to combined modality therapy was demonstrated after 10-year follow-up of the large EORTC H8F trial, which compared three cycles of",
"    <span class=\"nowrap\">",
"     MOPP/ABV",
"    </span>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ) hybrid plus involved field irradiation to subtotal nodal radiotherapy (mantle and paraaortic-splenic irradiation) without chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/11\">",
"     11",
"    </a>",
"    ]. While both arms had similar response rates and cumulative risk for second cancers, patients who received combined modality therapy had a significant 10-year overall survival benefit when compared with those who received radiotherapy alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2792?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical trials of specific regimens in favorable prognosis early (stage I-II) classical Hodgkin lymphoma\", section on 'Modified chemotherapy and involved field irradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For most patients with early stage favorable prognosis Hodgkin lymphoma, we suggest the use of combination chemotherapy plus involved-field radiation therapy rather than combination chemotherapy or radiation therapy alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Chemotherapy regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few randomized trials that have compared different chemotherapy regimens in combination with radiation therapy for the treatment of patients with favorable prognosis stage I-II Hodgkin lymphoma. Many of the early randomized trials that examined combined modality therapy used regimens that contained an alkylating agent, usually MOPP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) or an equivalent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. ABVD (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ) is the combination chemotherapy regimen preferred by most cooperative groups for the treatment of favorable prognosis stage I-II Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/11,19-21\">",
"     11,19-21",
"    </a>",
"    ]. Stanford V with radiation therapy remains an acceptable alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ABVD is administered every 14 days in 28-day cycles (",
"      <a class=\"graphic graphic_table graphicRef68131 \" href=\"UTD.htm?0/59/958\">",
"       table 4",
"      </a>",
"      ); two administrations are considered one cycle. Patients treated with combined modality therapy usually receive between two and four cycles of ABVD. As such, the total time of chemotherapy ranges from 8 to 16 weeks. Radiation therapy usually begins 4 to 6 weeks after the completion of chemotherapy. The main severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      acute toxicities are neutropenia,",
"      <span class=\"nowrap\">",
"       nausea/vomiting,",
"      </span>",
"      and alopecia. Long term toxicities include cardiopulmonary toxicity, which is more frequently seen in children and in combination with mediastinal irradiation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link&amp;anchor=H7#H7\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'ABVD chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stanford V incorporates weekly chemotherapy (agents vary weekly, but include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , and VP-16) followed one to three weeks later by radiation therapy. The original Stanford V regimen has been modified for favorable prognosis patients from the original 12 weeks to 8 weeks, with involved field irradiation to sites of initial involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/23\">",
"       23",
"      </a>",
"      ]. The main toxicities are neutropenia and constipation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link&amp;anchor=H14#H14\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'Stanford V'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2792?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical trials of specific regimens in favorable prognosis early (stage I-II) classical Hodgkin lymphoma\", section on 'Stanford V'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our preference for ABVD rather than other chemotherapy regimens for early stage favorable prognosis disease is largely based upon the extrapolation of trials that compared ABVD with other regimens in patients with more advanced Hodgkin lymphoma. ABVD has demonstrated superior efficacy (ie, freedom from progression) and less toxicity when compared with MOPP in patients with unfavorable prognosis, early stage and advanced stage Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Additional studies suggest that ABVD plus involved field irradiation may be more effective and less toxic than alkylating agent regimens plus radiation therapy in stage I-II Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. ABVD plus involved-field radiation has not been directly compared with Stanford V plus radiation therapy in the treatment of early stage favorable prognosis Hodgkin lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2792?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical trials of specific regimens in favorable prognosis early (stage I-II) classical Hodgkin lymphoma\", section on 'Chemotherapy plus radiation therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link&amp;anchor=H7#H7\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'ABVD chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5438104\">",
"    <span class=\"h3\">",
"     Number of cycles",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABVD (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ) is the preferred therapy for most patients with favorable prognosis stage I-II Hodgkin lymphoma. While most of the trials that have evaluated this approach used four or more cycles of ABVD, attempts have been made to decrease the number of chemotherapy cycles in an attempt to lessen toxicity without compromising efficacy.",
"   </p>",
"   <p>",
"    The German Hodgkin Study Group (GHSG) HD10 Trial randomly assigned 1370 patients with favorable prognosis early-stage HL to receive one of the following four treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Four cycles of ABVD followed by 30 Gy involved field radiation therapy",
"     </li>",
"     <li>",
"      Four cycles of ABVD followed by 20 Gy involved field radiation therapy",
"     </li>",
"     <li>",
"      Two cycles of ABVD followed by 30 Gy involved field radiation therapy",
"     </li>",
"     <li>",
"      Two cycles of ABVD followed by 20 Gy involved field radiation therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eligibility criteria for this trial included patients with no more than two sites of disease, no extranodal extension, no mediastinal mass greater than or equal to one-third the maximum thoracic diameter, and ESR less than 50 (less than 30 if B symptoms present). At a median follow-up of 7.5 years, there was no significant difference between four and two cycles of ABVD chemotherapy in five-year overall survival (97.1 versus 96.6 percent), freedom from treatment failure (93.0 versus 91.1 percent), and progression-free survival (93.5 versus 91.2 percent). Estimated eight-year survival rates were also similar (95 versus 94 percent). However, there were significant differences in major toxicity (WHO grade",
"    <span class=\"nowrap\">",
"     III/IV)",
"    </span>",
"    between four and two cycles of ABVD in the overall number of events (52 versus 33 percent) including leukopenia (24 versus 15 percent), infections (5.1 versus 1.7 percent) and hair loss (28 versus 15 percent)",
"   </p>",
"   <p>",
"    The results of this trial suggest that two cycles of ABVD followed by 20 Gy involved field radiation therapy may be sufficient treatment for patients with favorable presentations of stage I-II Hodgkin lymphoma, as defined by the GHSG. Three to four cycles of ABVD followed by 30 Gy involved field radiation therapy can be used for patients with favorable risk early stage disease that would not fit the enrollment criteria for the GHSG study (eg, those with three sites of disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20474631\">",
"    <span class=\"h3\">",
"     Radiation field size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over time there has been a movement to decrease the field of radiation in order to limit acute and long-term toxicities while maintaining survival rates. Various definitions have been applied. For our discussion, the following definitions will be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extended-field radiation &mdash; Radiation field includes not only the clinically involved nodes, but also the adjacent, clinically uninvolved sites (eg, mantle field or inverted-Y field).",
"     </li>",
"     <li>",
"      Involved-field radiation &mdash; Radiation field encompasses all of the clinically involved regions (eg, mediastinal plus low bilateral supraclavicular field which covers the entire mediastinum) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66021 \" href=\"UTD.htm?19/30/19937\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Involved-node radiation &mdash; Radiation field includes pre- and post-chemotherapy nodal volumes plus a margin of healthy tissue &le;5 cm (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77839 \" href=\"UTD.htm?12/18/12580\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/28-31\">",
"       28-31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients receiving combined modality treatment, we recommend involved field irradiation. Multiple trials have demonstrated decreased toxicity and similar survival rates when involved-field radiation is used in combination with chemotherapy instead of extended field radiation in patients with early stage HL. Most of these trials have been in patients with unfavorable prognosis early stage disease. The details of these trials are presented separately. Involved-node radiation therapy requires further investigation prior to its incorporation into routine practice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27496?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\", section on 'Radiation field size'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been presumed that any rise in mortality from recurrent Hodgkin lymphoma in patients receiving smaller field irradiation is balanced by an enhanced mortality from treatment-related causes (eg, cardiac disease, second tumors) in patients receiving more extensive radiation therapy (see",
"    <a class=\"local\" href=\"#H20474325\">",
"     'Monitoring for treatment complications'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Completed trials evaluating radiation volume when combined with chemotherapy in poor prognosis clinical stage I-II patients suggest that involved field irradiation is sufficient radiation when combined with two to four cycles of ABVD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial that included 138 patients with early stage HL (60 percent favorable) randomly assigned treatment with chemotherapy followed by either involved-field radiation or extended field radiation reported similar rates of freedom from progression rates at 12 years in the two treatment groups (94 and 93 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/32\">",
"       32",
"      </a>",
"      ]. There was no difference in overall survival.",
"     </li>",
"     <li>",
"      Among 996 patents enrolled in the EORTC H8U trial of",
"      <span class=\"nowrap\">",
"       MOPP/ABV",
"      </span>",
"      plus involved or extended field irradiation, the five-year event-free survival rates were approximately 87 percent for both groups [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/11\">",
"       11",
"      </a>",
"      ]. Survival differences were not seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While previously considered an acceptable therapy, mantle irradiation followed by paraaortic and splenic irradiation has a higher recurrence rate and poorer survival when compared with combination radiation therapy and chemotherapy in one trial. It appears to be associated with a higher risk of second malignancies and thus is not ideal treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20474638\">",
"    <span class=\"h3\">",
"     Radiation dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of trials that have evaluated the use of chemotherapy in combination with involved-field radiation therapy in early stage HL have administered the radiation at a dose of 30 Gy to 40 Gy (administered in single fractions of 1.8 to 2.0 Gy five times weekly), often with an optional boost of 6 Gy to individual nodes of concern [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/11,19,20,33\">",
"     11,19,20,33",
"    </a>",
"    ]. Short- and long-term toxicities increase as the dose of radiation increases. As such, attempts have been made to decrease the dose of radiation therapy administered to patients with early stage disease. While additional follow-up is necessary to investigate for long-term outcomes, lower radiation therapy doses appear to be associated with less short-term toxicity and similar efficacy.",
"   </p>",
"   <p>",
"    This was best illustrated in the German Hodgkin Study Group (GHSG) HD10 Trial that randomly assigned 1370 patients with favorable prognosis early-stage HL to receive one of the following four treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Four cycles of ABVD followed by 30 Gy involved field radiation therapy",
"     </li>",
"     <li>",
"      Four cycles of ABVD followed by 20 Gy involved field radiation therapy",
"     </li>",
"     <li>",
"      Two cycles of ABVD followed by 30 Gy involved field radiation therapy",
"     </li>",
"     <li>",
"      Two cycles of ABVD followed by 20 Gy involved field radiation therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eligibility criteria for this trial included patients with no more than two sites of disease, no extranodal extension, no mediastinal mass greater than or equal to one-third the maximum thoracic diameter, and ESR less than 50 (less than 30 if B symptoms present). At median follow-up of 7.5 years, there was no significant difference between 30 and 20 Gy involved field radiation therapy in five-year overall survival (OS, 97.7 versus 97.5 percent), freedom from treatment failure (FFTF, 93.4 versus 92.9 percent), and progression-free survival (PFS, 93.7 versus 93.2 percent). However, there were significant differences in major toxicity (WHO grade",
"    <span class=\"nowrap\">",
"     III/IV)",
"    </span>",
"    between 30 and 20 Gy involved field radiation therapy (all events, 8.7 versus 2.9 percent), dysphagia (3 versus 2 percent), and mucositis (3.4 versus 0.7 percent).",
"   </p>",
"   <p>",
"    The results of this trial suggest that two cycles of ABVD followed by 20 Gy involved field radiation therapy may be sufficient treatment for patients with favorable prognosis early-stage Hodgkin lymphoma, as defined by the GHSG. Three to four cycles of ABVD followed by 30 Gy involved field radiation therapy can be used for patients with favorable risk early stage disease that would not fit the enrollment criteria for the GHSG study (eg, those with three sites of disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Is there a role for chemotherapy alone?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of chemotherapy alone for the treatment of early stage HL is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/34\">",
"     34",
"    </a>",
"    ]. Nearly all of the trials evaluating chemotherapy with or without radiation therapy (RT) have been conducted in favorable prognosis patients. These trials have had a number of problems with design and patient accrual, as well as variations in the type of chemotherapy and field size of radiation therapy utilized.",
"   </p>",
"   <p>",
"    As an example, in the",
"    <span class=\"nowrap\">",
"     NCIC/ECOG",
"    </span>",
"    HD6 randomized trial, 405 patients with previously untreated stage IA or IIA non-bulky HL were randomly assigned treatment with four to six cycles of ABVD alone or to treatment that included 35 Gy RT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/17\">",
"     17",
"    </a>",
"    ]. The RT arm consisted of sub-total nodal RT without chemotherapy for patients with a favorable prognosis (n=123) and was two cycles of ABVD followed by sub-total nodal RT for patients with an unfavorable prognosis (n=276). At a median follow-up of 11.3 years, chemotherapy alone was associated with a lower rate of freedom from disease progression (FFDP, 87 versus 92 percent) but a higher rate of overall survival (OS, 94 versus 87 percent) at 12 years in the entire population. This improvement in survival was attributed to an increased rate of non-relapse mortality among patients treated with sub-total nodal RT. On a subset analysis of patients with a favorable prognosis, there was no significant difference in FFDP (98 percent in both groups) or OS (89 versus 87 percent).",
"   </p>",
"   <p>",
"    Many issues regarding the use of chemotherapy alone remain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease-free survival &mdash; When compared with combined modality therapy, chemotherapy alone is clearly associated with a higher rate of relapse. Patients who relapse require treatment with second line chemotherapy followed by high dose chemotherapy and hematopoietic stem cell rescue, a treatment that can cure approximately 50 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link\">",
"       \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Long-term toxicity &mdash; High doses of large field RT are clearly associated with a higher rate of secondary malignancy and cardiovascular deaths. However, modern RT techniques utilize lower doses of radiation (eg, 20 to 30 Gy) administered to smaller areas (eg, involved-field or involved-node). The long term rates of secondary malignancy and cardiovascular deaths with this approach appear to be significantly less than seen with larger field irradiation.",
"     </li>",
"     <li>",
"      Overall survival &mdash; The long term OS of patients with HL is determined based upon not only the risk of dying from HL, but also the risk of dying from long-term toxicity. Although OS may be superior with chemotherapy alone when compared with high doses of large field RT, it is possible that the OS advantage is reversed when small fields of lower dose RT are used. One meta-analysis of the randomized trials studying chemotherapy alone versus combined chemotherapy and RT (that did not include HD6) suggests better survival in the patients who receive combined modality therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As mentioned above, the EORTC H8F trial was the first trial to show that higher rates of freedom from recurrence may translate into an overall survival benefit at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/11\">",
"     11",
"    </a>",
"    ]. Extrapolating these survival differences, there is a concern that higher recurrence rates with chemotherapy alone might result similarly in a poorer survival. In addition, an ongoing EORTC trial using PET to determine the need for radiation after chemotherapy demonstrated higher recurrence rates in patients who were PET negative after two cycles of ABVD and went on to receive another two cycles without radiation compared with the addition of radiation therapy. The trial has closed the chemotherapy alone arm due to stopping rules.",
"   </p>",
"   <p>",
"    For most patients with favorable prognosis stage I-II HL, we suggest treatment with combined modality therapy rather than the use of chemotherapy or radiation therapy alone. This preference places a high value on the improved disease-free survival seen with this approach. It also assumes that the lower dose and smaller field size used in modern RT is associated with less long-term toxicity than higher dose larger field size treatment, without compromised efficacy. Chemotherapy alone is an acceptable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H201474595\">",
"    <span class=\"h1\">",
"     SPECIAL SCENARIOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general treatment principles for favorable prognosis stage I-II Hodgkin lymphoma apply to most disease presentations and patient populations. However, certain patient populations, such as pregnant women and older adults require special consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20475773\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of Hodgkin lymphoma during pregnancy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12793?source=see_link\">",
"     \"Management of classical Hodgkin lymphoma during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28940290\">",
"    <span class=\"h2\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;It appears that adult treatment protocols may be safe and provide comparable efficacy to pediatric protocols in the treatment of adolescents with HL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=see_link\">",
"     \"Overview of Hodgkin lymphoma in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22722315\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians often have concerns over the ability of older adults (ie, over age 60 years) to tolerate intensive chemotherapy and radiation therapy. The management of lymphoma in older adults can be complicated by an increased number of comorbidities. A comprehensive geriatric assessment may be useful in assessing comorbidity and functional status in the elderly patient, thus permitting the formulation of an appropriate, individualized treatment plan. Special considerations for the use of chemotherapy in the elderly population are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link&amp;anchor=H33#H33\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'Older adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We believe that older adults should be initially treated with the same dosing and schedule as younger adults with adjustments made to future cycles according to tolerance. This is principally because the amount of chemotherapy administered in the initial treatment of Hodgkin lymphoma may affect overall survival. In a potentially curable disease such as Hodgkin lymphoma, it is especially important to treat all patients aggressively, even older individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98393765\">",
"    <span class=\"h2\">",
"     HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with HIV who develop HL is complicated by their immunocompromised state and also requires specific treatment for their HIV. As such, treatment of these patients is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=see_link\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link&amp;anchor=H1560506291#H1560506291\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Hodgkin lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22722280\">",
"    <span class=\"h2\">",
"     Nodular lymphocyte predominant Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with the nodular lymphocyte predominant subtype of Hodgkin lymphoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34520?source=see_link\">",
"     \"Treatment of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20474802\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After completion of the initially planned treatment of Hodgkin lymphoma, patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20474811\">",
"    <span class=\"h2\">",
"     Response evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;One month following the completion of planned therapy (or sooner if the outcome is unfavorable), the response to treatment should be documented by history, physical examination, and laboratory studies (complete blood count, lactate dehydrogenase, and biochemical profile). The post-treatment imaging study of choice is the",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, which provides information on the size and activity of residual masses and allows for the distinction between active disease and fibrosis.",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    should be obtained six to eight weeks after completion of chemotherapy and three to six months after the completion of radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/36\">",
"     36",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging obtained earlier than this is likely to demonstrate increased uptake due to an inflammatory reaction to treatment. If the mid or post treatment PET scan are normal then subsequent follow-up scans should be done with contrast enhanced CT scans of the chest, abdomen, and pelvis, rather than PET scans.",
"   </p>",
"   <p>",
"    Using information gathered from the history, physical, and",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, disease response is determined by the International Working Group (IWG) response criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/37\">",
"     37",
"    </a>",
"    ]. A complete remission has been achieved if all of the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no evidence of disease or disease-related symptoms on history and physical examination.",
"     </li>",
"     <li>",
"      All post-treatment residual masses are negative on PET scan.",
"     </li>",
"     <li>",
"      The spleen and liver are non-palpable and without nodules.",
"     </li>",
"     <li>",
"      If a pre-treatment bone marrow biopsy was positive, a repeat bone marrow biopsy must be negative. If morphologically indeterminate, immunohistochemistry should be negative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A discussion of the accuracy of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    in the follow-up of patients with lymphoma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=see_link&amp;anchor=H7#H7\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\", section on 'After treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stage I-II patients whose",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    does not normalize with chemotherapy, but shows a significant response, should undergo radiation therapy as planned without further treatment. Patients with disease that fails to respond to chemotherapy or whose disease grows on chemotherapy are treated as having refractory disease. Treatment of refractory disease is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20475016\">",
"    <span class=\"h2\">",
"     Surveillance for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. Our approach is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3079?source=see_link&amp;anchor=H1167672602#H1167672602\">",
"     \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Follow-up for relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most relapses of early stage Hodgkin lymphoma occur within the first two to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In one series of 1044 patients in remission after therapy for early stage Hodgkin lymphoma, 32.6 percent relapsed; only 3.5 percent of these relapses occurred after five years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7784?source=see_link\">",
"     \"Relapse of classical Hodgkin lymphoma after initial radiotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the poor outcomes after relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/40\">",
"     40",
"    </a>",
"    ], the majority of patients who relapse after chemotherapy alone or when combined with radiation are now considered candidates for high dose chemotherapy and autologous hematopoietic cell rescue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21274?source=see_link\">",
"     \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20474325\">",
"    <span class=\"h2\">",
"     Monitoring for treatment complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the long-term follow-up data (15 years or longer) for early stage Hodgkin lymphoma are derived from laparotomy-staged patients who were treated with radiation therapy alone. Large, single institutional studies have found at 10 to 15 years an actuarial freedom from relapse rate exceeding 80 percent and a mortality rate below 10 percent following mantle and paraaortic irradiation for pathologically staged IA-IIA disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These results have been achieved through careful delineation of the extent of Hodgkin lymphoma, precise delivery of radiation therapy (since inadequate portals are associated with in-field or marginal recurrence rates as high as 33 percent versus 7 percent in those with adequate portals) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/44\">",
"     44",
"    </a>",
"    ], and treatment of patients who relapse with multiagent chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of early stage Hodgkin lymphoma has become so successful that at 15 to 20 years post-treatment, the overall mortality rate from causes other than Hodgkin lymphoma may exceed that seen from Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. In one series of 794 patients, for example, 124 died at a mean follow-up of 11 years: 56 from Hodgkin lymphoma, 36 from second malignancies, 15 from cardiac disease, and eight from other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/47,50\">",
"     47,50",
"    </a>",
"    ]. Deaths from Hodgkin lymphoma primarily occurred in the first 5 to 10 years, with almost no Hodgkin-related deaths after 15 years; in comparison, deaths from second malignancy primarily occurred after 10 years and continued to increase with time (",
"    <a class=\"graphic graphic_figure graphicRef50597 \" href=\"UTD.htm?34/3/34877\">",
"     figure 1",
"    </a>",
"    ). The estimated excess risk of mortality was approximately 1 percent per year over the first 20 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Second malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated risk of a second cancer is approximately 15 percent at 15 years after treatment of Hodgkin lymphoma. The most common second malignancies are acute nonlymphoblastic leukemia (which primarily occurs in the first 10 years and develops much more often after chemotherapy, especially MOPP, than radiation), non-Hodgkin lymphoma, and solid tumors (which account for about 75 percent of second malignancies and occur after both chemotherapy and radiation). This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of complications related to cardiac irradiation (arrhythmias, myocardial infarction and coronary artery disease, pericarditis, myocarditis, pericardial effusion and tamponade, and cardiac death) have been carefully documented after radiation therapy to the mediastinum [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/47,49-54\">",
"     47,49-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many of the initial studies, cardiac complications related to treatment techniques that resulted in a high radiation dose to the anterior mediastinum and heart. Current practice, which restricts the dose to the whole heart, blocks the subcarinal region part way into treatment, and limits exposure to cardiac toxins such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , has lowered this risk [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. A retrospective study of 2232 survivors of Hodgkin lymphoma treated at Stanford and followed for an average of 9.5 years found that 3.9 percent died from cardiac disease (myocardial infarction, heart failure, radiation pericarditis or pancarditis, cardiomyopathy, or valvular heart disease); the relative risk of death from heart disease was 3.1 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/54\">",
"     54",
"    </a>",
"    ]. This risk was increased only in those patients who received more than 30 Gy to the mediastinum. Blocking to limit cardiac exposure did not alter the risk of myocardial infarction, but did reduce the relative risk for other cardiac diseases from 5.3 to 1.4. The lack of protection against infarction may reflect exposure of the proximal portion of the coronary arteries to the full dose of radiation regardless of the amount of blocking used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study from Stanford University to determine long-term cardiac effects, 294 asymptomatic patients treated with mediastinal irradiation for Hodgkin lymphoma underwent electrocardiography and echocardiography screening at a median time of 15 years following initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/55\">",
"     55",
"    </a>",
"    ]. In this study, the prevalence of valvular abnormality increased significantly with increasing follow-up time. For patients who were more than 20 years post-RT, &gt;60 percent had at least one pathologic valvular abnormality (eg, aortic stenosis or regurgitation, mitral regurgitation or stenosis). Less than 10 percent of these patients had an audible murmur on examination.",
"   </p>",
"   <p>",
"    These results demonstrate the usefulness of screening echocardiogram in identifying patients with valvular disease who might benefit from endocarditis prophylaxis. The number needed to screen with echocardiography to identify a candidate for endocarditis prophylaxis decreased dramatically with time following irradiation: 13 for patients at 2 to 10 years, 4 for patients at 11 to 20 years, and 1.6 for those beyond 20 years following initial Hodgkin lymphoma therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22722640\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Death from favorable prognosis early stage Hodgkin lymphoma is unusual and mortality from causes other than Hodgkin lymphoma occurs many years later. Thus, survival is not a useful parameter to evaluate the results in early stage Hodgkin lymphoma. Efficacy must be judged by freedom from first recurrence rates, acute and chronic morbidity, and by new criteria such as quality of life and perhaps cost-effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/56\">",
"     56",
"    </a>",
"    ]. However, even those regimens that provide the highest freedom from first recurrence may not be optimal, since, depending on the regimen used, treatment-related mortality at 10 to 20 years may exceed Hodgkin lymphoma mortality in patients with favorable early stage disease (",
"    <a class=\"graphic graphic_figure graphicRef50597 \" href=\"UTD.htm?34/3/34877\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accordingly, current clinical trials are evaluating the use of alternative chemotherapy combinations, shortened courses of chemotherapy, chemotherapy with smaller radiation fields",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower radiation doses [",
"    <a class=\"abstract\" href=\"UTD.htm?11/31/11770/abstract/57-59\">",
"     57-59",
"    </a>",
"    ], and chemotherapy without radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once the diagnosis of Hodgkin lymphoma (HL, formerly called Hodgkin's disease) has been established, subsequent therapy is based upon the stage of the disease, as currently defined by the Cotswolds classification (",
"      <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"       \"Staging and prognosis of Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In this discussion, early stage Hodgkin lymphoma is defined as those patients with stage I or II disease (",
"      <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stage I &mdash; Involvement of a single lymph node region (I) or of a single extralymphatic organ or site (Ie).",
"     </li>",
"     <li>",
"      Stage II &mdash; Involvement of two or more lymph node regions on the same side of the diaphragm alone (II) or with involvement of limited, contiguous extralymphatic organ or tissue (IIe).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with early disease, there is subsequent stratification into favorable and unfavorable prognosis disease based upon the presence or absence of certain clinical features, such as age, B symptoms, and large mediastinal adenopathy. Cooperative research groups have used varying definitions of favorable and unfavorable prognosis disease. In the US, patients who have B symptoms, large mediastinal adenopathy, or more than three regions of involvement are considered unfavorable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10711?source=see_link\">",
"       \"Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with early stage favorable prognosis Hodgkin lymphoma, we suggest the use of combination chemotherapy plus involved-field radiation therapy rather than the use of chemotherapy or radiation therapy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Combined modality therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Specifically, we suggest ABVD (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ) chemotherapy in combination with involved-field (or modified involved-field) radiotherapy for patients with favorable prognosis stage I-II Hodgkin lymphoma (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Stanford V with radiation therapy remains an acceptable alternative. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chemotherapy regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients receiving combined modality treatment for early stage disease, we recommend involved-field irradiation rather than subtotal nodal irradiation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The involved fields may be modified slightly (eg, exclusion of high neck nodes or inferior mediastinum if uninvolved), but involved node treatment is not recommended at this time. (See",
"      <a class=\"local\" href=\"#H20474631\">",
"       'Radiation field size'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two cycles of ABVD followed by 20 Gy involved-field radiation therapy may be sufficient treatment for a subgroup of patients with favorable presentations of stage I-II Hodgkin lymphoma, as defined by the German Hodgkin Study Group (GHSG). Three to four cycles of ABVD followed by 30 Gy involved field radiation therapy can be used for patients with favorable risk early stage disease that would not fit the enrollment criteria for the GHSG study (eg, those with three sites of disease or extranodal extension). (See",
"      <a class=\"local\" href=\"#H5438104\">",
"       'Number of cycles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20474638\">",
"       'Radiation dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The general treatment principles for favorable prognosis stage I-II Hodgkin lymphoma apply to most disease presentations and patient populations. However, certain patient populations, such as pregnant women and older adults require special consideration. (See",
"      <a class=\"local\" href=\"#H20475773\">",
"       'Pregnant women'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22722315\">",
"       'Older adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After completion of the initially planned treatment of Hodgkin lymphoma, patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse or potential complications of therapy. (See",
"      <a class=\"local\" href=\"#H20474802\">",
"       'Patient follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/1\">",
"      Cosset JM, Henry-Amar M, Meerwaldt JH, et al. The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer 1992; 28A:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/2\">",
"      Engert A, Pl&uuml;tschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/3\">",
"      Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998; 16:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/4\">",
"      Shore T, Nelson N, Weinerman B. A meta-analysis of stages I and II Hodgkin's disease. Cancer 1990; 65:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/5\">",
"      Haybittle JL, Hayhoe FG, Easterling MJ, et al. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet 1985; 1:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/6\">",
"      Somers R, Tubiana M, Henry-Amar M. EORTC Lymphoma Cooperative Group studies in clinical stage I-II Hodgkin's disease 1963-1987. Recent Results Cancer Res 1989; 117:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/7\">",
"      Hoppe RT, Horning SJ, Hancock SL, Rosenberg SA. Current Stanford clinical trials for Hodgkin's disease. Recent Results Cancer Res 1989; 117:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/8\">",
"      Longo DL, Glatstein E, Duffey PL, et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J Clin Oncol 1991; 9:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/9\">",
"      Nissen NI, Nordentoft AM. Radiotherapy versus combined modality treatment of stage I and II Hodgkin's disease. Cancer Treat Rep 1982; 66:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/10\">",
"      Anderson H, Crowther D, Deakin DP, et al. A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10-year follow-up. Ann Oncol 1991; 2 Suppl 2:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/11\">",
"      Ferm&eacute; C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/12\">",
"      Fuller LM, Hutchison GB. Collaborative clinical trial for stage I and II Hodgkin's disease: significance of mediastinal and nonmediastinal disease in laparotomy- and non-laparotomy-staged patients. Cancer Treat Rep 1982; 66:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/13\">",
"      Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20:3765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/14\">",
"      Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104:3483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/15\">",
"      Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst 1988; 80:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/16\">",
"      Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004; 22:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/17\">",
"      Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012; 366:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/18\">",
"      Herbst C, Rehan FA, Brillant C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica 2010; 95:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/19\">",
"      Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24:3128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/20\">",
"      Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21:3601.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN clinical practice guidelines in oncology: Hodgkin disease/lymphoma. Fort Washington, PA: National Comprehensive Cancer Network, 2010. file://www.nccn.org/professionals/physician_gls/PDF/hodgkins.pdf (Accessed on September 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/22\">",
"      Advani RH, Hoppe RT, Maeda LS, et al. Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. Int J Radiat Oncol Biol Phys 2011; 81:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/23\">",
"      Advani RH, Hoppe RT, Baer D, et al. Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol 2013; 24:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/24\">",
"      Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/25\">",
"      Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/26\">",
"      Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005; 23:9198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/27\">",
"      Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002; 13 Suppl 1:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/28\">",
"      Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol 2008; 26:5170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/29\">",
"      Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006; 79:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/30\">",
"      Paumier A, Ghalibafian M, Beaudre A, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011; 80:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/31\">",
"      Koeck J, Abo-Madyan Y, Lohr F, et al. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys 2012; 83:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/32\">",
"      Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22:2835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/33\">",
"      Arakelyan N, Jais JP, Delwail V, et al. Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial. Cancer 2010; 116:4054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/34\">",
"      Meyer RM, Hoppe RT. Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. Blood 2012; 120:4488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/35\">",
"      Eichenauer DA, Bredenfeld H, Haverkamp H, et al. Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group. J Clin Oncol 2009; 27:6079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/36\">",
"      Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/37\">",
"      Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/38\">",
"      Bodis S, Henry-Amar M, Bosq J, et al. Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols. J Clin Oncol 1993; 11:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/39\">",
"      Garcia-Carbonero R, Paz-Ares L, Arcediano A, et al. Favorable prognosis after late relapse of Hodgkin's disease. Cancer 1998; 83:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/40\">",
"      Biti GP, Cimino G, Cartoni C, et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 1992; 10:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/41\">",
"      Hoppe RT, Coleman CN, Cox RS, et al. The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 1982; 59:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/42\">",
"      Mauch P, Tarbell N, Weinstein H, et al. Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988; 6:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/43\">",
"      Farah R, Ultmann J, Griem M, et al. Extended mantle radiation therapy for pathologic stage I and II Hodgkin's disease. J Clin Oncol 1988; 6:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/44\">",
"      Kinzie JJ, Hanks GE, MacLean CJ, Kramer S. Patterns of care study: Hodgkin's disease relapse rates and adequacy of portals. Cancer 1983; 52:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/45\">",
"      Roach M 3rd, Brophy N, Cox R, et al. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 1990; 8:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/46\">",
"      Healey EA, Tarbell NJ, Kalish LA, et al. Prognostic factors for patients with Hodgkin disease in first relapse. Cancer 1993; 71:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/47\">",
"      Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1995; 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/48\">",
"      Cosset JM, Henry-Amar M, Meerwaldt JH. Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol 1991; 2 Suppl 2:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/49\">",
"      Hancock SL, Hoppe RT, Horning SJ, Rosenberg SA. Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. Ann Intern Med 1988; 109:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/50\">",
"      Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/51\">",
"      Tarbell NJ, Thompson L, Mauch P. Thoracic irradiation in Hodgkin's disease: disease control and long-term complications. Int J Radiat Oncol Biol Phys 1990; 18:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/52\">",
"      Gottdiener JS, Katin MJ, Borer JS, et al. Late cardiac effects of therapeutic mediastinal irradiation. Assessment by echocardiography and radionuclide angiography. N Engl J Med 1983; 308:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/53\">",
"      Boivin JF, Hutchison GB, Lubin JH, Mauch P. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992; 69:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/54\">",
"      Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/55\">",
"      Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003; 42:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/56\">",
"      Ng AK, Kuntz KM, Mauch PM, Weeks JC. Costs and effectiveness of staging and treatment options in early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 2001; 50:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/57\">",
"      Prosnitz LR. Reducing treatment-related morbidity and mortality in early-stage Hodgkin's disease and why the recent Southwest Oncology Group Trial is not the way to go. J Clin Oncol 2002; 20:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/58\">",
"      Chronowski GM, Wilder RB, Tucker SL, et al. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/31/11770/abstract/59\">",
"      Eich H, Mueller R, Engert A, et al. Comparison of 30 Gy versus 20 Gy involved field radiotherapy after two versus four cycles ABVD in early stage Hodgkin's lymphoma: Interim analysis of the German Hodgkin Study Group Trial HD10 (abstract). Int J Radiat Oncol Biol Phys 2005; 63:S1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4754 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-AA34A315B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11770=[""].join("\n");
var outline_f11_31_11770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5438137\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28940500\">",
"      Studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28940507\">",
"      International prognostic score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5438145\">",
"      INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Combined modality therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5438104\">",
"      - Number of cycles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20474631\">",
"      - Radiation field size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20474638\">",
"      - Radiation dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Is there a role for chemotherapy alone?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H201474595\">",
"      SPECIAL SCENARIOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20475773\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28940290\">",
"      Adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22722315\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98393765\">",
"      HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22722280\">",
"      Nodular lymphocyte predominant Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20474802\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20474811\">",
"      Response evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20475016\">",
"      Surveillance for relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20474325\">",
"      Monitoring for treatment complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Second malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22722640\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4754\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4754|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/30/19937\" title=\"diagnostic image 1\">",
"      Radiation field stage I HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/18/12580\" title=\"diagnostic image 2\">",
"      Radiation field stage II HL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4754|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/3/34877\" title=\"figure 1\">",
"      Mortality stage IA IIIB HL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4754|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/23/19836\" title=\"table 1\">",
"      Cotswolds system in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/50/12077\" title=\"table 2\">",
"      IPS Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/6/27756\" title=\"table 3\">",
"      Radiation fields in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/59/958\" title=\"table 4\">",
"      ABVD chemotherapy for Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?4/32/4609?source=related_link\" title=\"calculator 1\">",
"      Calculator: International Prognostic Score in Hodgkin Lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=related_link\">",
"      AIDS-related lymphomas: Treatment of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2792?source=related_link\">",
"      Clinical trials of specific regimens in favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10711?source=related_link\">",
"      Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21274?source=related_link\">",
"      Hematopoietic cell transplantation in classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=related_link\">",
"      Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3079?source=related_link\">",
"      Long-term follow-up of the patient with classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12793?source=related_link\">",
"      Management of classical Hodgkin lymphoma during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=related_link\">",
"      Monitoring of the patient with classical Hodgkin lymphoma during and after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=related_link\">",
"      Overview of Hodgkin lymphoma in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=related_link\">",
"      Overview of the treatment of classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7784?source=related_link\">",
"      Relapse of classical Hodgkin lymphoma after initial radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34520?source=related_link\">",
"      Treatment of nodular lymphocyte-predominant Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=related_link\">",
"      Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27496?source=related_link\">",
"      Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_31_11771="Classification of candidal vaginitis";
var content_f11_31_11771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of candidal vaginitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Uncomplicated disease*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Complicated disease&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptom severity",
"       </td>",
"       <td>",
"        Mild or moderate",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequency",
"       </td>",
"       <td>",
"        Sporadic",
"       </td>",
"       <td>",
"        Recurrent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organism",
"       </td>",
"       <td>",
"        Candida albicans",
"       </td>",
"       <td>",
"        Nonalbicans species",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Host",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Abnormal (eg, uncontrolled diabetes mellitus, recurrent infections,",
"immunosuppression)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Patients must have ALL of these features.",
"     <br>",
"      &bull; Patients may have ANY of these features.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11771=[""].join("\n");
var outline_f11_31_11771=null;
var title_f11_31_11772="Seven-point checklist";
var content_f11_31_11772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The seven-point checklist of dermoscopy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         Major criteria",
"        </strong>",
"       </td>",
"       <td>",
"        Atypical pigment network",
"       </td>",
"       <td>",
"        Prominent (hyperpigmented or thick) and irregular network.",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        White-blue areas",
"       </td>",
"       <td>",
"        Irregular, structureless white-blue area with an overlying \"ground-glass\" film. It cannot occupy the entire lesion.",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atypical vascular pattern",
"       </td>",
"       <td>",
"        Linear irregular or dotted vessels, irregularly distributed outside areas of regression.",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        <strong>",
"         Minor criteria",
"        </strong>",
"       </td>",
"       <td>",
"        Radial streaming (streaks)",
"       </td>",
"       <td>",
"        Radial and asymmetric linear or bulbous projections at the edge of the lesion.",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irregular blotches",
"       </td>",
"       <td>",
"        Black, brown and/or gray structureless areas with irregular shape or distribution.",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irregular dots and globules",
"       </td>",
"       <td>",
"        Black or brown round structures irregularly distributed.",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regression structures",
"       </td>",
"       <td>",
"        White scar-like depigmentation and/or \"peppering\".",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    For the diagnosis of melanoma, a total score of 3 or more is required.",
"    <div class=\"footnotes\">",
"     * In the Revised 7-point checklist (Argenziano G, et al. Br J Dermatol 2011; 164:785), all scores have a value of 1 and the threshold for excision is 1 instead of 3.",
"    </div>",
"    <div class=\"reference\">",
"     Original table modified for this publication. Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: Results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11772=[""].join("\n");
var outline_f11_31_11772=null;
var title_f11_31_11773="Diagnostic criteria migraine";
var content_f11_31_11773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    International Headache Society diagnostic criteria for migraine",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Migraine without aura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. At least five attacks fulfilling criteria B through D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Headache attacks lasting 4 to 72 hours (untreated or unsuccessfully treated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        C. Headache has at least two of the following characteristics:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Unilateral location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Pulsating quality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Moderate or severe pain intensity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        D. During headache at least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Nausea, vomiting, or both",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Photophobia and phonophobia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E. Not attributed to another disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Migraine with aura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. At least two attacks fulfilling criterion B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        B. Migraine aura fulfilling criteria B and C for one of the following subforms:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Typical aura with migraine headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Typical aura with nonmigraine headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Typical aura without headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Familial hemiplegic migraine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sporadic hemiplegic migraine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Basilar-type migraine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. Not attributed to another disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Migraine with typical aura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. At least two attacks fulfilling criteria B through D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        B. Aura consisting of at least one of the following, but no motor weakness:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Fully reversible visual symptoms including positive (eg, flickering lights, spots, or lines) and/or negative features (ie, loss of vision)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Fully reversible sensory symptoms including positive (ie, pins and needles) and/or negative features (ie, numbness)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Fully reversible dysphasic speech disturbance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        C. At least two of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Homonymous visual and/or unilateral sensory symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        At least one aura symptom develops gradually over &ge;5 minutes and/or different aura symptoms occur in succession over &ge;5 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Each symptom lasts &ge;5 and &le;60 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. Headache fulfilling criteria B through D for migraine without aura begins during the aura or follows aura within 60 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E. Not attributed to another disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Features of migraine in children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Attacks may last 1 to 72 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache is commonly bilateral; an adult pattern of unilateral pain usually emerges in late adolescence or early adulthood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Occipital headache is rare and raises diagnostic caution for structural lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Photophobia and phonophobia may be inferred by behavior in young children",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia 2004; 24:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11773=[""].join("\n");
var outline_f11_31_11773=null;
var title_f11_31_11774="Pneumatosis intestinalis plain";
var content_f11_31_11774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumatosis intestinalis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 126px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A is a magnified image of a single fold in the colon demonstrating air within the wall of the colon, which appears as a thin linear lucency on this plain film (arrow). Panel B is a plain film from a 68-year-old male with ischemic bowel, demonstrating numerous linear collections of air within the bowel wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan B Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11774=[""].join("\n");
var outline_f11_31_11774=null;
var title_f11_31_11775="Live births after clomiphene";
var content_f11_31_11775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Live birth following clomiphene citrate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 371px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A two-step nomogram predicting chances for live birth following clomiphene citrate on the basis of initial screening characteristics.",
"    <div class=\"footnotes\">",
"     FAI: free androgen index.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Imani, B, Eijkemans, MJ, te Velde, ER, et al. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 2002; 77:91. Copyright &copy; 2002 American Society for Reproductive Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_31_11775=[""].join("\n");
var outline_f11_31_11775=null;
